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Abstract 
The Epidemiology of Antimicrobial Resistant Escherichia coli in Hospitalised Companion 
Animals 
Ian R Tuerena 
Antimicrobial resistance (AMR) among E. coli is a significant and growing problem in human 
medicine with particular concern regarding production of extended spectrum beta 
lactamase (ESBL) and AmpC enzymes which confer resistance to third and fourth 
generation cephalosporins.  AMR among E. coli of animal origin is well documented, 
including ESBL-producing E. coli and an increasing number of pets may be at risk of 
nosocomial colonisation and infection with these organisms.   
The mains aims of the work presented in this thesis were to determine the prevalence of 
antimicrobial resistance E. coli, including several important AMR phenotypes and 
genotypes, from both the faecal microflora of animals hospitalised in referral practices and 
their practice environment.  A further aim was to determine the risk factors for carriage of 
important resistance phenotypes by faecal commensal E. coli in these practices. 
Faecal (n = 333) and environmental (n = 257) samples were collected from dogs and cats 
hospitalised at five referral practices in Northwest England.  Microbiological and molecular 
analyses including sequencing were performed to determine the resistance profile of each 
E. coli isolate and to identify ESBL and AmpC producing E. coli.  Univariable followed by 
multivariable analyses were performed to identify risk factors associated with carriage of 
important resistance outcomes.   
The adjusted prevalence of important resistance types among faecal sample isolates were: 
clavulanic acid potentiated amoxicillin (CAPA) 14% (95% CI 6.7-27); ciprofloxacin 9.2% (95% 
CI 3.2-23.9); multidrug resistance (MDR) 13.1% (95% CI 6.9-23.6); ESBL-producer 14.0% 
(95% CI 5.3-35.0) and AmpC-producer 7.7% (95% CI2.5-21.1). There was significant 
variation by practice suggesting practice factors are potentially important.  Among MDR 
isolates ciprofloxacin and CAPA resistance featured frequently.  The blaCTX-M-15 and blaTEM-158 
(inhibitor resistant) gene variants were the two most frequently identified ESBL genes.  
Among environmental samples similar resistance trends were observed in isolates to those 
isolated from faecal samples.  Resistant isolates were more likely to be found in outside 
walking areas and ward floors than tables and keyboards.  Neurosurgery and soft tissue 
surgery cases were generally at increased risk of several resistance outcomes compared to 
medical and orthopaedic  cases.  Use of fluoroquinolones and CAPA were associated with 
increased risk of a number of resistance outcomes, including ESBL production, and isolation 
of environmental AmpC-producers was associated with increased risk of CAPA resistance.  
Increased hospitalisation time was also identified as a risk factor for some outcomes. 
This study shows the presence of high rates of carriage of important AMR types in UK 
companion animal hospitals.  The environment is likely to play an important role in the 
acquisition and spread of these bacteria within a hospital.  Use of antimicrobials, 
hospitalisation, case type and individual practice were shown to be important risk factors 
for AMR acquisition.   
3 
 
Chapter 1 
General Introduction and Literature Review 
Since their discovery in 1928 antimicrobials have been used widely in human and 
veterinary medicine with great success.  The first widespread use of antimicrobials was in 
the 1940’s, resistance in bacteria previously sensitive to antimicrobials in use was reported 
in the same decade.  It is widely acknowledged that the use of antimicrobials exerts a 
selection pressure on a population of sensitive bacteria which drives the evolution of 
resistant phenotypes.  The link between antimicrobial use and the development of 
resistance is well established and documented in many studies.  In humans a link has been 
shown between the prescription of antimicrobials in a primary care setting and the 
subsequent development of resistance to those antimicrobials in the individuals concerned 
(Costelloe et al., 2010).  A link has also been shown between the volume of antimicrobial 
use and the level of resistance in populations (Austin et al., 1999).  The use of certain 
classes of antimicrobial (tetracyclines, cephalosporins and quinolones) in human hospital 
patients has also been shown to be independently associated with the development of 
resistance in E. coli (Batard et al., 2013).  In animals the use of antimicrobials has also been 
linked to an increased levels of resistance in bacteria isolated from food producing animals 
(Mayrhofer et al., 2006, Oliver et al., 2011, Seiffert et al., 2013b, Cabello et al., 2013, 
Ludwig et al., 2013).  Ludwig et al (2013) found an association between the use of beta 
lactams, tetracyclines and quinolones and the isolation of resistant bacteria from the 
faeces of pigs (Ludwig et al., 2013).   
Though any use of an antimicrobial is likely to contribute to the development of resistance 
(AMR) inappropriate use, such as treating with a sub optimal dose, use of an inappropriate 
class of antimicrobial for the pathogen concerned, mis-timing of doses or inadequate 
length of treatment are likely to have a greater influence due to a reduced efficacy of the 
drug whilst still exerting a selection pressure on resident bacteria (Holloway, 2011).  In 
humans antimicrobial prescription patterns have been linked to increased colonisation of 
patients with resistant organisms (Hurford et al., 2012).  Inappropriate use of antimicrobials 
has also been linked to poorer clinical outcomes in many clinical conditions in humans 
(Kang et al., 2013, Moreira et al., 2013, Vardakas et al., 2013).  It is not unreasonable to 
assume that the drivers and consequences of antimicrobial resistance in animals are similar 
to those seen in humans.   
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Bacteria can resist the action of antimicrobial agents by three broad methods (Clarke, 
2006).  In many cases there are stringent requirements for the interaction of a drug with its 
target site.  Resistance to an antimicrobial agent can be conferred by mutations which alter 
the structure of these target sites - ribosomal binding sites (e.g. chloramphenicol, 
tetracyclines), enzymes involved in the synthesis and function of nucleic acids (e.g. 
quinolones) and enzymes involved in the synthesis of bacterial cell walls (e.g. β lactam 
antimicrobials).  Altering the structure of this site reduces the ability of the antimicrobial to 
bind and therefore reduces its efficacy.   
Another way resistance to antimicrobials can be conferred is by the prevention of the drug 
from reaching an effective concentration at its site of action either by preventing its 
transport across the cell membrane or by actively pumping the drug out of the bacterial 
periplasmic space (Mallea et al., 1998, Clarke, 2006).  Reducing the permeability of the cell 
wall or cell membrane can be achieved by a reduction in the number of transmembrane 
proteins called porins which allow the movement of water soluble molecules into the cell.  
The active removal of drugs from the bacterial cell can be achieved by active efflux pumps 
in the cell membrane.  These mechanisms are less specific than the alteration of the 
structure of a specific target site and are more likely to confer multi-drug resistance (MDR) 
phenotypes, indeed MDR pumps exist which are active for a number of different substrates 
with different chemical properties (Clarke, 2006). 
The third broad method by which AMR can be achieved is via the active destruction or 
alteration of the structure of the antimicrobial molecule itself in such a way as to render it 
ineffective.  An example of this is the hydrolysis of the beta-lactam ring of penicillins and 
cephalosporins by beta lactamase enzymes which can be produced by a variety of 
pathogenic bacteria (Clarke, 2006).   
The most obvious and significant consequence of an increase in antimicrobial resistance for 
both human and veterinary patients is either the delay of effective treatment or, in the 
worst case scenario, complete treatment failure.   Both of these can be potentially very 
serious for the patient leading to increased morbidity and mortality (Merz et al., 2010).  
One estimate places the healthcare costs of antimicrobial resistance in the US to be $20bn 
and the costs to society in lost productivity to be $35bn (Smith and Coast, 2013).  The costs 
of managing human in-patient infections caused by MDR organisms (including extended 
spectrum beta lactamase (ESBL)) producing Enterobactericeae) have been shown to be 
significantly higher than the treatment of those caused by non MDR organisms (Tansarli et 
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al., 2013).  Though it is difficult to judge the exact economic impact it is likely to be high.  In 
veterinary patients the treatment costs of MDR infections are likely to be similarly 
increased.  Whether this cost would be met by the owner or practice in the case of 
nosocomial infection is unclear.  There is also potential for significant disruption of income 
due to a need to close wards and clinics as shown by an outbreak of MDR salmonellosis in a 
large animal veterinary teaching hospital in the US, where the total loss was estimated at 
$4.12 million (Dallap Schaer et al., 2010).  Added to these potential economic burdens is 
the problem of public image which is very important in the veterinary industry, given the 
great publicity given to AMR infections in people the potential for loss of business could be 
great.   
Acquisition and transfer of resistance genes 
Antimicrobial resistance arises as a result of random mutations in the genetic code.  These 
mutations can then act in several ways as described above, to reduce the efficacy of an 
antimicrobial against the organism.  Although mutation rates are low the high rate of 
replication of bacteria means emergence of resistant mutants can occur quickly.  The use of 
antimicrobials favours the emergence and multiplication of resistant mutants by promoting 
the survival of resistant mutants or inducing the expression of existing resistance genes 
(Clarke, 2006).   
One of the biggest problems with the spread of AMR is the plasmid-mediated horizontal 
transfer of resistance genes between bacteria of the same generation, in some cases this 
can occur between different species and genera.  This horizontal transfer of genes greatly 
increases the potential for resistance spread.   
The main method of horizontal resistance transfer is via conjugation, where genes on 
plasmids are transferred from donor to recipient bacteria via an intercellular bridge (Clarke, 
2006).  It is well established that this can occur between different bacterial species 
(Rayamajhi et al., 2009, Clarke, 2006, Bourgeois-Nicolaos et al., 2006).  Commensal E. coli in 
animals have been shown to possess a number of transferrable elements which can confer 
AMR (Karczmarczyk et al., 2011, Batchelor et al., 2005a) and it has been shown that gene 
transfer readily occurs between E. coli located in the intestinal tract of humans (Karami et 
al., 2007), mice and chickens (Hart et al., 2006).  In addition plasmid mediated gene 
transfer has contributed to the dissemination of ESBL’s in Enterobacter species (Sidjabat et 
al., 2007) and E. coli (Sun et al., 2010) isolated from pets.  E. coli are good recipients of 
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mobile genetic elements, combined with its commensal status in many animal species it is 
regarded as a good indicator of the exposure of an animal to resistant organisms and 
antimicrobials (Martins et al., 2013).  There is also concern that E. coli can act as a reservoir 
of resistance, acting as a source of resistance genes to other bacteria which may be more 
pathogenic (Hart et al., 2006). 
Beta-lactam antimicrobials 
The most famous member of the beta-lactam group is penicillin, discovered by Fleming in 
1928.  Members of the beta-lactam group are characterised by the presence of a beta-
lactam ring in the molecular structure.  The principle members of the beta-lactam group of 
antimicrobials are the penicillins, cephalosporins, carbapenams and monobactams (Poole, 
2004).  Penicillins contain 6-aminopenicillic acid (6APA) and many natural and synthetic 
penicillins exist with different side chains added conferring different properties.  
Cephalosporins contain a nucleus of 7-aminocephalosporanic acid (7ACA) which can be 
modified to give different properties (Kong et al., 2010).  They are often grouped into 
generations.  With each generation there is an increase in activity of cephalosporins against 
Gram negative organisms, this is often at the expense of efficacy against Gram positive 
organisms, however fourth generation drugs are effective against both and are viewed as 
broad spectrum agents.  Third generation cephalosporins are widely used to treat hospital 
acquired infections caused by Enterobacteriaceae (El Salabi et al., 2013).    
Beta-lactam antimicrobials work by inhibition of cell wall formation by entering the 
periplasmic space via porin channels and targeting enzymes involved in its synthesis called 
penicillin binding proteins.  This results in the cell swelling and lysis (Siu, 2002).   
Beta-lactam antimicrobials are commonly used in human and veterinary medicine.  In 2010 
penicillins were the most commonly used antibiotic in human medicine in the community 
in European countries (ECDC 2010).  In ten of twenty six countries, the penicillins 
accounted for at least 50% of total antimicrobial consumption in the community and in 
some cases was a lot higher, the median defined daily dose (DDD) for the penicillins was 
8.9 per 1000 individuals.  The most commonly used penicillins across Europe were 
amoxycillin and amoxycillin-enzyme inhibitor combinations.  Broad spectrum penicillins 
were the most commonly used penicillin subgroup in the UK.  The use of cephalosporins in 
human medicine is substantially lower in the 2010 survey with a median DDD (for non-
penicillin beta-lactams) of 1.6 per 1000 individuals across Europe.  Second generation 
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cephalosporins were the most commonly used type across Europe though in the UK the 
most commonly used type was first generation (ECDC, 2010).   
The vast majority of veterinary antimicrobials sold in Europe are sold for use in food 
producing animals (FPA) (including horses) with premixes and oral powders making up the 
majority of pharmaceutical formulations.  Penicillins are commonly used in FPA’s making up 
19% of sales (these measurements are by ton of active ingredient rather than by animals 
treated) in the UK (as opposed to 23% across Europe).  The use of cephalosporins is much 
lower making up 0.5% of total sales (0.2% first and second generation and 0.3% third and 
fourth generation) in the UK with a similar picture across Europe.  In the UK veterinary 
antimicrobials in tablet form (seen as the best estimate for use in companion animals) 
made up 2.8% of sales.  Across Europe there is a similar picture with the maximum 
proportion of tablets sold being 13.3% (in Finland).  Across Europe the most commonly sold 
antimicrobials in tablet form are penicillins (44% total sales) and first and second 
generation cephalosporins (30% total sales).  The trend in the UK follows these proportions 
(ESVAC, 2010).  From these reports it is clear that penicillins are widely used across Europe 
in humans, food producing animals and companion animals.  This picture suggests a 
relatively high level (by proportion) of cephalosporin use in companion animals.  Beta-
lactam antimicrobials are the most commonly prescribed antimicrobial in UK companion 
animal practice (Radford et al., 2011) which appears to concur with the overall sales 
figures.   
Beta-lactamases 
The main resistance mechanism bacteria have developed against beta-lactam 
antimicrobials is the production of beta-lactamase enzymes.  The amide bond in the beta-
lactam ring is attacked by a serine residue at the active site of the enzyme.  Ultimately the 
beta-lactam ring is hydrolysed destroying the antimicrobial molecule, the active enzyme is 
regenerated and is free to attack other beta-lactam molecules (Sykes and Matthew, 1976, 
Siu, 2002).   
To date more than 500 beta lactamases have been reported.  The level of activity against 
different substrates (antimicrobial agents) varies between these types.  Beta-lactamases of 
the enzyme families TEM and SHV have been reported in Enterobacteriaceae for a number 
of decades, these confer resistance to amino-penicillins and first generation 
cephalosporins.  Genes encoding beta lactamases are often found on plasmids and are 
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therefore readily exchanged between bacteria and as a result are widely disseminated 
(Pfeifer et al., 2010).  These genes can be located on plasmids alongside genes which confer 
resistance to different antimicrobials (e.g. fluoroquinolones, tetracyclines etc.) thus the 
transfer of one plasmid between bacteria can potentially confer resistance to a wide range 
of antimicrobials (not just beta-lactams) (Hawkey and Jones, 2009).    
Use of extended spectrum cephalosporins in the 1980’s has driven the emergence of more 
resistance by driving the development of new variants of TEM/SHV beta lactamases which 
have an extended spectrum of activity (ESBL’s) with mutations allowing them to attack the 
oxymino-cephalosporins and confer greater activity against ceftazidime.  Another type of 
ESBL commonly found in Enterobacteriaceae are members of the CTX-M enzyme family.  
They confer a similar phenotype as TEM and SHV ESBL’s, but are likely to have transferred 
from members of the Kluyvera genus on mobile genetic elements probably in response to a 
selection pressure exerted by the use of antimicrobials.  The name CTX-M is a reference to 
the normally increased activity of these enzymes against cefotaxime compared to 
ceftazidime (Jacoby and Munoz-Price, 2005, Pitout and Laupland, 2008).  There is a lot of 
heterogenicity in members of the CTX-M family in Enterbacteriaceae which probably 
reflects the fact that gene transfer has occurred in multiple separate events in the past 
(Bonnet, 2004).  In addition the use of carbapenams has led to the emergence of 
carbapenamases which can confer resistance to all beta-lactams (Pfeifer et al., 2010).  
Production of these different ESBL’s extends the spectrum of resistance of bacteria in a 
variety of similar phenotypes though they remain susceptible to beta lactamase inhibitors 
(e.g. clavulanic acid).  Table 1 shows summarises the classification scheme for beta-
lactamases. 
E. coli can also gain AmpC enzyme mediated resistance to cephalosporins.  The blaAmpC 
genes were first reported in 1989 (Bauernfeind et al., 1989), they are present widely in 
Enterobacter species and subject to complex regulation, they are generally not expressed 
unless derepression occurs.  Resistance occurs due to an increased amount of AmpC 
present, this can happen either by generation of more efficient blaAmpC gene promoters by 
mutation of the promoter region, or by acquisition of more blaAmpC genes from other 
bacteria via mobile genetic elements.  AmpC production confers broad spectrum resistance 
to cephalosporins and significantly are unaffected by beta lactamase inhibitors (Pfeifer et 
al., 2010).   
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Table 1: Classification scheme for beta-lactamases modified from Pfeifer et al, 2010. 
Serine beta-lactamases β lactamase class β lactamases Examples Resistance 
phenotype 
A Broad spectrum TEM 1 and 2, SHV 1 and 
11 
Ampicillin, 
cephalotin 
ESBL (TEM) TEM-3 and 52 Penicillins and 
third gen 
cephalosporins 
ESBL (SHV) SHV-5 and 12 
ESBL (CTX-M) CTX-M-1, 14 and 15 
Carbapenemases KPC GES SME All beta-lactams 
C AmpC (chromosomal) AmpC Cefamycins and 
third gen 
cephalosporins 
D AmpC (plasmid) CMY 
Broad Spectrum Beta 
Lactamases 
OXA-1 and 9 Oxacillin, 
ampicillin and 
cephalotin 
ESBL (OXA) OXA-2 and 10 Pencillins and 
third gen 
cephalosporins 
Carbapenemases OXA-23 All beta lactams 
Metallo-beta-lacatmases B Carbapenemases VIM, IMP 
 
Extended Spectrum Beta-Lactamases in Humans 
The first ESBL’s to be described were variants of the SHV and TEM beta lactamases which 
had mutations conferring extended spectrum of activity as described above (Philippon et 
al., 1989).  The CTX-M and AmpC enzymes emerged later in the decade (Bauernfeind et al., 
1989, Bauernfeind et al., 1990).  The emergence of these ESBL’s is likely to have been 
driven by extensive use of second and third generation cephalosporins in the 1980’s.   
ESBL-production is now found in bacteria throughout the world though there is significant 
variation in prevalence in human populations between regions of the world.  Prevalence of 
ESBL production in isolates from human hospital-acquired infections from different areas of 
the world is shown in table 2. 
Table 2: Prevalence of ESBL-producers in E. coli and Klebsiella pneumoniae isolates from human hospital 
acquired infections in different areas of the world (Reinert et al., 2007) 
 Latin America Asia/Pacific Rim Europe North America 
E. coli 13.5% 12% 7.6% 2.2% 
K. pneumoniae 44% 22.4% 13.3% 7.5% 
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Production of CTX-M enzymes is also a significant problem in the community, while TEM 
and SHV types are more associated with hospital-associated infections than community 
acquired infections (Pitout and Laupland, 2008), there is potential for crossover with 
community acquired infections becoming severe enough to warrant hospitalisation.  Of 
particular concern in the community is the presence of CTX-M enzymes in E. coli which is 
common in the gastro-intestinal tract of most humans.  The blaCTX-M genes have been found 
on plasmids (Accogli et al., 2013) and, given the potential for transfer of AMR between 
bacteria via plasmids, there is great concern that spread of CTX-M mediated resistance can 
occur in this way.   
Risk factors for community acquired infections by ESBL-producing organisms in humans 
have been identified as: existing diabetes mellitus; increased age; female gender; recurrent 
urinary tract infections; residence in a nursing home; renal/liver pathology and recent 
treatment with beta-lactam or fluoroquinolone antimicrobials (Soraas et al., 2013, Pitout 
and Laupland, 2008).  Risk factors identified in a hospital setting are: length of 
hospitalisation; severity of illness; urinary catheterisation; length of stay in intensive care 
unit; ventilation; multiple co-morbid conditions; non-home residence and previous 
treatment with antimicrobials (Pitout and Laupland, 2008, Hayakawa et al., 2013, Jacoby 
and Munoz-Price, 2005). 
Aside from the obvious impacts on patient morbidity and mortality, healthcare provision 
and costs the production of ESBL’s frequently co-exists with a phenotype of multi-drug 
resistance (e.g. fluoroquinolones) which blaESBL genes do not confer (Schultsz and Geerlings, 
2012).  Surveys from several countries show that co-resistance to non-beta-lactamase 
antimicrobials among ESBL-producing bacteria in the community is common (Pitout and 
Laupland, 2008, Pitout et al., 2007).   Of particular interest is that ESBL-producing bacteria 
in a community healthcare setting (as opposed to a hospital) in the UK were identified to 
be more likely to be multi-drug resistant than those which were not ESBL producers 
(Woodford et al., 2004).   
The blaCTX-M gene has rapidly become the most widely disseminated and frequently isolated 
of the beta-lactamase genes.  There are many different types of CTX-M enzyme, some of 
which occur in specific regions but the most important is the CTX-M-15 which is found 
worldwide (Pitout and Laupland, 2008).  Several studies have recently identified blaCTX-M as 
the most common ESBL gene.  In a case-control study in a large medical centre in the USA 
85% of ESBL-producers were blaCTX-M positive with blaCTX-M-15 being the most prevalent type.  
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The presence of a blaCTX-M gene was also associated with an increased likelihood of multi-
drug resistance (Hayakawa et al., 2013).  In Canada, 64% of ESBL-producing E. coli isolated 
from the community were identified as CTX-M producers, here the most prevalent type 
was CTX-M-14, however this was closely followed by CTX-M-15 and peaks of each types 
occurred at different time periods within the duration of the study with the peak of CTX-M-
15 being towards the end of the study.  CTX-M producers were also found to be 
significantly more resistant to fluoroquinolones (Pitout et al., 2007).  In a study of E. coli 
isolated from urinary tract infections (UTI’s) over a wide geographical area in Morocco the 
overall prevalence of ESBL producers was relatively low at 4.1%, the most commonly 
produced ESBL type was CTX-M though SHV and TEM types were also isolated.  Other 
recent studies in Swiss primary care patients (Nuesch-Inderbinen et al., 2013), hospitalised 
Indian neonates (Roy et al., 2013), hospitalised children in Gabon (Schaumburg et al., 
2013), urinary isolates from the community in Morocco (Barguigua et al., 2013) and even a 
remote community of Amerindians in French Guiana (Woerther et al., 2013) have also 
found CTX-M enzymes to be the most commonly produced ESBL.  These studies 
(summarised in table 3 below) show that blaCTX-M is the predominant ESBL gene found in 
many different geographic areas and clinical settings.    
Table 3: Summary of selected recent studies in different regions and populations where blaCTX-M was detected 
at a higher prevalence than other ESBL types 
Study Study subjects CTX-M prevalence Other ESBL prevalences 
(Nuesch-Inderbinen et al., 
2013) 
Swiss primary care patients 13/15 ESBL producing 
isolates were positive for 
blaCTX-M 
1/15 blaSHV-12 
3/15 blaCMY-2 
(Roy et al., 2013) Hospitalised Indian neonates 100% of ESBL producers 
positive for blaCTX-M 
blaSHV 5% 
blaTEM 52% 
blaOXA-1 81% 
(Woerther et al., 2013) Remote Amerindian 
community in French Guiana 
100% of ESBL producing 
isolates positive for blaCTX-M 
(in the 2010 isolates) 
None (2010 isolates) 
(Schaumburg et al., 2013) Hospitalised children in 
Gabon 
blaCTX-M 86.7% (of ESBL 
producing) 
blaTEM 56.7% 
blaSHV 6.7% 
(Barguigua et al., 2013) Moroccan community isolates 
(from UTI’s) 
Highest CTX-M prevalence 
was CTX-M-15 at 63% of ESBL 
producing isolates 
Most prevalent non-CTX-
M ESBL gene was blaSHV-
12 at 12%  
 
ESBLs in Food Producing Animals 
ESBL production has been found in food producing animals in a variety of studies in various 
regions of the world.   
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It has been shown that the intestinal tract of the chicken can act as a reservoir for ESBL-
producing E. coli (Costa et al., 2009).  In 2013 a longitudinal study of broilers in Germany, 
revealed high levels of ESBL and AmpC production in E. coli from both the broilers and the 
environment.  Although levels did increase over time there was a high detection rate from 
both the environment at the onset of the study and 1 day old chicks suggesting that the 
ESBL-producers found were either brought in with hatched chicks or due to contamination 
from the environment (Laube et al., 2013).  Many other studies have reported the presence 
of relatively high levels of ESBL-producing bacteria in poultry flocks from Switzerland (Geser 
et al., 2012), Tunisia (Ben Sallem et al., 2012), Holland (Leverstein-van Hall et al., 2011) and 
the UK (Horton et al., 2011).  The blaCTX-M and blaAmpC genes have also been found on British 
turkey farms (Randall et al., 2013) indicating that the problem is not restricted to chickens.  
A study in 2012 comparing a flock which had feed containing antimicrobials with a flock 
that did not found no difference in ESBL-producing bacteria levels, indeed in a separate 
part of the study a flock fed antimicrobials (salinomycin, gentamicin and enramycin)  and 
kept in a controlled environment did not develop ESBL-producer carriage suggesting that 
environmental contamination plays at least a partial role in the entry of ESBL-producers 
into a flock (Hiroi et al., 2012).  ESBL-producers in poultry are of particular concern from a 
public health point of view as a number of studies have identified not only a high level of 
contamination of chicken meat on sale but also genetic similarities between the ESBLs 
found within poultry flocks, on meat and circulating within the human population 
(Leverstein-van Hall et al., 2011, Laube et al., 2013, Kola et al., 2012, Stuart et al., 2012, 
Overdevest et al., 2011).  Some of these studies also identified high levels of co-resistance 
to non-beta-lactam antimicrobials in these ESBL-producers (Overdevest et al., 2011, Stuart 
et al., 2012).  In Spain high levels of CTX-M producing E. coli with associated high levels of 
quinolone resistance have also been found in turkey meat on sale (Egea et al., 2012).  
These findings are of great concern and indicate that it is highly likely that ESBL producers 
are circulating between human and poultry populations.   
ESBL producing E. coli have also been frequently isolated from cattle and pigs.  In studies in 
the UK and Switzerland comparing levels across species cattle and pigs have had a much 
lower detection rate than that of poultry with pigs having a slightly increased detection 
rate over cattle.  In these studies the most common type of ESBL gene identified was blaCTX-
M (Horton et al., 2011, Geser et al., 2012).  In Korea pigs have been found to have very high 
levels of ESBL-producers compared to very rare isolation rates from cattle (Tamang et al., 
2013).  In Tunisia a study of healthy food producing animals found high levels of ESBL-
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producers in poultry and none in cattle (Ben Sallem et al., 2012).  In a recent study of wild 
hunted deer in Switzerland extremely low levels of ESBL-production were found (Stephan 
and Hachler, 2012) suggesting that farmed animals are more likely to carry ESBL-producers 
than wild animals.   
Risk factors identified for the occurrence of blaESBL genes in E. coli isolated from food-
producing animals (FPAs) are generic antimicrobial use and specific cephalosporin use 
while international trade is a risk factor for dissemination of these genes.  It has been 
proposed that the use of antimicrobials and particularly cephalosporins in FPA’s should be 
reduced in order to reduce these isolation levels (Liebana et al., 2013).  In a study on 
German dairy and beef farms the use of antimicrobials was identified as a risk factor for the 
detection of blaESBL, interestingly most farms in this study did not use beta lactam 
antimicrobials and the use of non beta-lactam antimicrobials was proposed to be selecting 
for ESBL-producing bacteria due to co-resistance to different antimicrobial classes (Schmid 
et al., 2013).  In Denmark the levels of extended spectrum cephalosporinase isolation from 
pigs was significantly reduced after stopping the use of cephalosporins further implicating 
the use of these antimicrobials in mediating the presence of ESBL producers in food 
producing animals (Agerso and Aarestrup, 2013).   
The detection of high levels of ESBL-producers in FPA’s is of particular concern from a 
public health point of view with evidence for transmission between these animals and 
humans.  In Europe poultry are associated with particularly high levels of ESBL-producer 
isolation with pigs and cattle having lower isolation rates.  Though rates are lower in cattle 
and pigs they are still cause for concern as high density shedders have been identified 
(Horton et al., 2011) in these species with potential for the contamination of human food 
supplies.   
Of additional concern is the potential link between FPA’s and companion animals where 
they are fed raw meat diets.  Antimicrobial resistance has been demonstrated in bacteria 
from raw meat fed to dogs (Finley et al., 2008) and it has been shown that dogs fed a raw 
meat diet are more likely to have Salmonella species isolated from their faeces (Leonard et 
al., 2011).  These studies raise the possibility of resistant bacteria from food producing 
animals  colonising dogs which, given closer contact with humans and human living 
environments may have greater potential to transmit the same bacteria to humans.  The 
isolation of ESBL-producing E. coli from raw meat mentioned above suggests that this could 
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be a route for the colonisation of companion animal gastro-intestinal tracts with ESBL-
producing E. coli.   
ESBLs in Companion animals  
ESBL producing E. coli are being found frequently in companion animals throughout the 
world.  This is of concern as a significant proportion of pets come into close contact 
humans whether it be indirect (e.g. via food preparation areas) or direct (Westgarth et al., 
2008).  This contact with pets is likely to be the closest contact with animals most of the 
human population will have and the potential for interspecies transmission of both 
commensal and pathogenic bacteria is a concern.  There is also a clear implication for 
animal welfare if treatment of infections is prolonged or not possible at all.     
Antimicrobials are frequently used in companion animal practice – a study of dogs 
attending a veterinary hospital in the USA found that 56% had received treatment with an 
antimicrobial in the last 12 months, with 40% being treated with beta-lactam type 
antimicrobials (Baker et al., 2012).  In the UK the prescription of antimicrobials for pets 
attending veterinary clinics for the investigation of disease is common.  A study in the UK 
found that non routine consultations involved the prescription of a systemic antimicrobial 
in 35.1% and 48.5% of the time for dogs and cats respectively.  The three most frequently 
prescribed classes being clavulanic acid potentiated amoxicillin (CAPA), amoxicillin and 
cefovecin.  Beta-lactam antimicrobials made up 76% of all the antimicrobials prescribed 
(Radford et al., 2011).  Frequent use of beta-lactams was also shown in a survey of 
companion animal practitioners in the UK by Hughes and others (2011), where 
practitioners were presented with four potential clinical scenarios and asked to give 
information on likely prescriptions.  In three out of four scenarios the most commonly 
prescribed antimicrobial was CAPA and in the remaining scenario it was cefalexin.  The 
study also demonstrated that a proportion of vets are likely to prescribe sub-optimal doses 
for CAPA (4%), amoxicillin (8%) and cefalexin (7%), in addition to other non-beta-lactam 
antimicrobials (Hughes et al., 2012).  These studies demonstrate the frequent use of beta-
lactam antimicrobials  in UK veterinary practice and are reinforced by the tablet sales data 
mentioned previously (ESVAC, 2010).  This is likely to be exerting a selection pressure for 
resistance to these antimicrobials.     
In the UK a study of faecal samples from horses across the country in the community 
showed widespread resistance to antimicrobials.  Of the horses samples 69.5% had E. coli 
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resistance to at least one antimicrobial.  ESBL-producing E. coli were however detected at a 
much lower rate of 6.3% (Maddox et al., 2012).  A recent study investigating the effect of 
hospitalisation on faecal carriage of antimicrobial resistant E. coli found that the levels of 
resistance to most classes of antimicrobial were significantly increased over the period the 
horse was hospitalised.  At day one of hospitalisation 35% of samples were found to 
contain MDR E. coli, by day 7 this proportion had increased to 80%.  Treatment while in 
hospital, age and breed were not associated with increased risk.  The reason for admission 
was investigated and acute gastrointestinal (medical and surgical) and musculoskeletal 
cases were associated with increased risk (Williams et al., 2013).  Maddox et al (2011) also 
demonstrated high levels of MDR and ESBL-producing E. coli in the faeces of hospitalised 
horses with an increased risk of isolation during hospitalisation (Maddox et al., 2011).  
These studies suggest that a widespread low level of AMR exists in horses in the 
community in the UK.  Levels of AMR and ESBL-producer isolation are significantly higher in 
hospitalised horses with the risk of isolation of these organisms rising with length of 
hospitalisation.    
A cross sectional study of 183 healthy dogs in the community in the UK by Wedley and 
others (2012) found carriage of AMR in 29% and MDR in 15% of the dogs studied.  ESBL 
production was detected at low levels with one isolate testing positive for ESBL production 
using phenotypic methods (Wedley et al., 2011).  The finding of a relatively high level of 
resistant and particularly MDR in dogs in the community is cause for concern from both an 
animal and human health perspective.   
In Tunisia a study of healthy dogs and cats attending a private veterinary clinic for 
grooming or vaccination collected eighty faecal samples and tested for the presence of 
AMR E. coli.  Animals were not hospitalised and were only included if they had received no 
prior treatment with antimicrobials in the previous three months.  Fourteen out of eighty 
samples contained E. coli resistant to cefotaxime, of these thirteen E. coli isolates were 
found to be ESBL producers.  All of these ESBL producers were positive for blaCTX-M-1which is 
the most common ESBL gene found in commensal E. coli from FPA’s and humans in Tunisia, 
blaTEM and blaCMY genes were also detected (Ben Sallem et al., 2013).  This study 
demonstrates the presence of ESBL-producers in companion animals which were not 
hospitalised and which had not been treated with antimicrobials recently, suggesting 
circulation in a community setting.   
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A study carried out in China looked at the relative levels of ESBL producing E. coli in healthy 
and unwell pets.  Samples (predominantly faecal) were taken from healthy pets from pet 
shops and visiting veterinary hospitals and from those undergoing treatment.  Animals 
undergoing treatment were more likely to have ESBL producing E. coli isolated from their 
samples than healthy animals with 54.5% of isolates from unwell pets yielding ESBL 
producers compared to 24.5% from healthy animals.  In total the approximate proportion 
of ESBL-producing isolates was 40% which reflects the situation in the human population of 
the area of China where the study was carried out.  The most common ESBL gene identified 
was blaCTX-M.  The most frequent types being blaCTX-M-14 and blaCTX-M-55.  It was suggested in 
the study that the use of amikacin in some of the animals co-selected for ESBL production 
due to the presence of different resistance genes on the same plasmids and that horizontal 
spread among the pet population was mediated by these plasmids (Sun et al., 2010).  This 
finding of relatively high levels of ESBL producers in healthy pets not undergoing treatment 
is a concern and indicates that they are also circulating in healthy pets, rather than just in 
those undergoing treatment, and shows the great potential for community acquired 
infections with ESBL-producing E. coli.  The increased isolation rates from unwell animals 
undergoing treatment could be a reflection of the use of antimicrobials in these animals or 
potentially increased exposure to ESBL producing organisms in a hospital environment.   
In South Korea a study of E. coli isolates from rectal swabs of dogs found high levels of 
blaCTX-M and blaAmpC.  Of sixty three isolates twenty one were found to be positive for blaCTX-
M fifteen were found to be positive for blaAmpC and twelve were found to be positive for 
both blaCTX-M and blaAmpC.  All twenty four of these CTX-M/AmpC producing isolates were 
found to be ciprofloxacin resistant also.  Similar mutations were found in gyrA and parC 
genes from isolates from dogs as are found in the human population suggesting a similar 
genetic background.  This study also found identical serotypes of E. coli in one veterinary 
hospital suggesting a localised clonal outbreak within that hospital.  In most isolates the 
blaESBL genes were found to be localised on plasmids lending weight to the theory that 
spread is greatly facilitated by the horizontal transmission of these mobile genetic elements 
(So et al., 2012).  This study indicates that there may be high levels of ESBL/AmpC 
producing E. coli in Korean veterinary hospitals.  The finding that all ESBL/AmpC producers 
were ciprofloxacin resistant indicates that co-resistance to different antibiotic classes is a 
very real potential problem for veterinary hospitals.   
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Also in South Korea a study of E. coli isolates from stray dogs isolated ESBL and AmpC 
producer phenotypes at a relatively low rate – 1.9% and 3.5% respectively.  All the isolates 
with ESBL-producer phenotypes tested positive for blaCTX-M type ESBL genes with blaCTX-M-14 
being the most common type (Tamang et al., 2012)  While the prevalence was low they do 
indicate the presence of the blaESBL/blaAmpC genes within the stray dog population in Korea 
and indicate the potential for community as well as hospital acquired infections.  Nam and 
others (2010) in a different publication from the same study compared the faecal carriage 
of MDR E. coli in dogs from stray animal shelters to that of dogs hospitalised in small animal 
clinics across the country.  Isolation of MDR E. coli from the faeces of animals from 
veterinary clinics was higher than that from dogs housed in shelters (48% of isolates were 
MDR from clinics as opposed to 32%).  Cefotaxime resistance was also higher (2.4% and 
3.9% respectively) in isolates from hospitalised animals as opposed to those in shelters.  It 
was also found that more isolates from shelters were sensitive to all antimicrobials tested 
than those from hospitalised animals.  Younger animals were found to have higher levels of 
resistance among faecal bacteria than older animals (Nam et al., 2010).  These studies 
indicate that ESBL and AmpC-producers are present in the faeces of both hospitalised and 
non hospitalised dogs in South Korea with a suggestion that hospitalisation is associated 
with an increased risk of MDR E. coli isolation which may reflect environmental 
contamination or a population of dogs more likely to have been exposed to antimicrobials.   
In Europe Franiek and others (2012) in Germany estimated the prevalence of faecal 
carriage of ESBL-producing E. coli in dogs and cats to be 5.3%.  Most of the positive samples 
were from animals housed in shelters.  The most commonly isolated blaESBL type was the 
blaCTX-M-1 group with groups 2 and 9 also being detected (Franiek et al., 2012).  A recent 
study in Germany found the most common blaESBL gene isolated from diseased animals to 
be blaCTX-M-1 (Schink et al., 2013).  A similar low prevalence (2.5%) of ESBL-producing 
bacteria in community based animals was detected in a study in Switzerland, prior 
treatment with antimicrobials was identified as a risk factor for ESBL-producer carriage 
(Korzeniewska and Harnisz, 2013).  
In Holland in 2012, Dierikx and others tested 2700 clinical isolates (mostly from urine 
samples) of Enterobacteriaceae from dogs, cats and horses for resistance to 
ceftiofur/cefoquinome.  Samples were collected from a wide geographical area.   
Resistance was found in 3%, 4% and 8% of isolates from dogs, cats and horses, respectively.  
The majority of these isolates (74%) were MDR and in addition to ceftiofur/cefoquinome 
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resistance most showed resistance to cefotaxime and ceftazidime.  Both blaESBL and blaAmpC 
genes were identified with blaCTX-M-1 being the most frequently found.  All of the isolates 
were from animals with different owners apart from two from two horses with the same 
owner.  No relationship was found between any of the serotypes apart from the two from 
horses with the same owner which were identical suggesting that transmission had 
occurred between these horses (Dierikx et al., 2012).  This study demonstrates the 
presence of ESBL/AmpC producing Enterobacteriaceae in clinical samples and though there 
is no evidence to suggest that they were pathogenic at the time of sample collection their 
presence in potentially pathogenic bacteria is cause for concern and indicates the potential 
for community acquired infections with ESBL/AmpC producing bacteria in companion 
animals. The most commonly found gene (blaCTX-M-1) is also the type most commonly 
isolated from poultry (Dierikx et al., 2010), poultry meat and human patients (Leverstein-
van Hall et al., 2011) in Holland indicating that there may be interspecies transmission.   
Carattoli and others (2005) tested E. coli isolates from healthy and sick animals and from 
necropsies.  In total, 7% of these isolates showed resistance to extended spectrum 
cephalosporins and within these 76% were found to be CTX-M-1 producers.  The blacmy-2 
and blaSHV-12 genes were also detected.  Molecular typing of isolates indicated an absence 
of clonal spread for the most part.  However in one kennel isolates from different dogs 
were similar, suggesting dissemination of the same strain among dogs occupying this 
kennel (Carattoli et al., 2005).   
Huber and others (2013) examined uropathogenic E. coli isolates from dogs and cats in 
Switzerland.  Just under 4% of animals in the study had uropathogenic ESBL-producing E. 
coli in their urine.  High levels of MDR were associated with ESBL-producing strains 
compared to non ESBL producers (again including many non beta-lactam agents).  The ESBL 
genes identified in these animals were blaCTX-M-15 in all four and additionally blaTEM types in 
three (Huber et al., 2013).   In 2010 O’Keefe and others examined 150 isolates from dogs 
and cats where there was evidence of a UTI.  Sixty of these showed evidence of reduced 
susceptibility to cefpodoxime and ceftazidime.  Of these 60, an ESBL-producer phenotype 
was shown in 6 but the presence of an ESBL gene was demonstrated by sequence analysis 
in 11 isolates.  This discrepancy is likely due to the high prevalence of blaAmpC genes (blaCMY-
2) found in this study with 53/60 isolates positive, which can mask ESBL-producer 
phenotypes.  Of the 11 ESBL producers one was identified as an SHV type and 10 were 
identified as CTX-M types, of these 9 were CTX-M-15 producers and 1 was a CTX-M-14 
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producer (O'Keefe et al., 2010).  This was the first report of SHV and CTX-M type ESBL 
production in companion animals in the USA.  The studies by Huber (2013) and O’Keefe 
(2010) demonstrate that ESBL-production can occur in pathogenic as well as commensal 
organisms.  
In Portugal Costa and others (2008) examined the prevalence of AMR in from faecal 
samples of healthy dogs and cats which had not been exposed to antimicrobials in the 
previous 4 months.  The prevalence of resistance was low with most isolates being 
susceptible to all antimicrobials tested.  ESBL production was however detected in two 
isolates from the same dog.  This dog was young and there was no history of exposure to 
antimicrobial agents (Costa et al., 2008).  This was a study of animals with no recent 
exposure to antimicrobials and therefore a low prevalence is not unexpected.  The 
detection of ESBL production in one animal with no history of AM exposure suggests it was 
acquired from the environment or another animal or human though there is no evidence 
for this.      
In the USA, Shaheen and others (2011) examined 944 E. coli isolates from samples from 
companion animals with UTI’s and other infections.  Approximately 6% of these isolates 
showed reduced susceptibility to ceftazidime or cefotaxime and of these approximately 
half were shown to be ESBL producers.  The prevalence of ESBL-producing E. coli causing 
clinical infections in companion animals in this study was 3%.  High levels of resistance to 
other antimicrobials were found in the ESBL producers with all but one exhibiting a MDR 
phenotype.  The prevalence of resistance to enrofloxacin was particularly high among these 
isolates at 92%.  Among the confirmed ESBL producers all isolates were positive for blaCTX-M 
genes and most were positive for blaAmpC genes.  The CTX-M-1 group was found in all of 
these ESBL isolates with CTX-M-15 being found most frequently.  The blaTEM and blaSHV 
genes were also identified.  Genes were identified on plasmids and the genetic 
heterogenicity identified in this study suggests that the dissemination of blaESBL genes in 
companion animals in the USA is not due to a single clonal outbreak and horizontal 
transmission of plasmids is highly likely to play an important role (Shaheen et al., 2011).   
Again this study shows the presence of blaESBL genes in bacteria causing clinical infections in 
the USA (though at a low rate).  The presence of the pandemic CTX-M-15 ESBL subtype at 
high prevalence among the ESBL producers is a public health concern, as are the high levels 
of MDR.   
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Interestingly in Canada in 2009, Murphy and others found low levels of resistance in 
commensal E. coli in 188 healthy dogs and 39 healthy cats.  These animals were presenting 
at veterinary hospitals over a wide area and mostly were from hospitals/practices with 
smaller numbers of animals.  There was no history of exposure to antimicrobials in any of 
the animals.  Some resistance was found but at low levels, no ESBL producers were 
detected and blaAmpC genes were detected in two dogs though the absence of plasmids 
suggested that these were chromosomal in origin (Murphy et al., 2009).  This may suggest 
that levels of resistance are lower in Canada though it is more likely to reflect a reduced 
risk of antimicrobial resistance without antimicrobial exposure.   
A study in Chile by Moreno and others (2008), compared the levels of AMR E. coli in 
commensal E. coli from cats and dogs treated with enrofloxacin (n=15) against those which 
had not (n=15).  Compared to animals not treated those which had been treated had 
broader antimicrobial resistance profiles with high levels of MDR, including resistance to 
drugs used exclusively in humans.  They also had high levels of resistance to cefotaxime, 
ceftazidime and cefpodoxime.  ESBL-production was detected in isolates from five out of 
fifteen treated animals and no untreated animals (Moreno et al., 2008).  This is another 
study demonstrating the impact of antimicrobial exposure on resistance profiles.  The fact 
that the exposure is to a non-beta-lactam agent lends weight to the theory of co-selection 
for MDR.   
Karczmarczyk and others (2011), carried out a study in an Irish university veterinary 
hospital of 72 E. coli isolates which were resistant to three or more different classes of 
antimicrobial. blaAmpC genes were detected in an isolate from a dog while blaCTX-M-2 genes 
were detected in isolates from horses (Karczmarczyk et al., 2011).   
Treatment with antimicrobials was confirmed as a significant risk factor for the recovery of 
MDR E. coli from rectal swabs in a study by Gibson and others (2011) in Australia.  A case 
control study was carried out and treatment with cephalosporins in the 42 days prior to 
hospitalisation was found to increase the risk of MDR E. coli isolation by 5 times and 
treatment with cephalosporins and metronidazole whilst hospitalised was found to 
increase the risk by 5 and 7 times respectively.  Treatment with other antimicrobial classes 
was also found to be a risk factor.  Hospitalisation for more than six days was also a 
significant risk factor independent of any treatment with antimicrobials.  The strains 
isolated were in most cases the same (or similar) as those from extra-intestinal clinical 
infections indicating that pathogenic potential of these commensal organisms (Gibson et 
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al., 2011).  A recent study in Portugal has identified antimicrobial exposure and residence in 
an animal shelter to be risk factors for the isolation of both ESBL and AmpC-producing E. 
coli from dogs (Belas, 2014).  
In summary, ESBL-production has been detected in E. coli isolated from companion animals 
in studies throughout the world (Karczmarczyk et al., 2011, Moreno et al., 2008, Shaheen et 
al., 2011, Costa et al., 2008, Huber et al., 2013, Carattoli et al., 2005) indicating that, like in 
humans, it is a global problem.  The most common type of blaESBL identified in these studies 
is the blaCTX-M type.  This is the case in many different countries indicating that, like in 
humans (Pitout and Laupland, 2008), the CTX-M ESBLs have a worldwide distribution.    
Several studies have suggested a link between antimicrobial exposure and ESBL-producer 
isolation with higher levels associated with exposure and lower levels associated with an 
absence of exposure (Gibson et al., 2011, Moreno et al., 2008, Murphy et al., 2009, Costa et 
al., 2008, Korzeniewska and Harnisz, 2013).  Length of hospitalisation has also been 
implicated as a risk factor for isolation of commensal ESBL-producing E. coli (Gibson et al., 
2011).  ESBL producers have been isolated from both healthy (Murphy et al., 2009, Costa et 
al., 2008, Ben Sallem et al., 2013) and sick (Carattoli et al., 2005, Sun et al., 2010, Shaheen 
et al., 2011) populations indicating that, as with humans (Pitout and Laupland, 2008), they 
are present in the community as well as a hospital setting.  Levels of blaESBL isolation are 
generally higher in animals described as sick or hospitalised (Sun et al., 2010, Nam et al., 
2010) although this may reflect the increased likelihood that a sick or hospitalised animal 
will have been exposed to antimicrobials or environmental contamination.  Multiple studies 
have demonstrated an association between ESBL production and MDR, including resistance 
to antimicrobial classes which are unrelated to beta lactam agents (Moreno et al., 2008, 
Shaheen et al., 2011, Huber et al., 2013, Nam et al., 2010).  This is described in human 
medicine (El Salabi et al., 2013) and lends weight to the theory that co-selection for MDR is 
occurring in companion animals. 
The occurrence of blaESBL genes on plasmids has been shown (Schink et al., 2013) and it has 
been demonstrated that transfer between bacteria can occur in companion animals 
(Karczmarczyk et al., 2011).  This has long been acknowledged to be the case in human 
medicine and it is unsurprising to find the same situation with bacteria from companion 
animals.  As with humans these findings demonstrate the great potential for spread of 
ESBL-mediated resistance among companion animals. 
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The finding of ESBL-producing E. coli in clinical isolates is relatively rarely reported in 
animals.  To date ESBL-producers have been isolated from urinary tract infections (O'Keefe 
et al., 2010), preputial infections, wounds (Steen and Webb, 2007) and bile in a 
cholangiohepatitis case (Timofte et al., 2011).   The potential for ESBL production in 
pathogenic bacteria as opposed to commensal bacterial in companion animals is clearly 
demonstrated by these studies.  In human medicine ESBL production is widely reported in 
clinical isolates.  It is likely that the infrequent reporting in companion animals is a result of 
a lack of surveillance and the true prevalence is likely to be higher.  Indeed it is not 
unreasonable to assume that any infection caused by (or any other organism capable of 
ESBL production given the genes) could potentially involve ESBL producers resulting in 
reduced treatment options and increased morbidity.   
Transfer of ESBL producing and MDR E. coli between companion animals and humans 
The potential transfer of ESBL producing E. coli from companion animals is of great public 
health concern given the close relationship between humans and their pets.  As veterinary 
medicine improves and client expectations increase the companion animal population is 
likely to grow older and the use of antimicrobials in this population more widespread (da 
Costa et al., 2013).  These factors are likely to lead to a higher proportion of the pet 
community being animals with a history of repeated or long term exposure to 
antimicrobials.  Increased exposure to antimicrobials is likely to lead to increased numbers 
of resistant bacteria circulating in the population.   
Several studies have found similarities between ESBL producers found in companion 
animals and those circulating within the human population and food producing animals 
(Dierikx et al., 2012, Wieler et al., 2011, Ewers et al., 2010, So et al., 2012).  In 2008 Pomba 
and others isolated O25-ST131 human virulent E. coli producing CTX-M-15 from the bladder 
of a dog suggesting that transfer between species had occurred (Pomba et al., 2009).  
However the finding of genetic similarities between isolates does not indicate the direction 
of transfer (if indeed transfer has taken place), it is entirely possible that transfer is 
occurring from humans to animals.  
In animals there is some variation in the type of blaCTX-M which is isolated according to 
geographical area with blaCTX-M-1 being the most widely disseminated type in Europe and 
blaCTX-M-14 in Asia.  In humans it is a different picture, blaCTX-M-14 and blaCTX-M-15 are the most 
widely disseminated and commonly detected regardless of the geographical origin.  This 
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suggests that among humans, person to person transmission is probably the most 
important route for transmission of AMR (Ewers et al., 2012).    
There is a lot of potential for close contact between pets and humans within a household 
which can aid the transmission of bacteria between humans and dogs (da Costa et al., 
2013).  Westgarth and others (2008) found a high frequency of behaviours within a 
community of dogs which have high potential for interspecies bacterial transmission.  
These include feeding human food from the hand (62%) or directly from the plate (11%) 
and restriction to the kitchen when alone (24%).  Washing hands after touching a dog was 
only reported by 50% of respondents.   Physical interaction with dogs was reported to be 
frequent in 76% of respondents (Westgarth et al., 2008).   
The potential for transmission of E. coli clones within a household both between people 
and a dog has been demonstrated (Johnson and Clabots, 2006).  In 2013, Martins and 
others investigated the resistance profiles of commensal E. coli isolates from companion 
animals, humans and the environment within a household.  The highest level of MDR was 
found in isolates from the dog and a human which had previously been treated with 
antimicrobials (the dog had a chronic skin condition).  However strains from the 
environment and also from other residents (two humans and a cat) were also found to 
have high levels of MDR with genetic similarities to those from the dog and other human.  
These other residents had no history of exposure to antimicrobials suggesting that transfer 
of resistance had occurred between these two groups although it is unclear by which route 
this could have occurred (Martins et al., 2013).   
In a study of 231 people attending a symposium ESBL-producing E. coli were isolated from 
rectal swabs from 8 attendees.  Ownership of domestic animals was identified as a risk 
factor with an odds ratio of 6.7 though the lower confidence interval extended to one so 
the significance of this finding is unclear (Meyer et al., 2012). 
There is also potential for interspecies transmission of E. coli via the environment (rather 
than directly or within the household).  Both antimicrobial agents and resistant bacteria 
can be excreted into the environment where, if they survive, they could exploit 
opportunities to colonise or infect new hosts (da Costa et al., 2013).  Antimicrobial resistant 
and ESBL-producing have been isolated from river water in the UK suggesting at least a 
transient contamination of water supplies is possible (Dhanji et al., 2011).  In a recent study 
in Poland samples were collected from sewage, the air at a waste water treatment plant 
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and a river receiving effluent from the plant.  ESBL-producing Enterobacteriaceae were 
detected in 100%, 23.8% and 33.3% of samples respectively suggesting that sewage is a 
potent source of environmental contamination and waste water treatment is not effective 
in removing this (Korzeniewska and Harnisz, 2013).  There is no indication that the results 
in either of these studies was due to animal related contamination of the environment, 
indeed it is likely to be human sewage that was the source.  However it is likely that AMR 
bacteria excreted by animals have the potential to contaminate the environment in the 
same way.     
Summary and aims 
Antimicrobial resistance is a natural phenomenon and purely reflects evolution of bacteria 
in response to a selection pressure.  However the widespread use of antimicrobials has 
provided a potent selection pressure for the development of AMR throughout the world in 
both a hospital and a community setting.    
ESBL-producing E.coli are a major problem in human medicine and are emerging as a 
serious problem in veterinary medicine.  Not only are ESBL-producers resistant to extended 
spectrum cephalosporins they are often resistant to several different classes of 
antimicrobial due to co-selection for resistance cause by plasmids expressing multiple AMR 
genes (including ESBL genes).  ESBL-producing bacteria are now commonly found in studies 
of food producing and companion animals throughout the world including in healthy 
animals, which is of concern.   
Some evidence exists suggesting a link between the epidemiology of ESBL-producers in 
humans and animals, there are many similarities but also differences so it is difficult to 
make a definitive judgement at this time.  ESBL-producing E.coli are present within the 
companion animal population both as commensals and pathogens and current trends 
within veterinary practice suggest that levels are likely to increase in the future.  There is a 
high frequency of close contact between pets and their owners, which increases the 
potential for transmission between these populations.  It is likely that transfer is occurring 
between the populations and is probably dynamic and occurring in both directions.     
The challenges facing the veterinary profession regarding ESBL-production by bacteria are 
similar to those facing the medical profession.  However, far less research has been done 
on the prevalence and risk factors for colonisation or infection with ESBL-producing E. coli 
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in companion animals.  Increased collection of data in these areas will help to further our 
understanding of this area and help combat this very real threat.   
The primary aim of this thesis was to determine the prevalence of antimicrobial resistant E. 
coli, including several important AMR phenotypes and genotypes, from both the faecal 
microflora of animals hospitalised in referral practices and their practice environment. A 
further aim was to determine the risk factors for carriage of important resistance 
phenotypes by faecal commensal E. coli in these animals . 
Chapter two describes the design of the study and the results present the prevalence of 
important AMR phenotypes and genotypes across the hospitals.  This chapter also 
describes molecular methods and results characterising the genes associated with ESBL-
producing and AmpC producing E. coli 
Chapter 3 describes data collection and multilevel, multivariable analysis to determine risk 
factors for carriage of specific resistance phenotypes and genotypes by faecal commensal 
E. coli.  
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Chapter 2 
Longitudinal study of antimicrobial resistant Escherichia coli 
in hospitalised companion animals and their hospital environment. 
 
INTRODUCTION 
Bacterial resistance to antimicrobials is a global issue in both human and veterinary 
medicine with serious consequences.  The increased financial burden of managing multi-
drug resistant (resistant to 3 or more classes of antimicrobial, MDR) infections has been 
shown to be significant in both human (Smith and Coast, 2013, Tansarli et al., 2013) and 
veterinary (Dallap Schaer et al., 2010) situations.  Furthermore increased patient morbidity 
and mortality associated with treatment failure, public image problems and the potential 
public health impact together make antimicrobial resistance one of the most important 
problems faced by human and veterinary medicine today.   
There are a number of different mechanisms by which bacteria can gain resistance to 
antimicrobials.  Among Escherichia coli  one of the most important mechanisms of 
resistance is the production of enzymes called beta-lactamases which hydrolyse the beta 
lactam ring and confer resistance to beta lactam antimicrobial agents (Sykes and Matthew, 
1976).  This is a mechanism of resistance which has been long established, the early beta-
lactamases conferred resistance to only a limited range of beta lactam antimicrobials 
(principally amino-penicillins and first generation cephalosporins.  However use of 
extended spectrum (third and fourth generation) cephalosporins has driven the evolution 
of some beta-lactamase enzymes to extend their spectrum of activity to later generation 
cephalosporins and confer resistance to these agents, although they remain sensitive to 
beta-lactamase inhibitors, such as clavulanic acid.  In human medicine the last few decades 
has seen this resistance to extended spectrum cephalosporins emerge as an important 
element of many nosocomial infections.  In E. coli some extended spectrum beta-
lactamases (ESBLs) emerged due to mutations in existing beta-lactamases which extended 
the spectrum of activity (TEM and SHV type), in other cases the emergence of a new type 
of ESBL in E. coli occurred due to transfer of mobile genetic elements from Klyuvera species 
(CTX-M types)(Bonnet, 2004).  This ability of bacteria to exchange resistance genes via 
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horizontal transfer of plasmids is extremely important to the spread of resistance among 
bacterial populations (Pfeifer et al., 2010). 
E. coli can also gain resistance to beta-lactam agents by the production of the 
cephamycinase AmpC enzymes.  It is important to note that bacteria with this mechanism 
of resistance are also resistant to beta lactamase inhibitors, which distinguishes them from 
ESBL-producing bacteria which are sensitive.  The production of ESBL’s has been shown to 
be associated with the occurrence of MDR due to the co-existence of different resistance 
genes on the same plasmids as the blaESBL genes which can then be shared within bacterial 
populations (Schultsz and Geerlings, 2012, Pitout et al., 2007, Pitout and Laupland, 2008, 
Woodford et al., 2004).  This adds to the resistance burden within populations with a wider 
range of resistance further limiting treatment options, for example ESBL production has 
been shown to be associated with fluoroquinolone resistance in a study of companion 
animals (Moreno et al., 2008).  This is an important phenomenon as it means that the use 
of one antimicrobial class could select for resistance to multiple classes of antimicrobial by 
favouring the spread of plasmids conferring MDR. 
ESBL-producing bacteria are now being reported commonly in companion animals.  They 
have been reported from healthy dogs in the community in: Tunisia (Ben Sallem et al., 
2013); China (Sun et al., 2010); South Korea(Tamang et al., 2012); Switzerland (Gandolfi-
Decristophoris et al., 2013); Italy (Carattoli et al., 2005); Germany (Franiek et al., 2012); 
Portugal (Belas, 2014) and the UK where a high level of MDR E. coli was also detected 
(Wedley et al., 2011).  A study in South Korea found a significant ESBL producer burden in 
commensal E. coli from hospitalised animals (So et al., 2012) and another study compared 
the isolation rates from community animals with hospitalised animals and found a higher 
rate of isolation from the animals which were hospitalised (Nam et al., 2010).  A study in 
China detected increased levels of ESBL producing bacteria in animals undergoing 
treatment compared to healthy animals (Sun et al., 2010).  ESBL production has been 
reported in bacteria associated with urinary tract infections in Holland (Dierikx et al., 2012), 
Switzerland (Huber et al., 2013) and the USA (O'Keefe et al., 2010, Shaheen et al., 2011) 
and additionally wound infections (Steen and Webb, 2007) and a case of cholangiohepatitis 
in the UK (Steen and Webb, 2007, Timofte et al., 2011).  These studies show that ESBL 
producing bacteria are circulating within community based healthy animals and 
hospitalised animals in many parts of the world.  ESBL production can occur in isolates 
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which can cause clinical infections which will lead to limited treatment options with these 
infections.   
The aim of this study was to determine the prevalence of important antimicrobial 
resistance (AMR) phenotypes from both the faecal microflora of animals hospitalised in 
referral practices and their practice environment.   
MATERIALS AND METHODS 
Practice selection and sample collection 
Five referral hospitals in Northwest England, that were willing to participate, were selected 
on a convenience basis to take part in the study.  The main criterion for selection was that 
the hospital must see secondary referral patients with a substantial referral caseload 
including cases likely to be hospitalised.  The limitation to the Northwest was in order to 
facilitate sample collection and minimise time between collection and processing. 
Sample size estimates indicated that with an expected prevalence of ESBL-producing E. coli 
of 10%, a sample size of 385 faecal samples would be required to determine the prevalence 
with a precision of 3% and 95% confidence. Hence the aim was to collect 385 animal faecal 
samples in addition to environmental samples.  
Once hospitals agreed to participate they were provided with an information sheet and 
sampling guidelines. Written informed consent was obtained, by the veterinary surgeon, 
from all owners whose animals took part in the study.  Ethical approval for the study was 
granted by the University of Liverpool’s Research Ethics Committee.  
In order to avoid clustering of samples from one time of year at one hospital  sampling was 
rotated and  performed in three blocks of two weeks (six weeks sampling in total) at each 
of the practices.  Some blocks overlapped such that sampling from 2 hospitals took place at 
the same time.  One practice also included a pilot week (seven weeks sampling in total).   
Animals defined as eligible for the study were all dogs and cats hospitalised overnight in the 
practice whose owners consented to take part.  Day cases were excluded as were animals 
receiving chemotherapy or radiotherapy and those in isolation. The target for sample 
collection was one faecal sample per hospitalised animal per day. Samples were collected 
by practice staff and labelled (with name, ID number, date of collection and where the 
animal was hospitalised at the time of sampling), stored in cool-boxes at the practice and 
collected at regular intervals (2-3 days) for return to the University of Liverpool for 
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processing.  If staff collected more than one faecal sample for an animal in the same day 
the first one to be removed from the box was processed and any others were discarded.   
Environmental samples were collected once in each week of sampling from each practice.  
There was some variation in exact sites sampled in each practice necessitated by the 
different layouts of each practice.  However areas sampled from all practices were: ward 
floors; computer keyboards in kennel rooms and treatment areas; examination tables in 
treatment areas (not in consulting rooms) and the outside dog walking areas.  In addition 
floor samples were taken from a central treatment area in three practices and a lift used 
for patient transport in one practice.  In the case of multiple keyboards/examination tables 
in the same area one was selected on the first week of sampling and this was used for all 
subsequent sample collection.  Samples from floors were collected using disposable 
absorbent overshoes (bootsocks) dampened with 2-3ml saline.  These were worn and 
walked around rooms in the same pattern each week.  Samples were taken from keyboards 
and tables using sterile cloths moistened with sterile saline.     
Isolation of resistant bacteria from samples 
Samples were processed immediately after collection and transported to the University of 
Liverpool.  Two grams of faeces were placed in a 5ml container and 2ml of brain heart 
infusion broth (LabM, UK) was added.  The mixture was vortexed to create a homogenate 
which was inoculated onto eosin methylene blue agar (EMBA, LabM, UK).  Discs (Mast Ltd, 
UK) impregnated with ampicillin (10μg), augmentin (30μg), ciprofloxacin (1μg) and 
trimethoprim (2.5μg) were added to the plate and it was incubated overnight at 37oC 
(Bartoloni et al., 2006).   
Bootsocks were soaked in buffered peptone water (LabM, UK) for two minutes and 10ml of 
the supernatant incubated overnight.  Swabs from surfaces were incubated in buffered 
peptone water overnight.  After incubating overnight environmental samples were 
processed as described below. 
In order to isolate E. coli resistant to cephalosporins 0.5ml of the faecal homogenate was 
added to 4.5ml buffered peptone water (LabM, UK) and incubated overnight at 37oC.  Five 
microlitres of this mixture was then streaked onto one EMBA plate containing 1μg/ml 
cefotaxime and another EMBA plate containing 1μg/ml ceftazidime.  Both plates were 
incubated overnight at 37oC.  If present, for each sample one colony resembling E. coli was 
removed from each of the antimicrobial inhibition zones and from the cephalosporin 
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containing EMBA plates and inoculated onto nutrient agar (LabM, UK) and incubated 
overnight at 37oC in order to obtain pure cultures.   
In all a maximum of six AMR isolates could be obtained from each faecal sample one isolate 
each from the  four inhibition zones on the plate containing antimicrobial discs, one from 
the plate containing EMBA with ceftazidime and one from the plate containing EMBA with 
cefotaxime.   Environmental samples were only tested for cephalosporin resistance initially 
so one environmental sample would yield a maximum of two isolates.  
Antimicrobial susceptibility and ESBL phenotypic testing 
Full susceptibility testing was performed on all isolates.  Colonies from nutrient agar plates 
were suspended in sterile water to make a solution equivalent to 0.5 McFarlands Turbidity 
Standard (0.5MTS).   
For general antimicrobial susceptibility testing 0.5ml of the above 0.5MTS solution was 
pipetted into 4.5ml sterile water and this solution was inoculated onto iso-sensitive agar 
(LabM, UK).  Discs impregnated with 10μg ampicillin, 30μg augmentin, 30μg 
chloramphenicol, 30μg nalidixic acid, 1μg ciprofloxacin, 2.5μg trimethoprim and 30μg 
tetracycline were placed onto the agar and it was incubated overnight at 37oC.  Sensitivity 
or resistance was interpreted according to BSAC guidelines (BSAC, 2013).   
Isolates demonstrating resistance to third generation cepahalosporins were tested for 
ESBL-producer phenotypes.  The 0.5MTS solution was inoculated directly onto iso-sensitive 
agar.  Discs impregnated with 30μg ceftazidime, 30μg ceftazidime and 10μg clavulanic acid, 
30μg cefpodoxime, 30μg cefpodoxime and 10μg clavulanic acid, 30μg ceftazidime and 30μg 
ceftazidime and 10μg clavulanic acid (ESBL identification set, Mast Ltd, UK) were added and 
the plates were incubated overnight at 37oC.  The diameter of the inhibition zone was 
measured for each disc and ESBL production was confirmed if there was more than 5mm 
increase in zone diameter with the disc with clavulanic acid compared to the one without 
according to the manufacturers (MAST group) instructions (M'Zali et al., 2000).   
Cell lysates were prepared by adding 2-3 colonies from the pure culture to 0.5ml sterile 
water and heating at 100oC for 20 minutes, they were then refrigerated for subsequent 
DNA analysis.   
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Genotypic analysis 
All isolates consistent with E. coli were confirmed using primers uidAF and uidAR targeting 
the uidA gene as described previously (McDaniels et al., 1996).  A master mixture of 1.8ml 
1.1xReddymix (Abgene) and 20μl each of primers (100pmol/ml) uidAF and uidAR was 
prepared and 24μl of this was added to each PCR tube.  To this was added 1μl of DNA 
lysate to make a total reaction mixture volume of 25μl.  Samples were placed at 94oC for 4 
minutes, then subjected to twenty five cycles of: 94oC for 20 seconds; 58oC for 30 seconds 
and 72oC for 1 minute.  After this the mixture was held at 72oC for 7 minutes then at 4oC 
until analysis.   
All isolates demonstrating resistance to cefotaxime and ceftazidime on sensitivity testing 
were tested for the presence of blaCTX-M genes using universal blaCTX-M primers CTXMU1 and 
CTXMU2 (Batchelor et al., 2005b).  A master mixture comprising 1.8ml 1.1xReddymix 
(Abgene) and 20µl of each primer was made and 24µl of this was pipetted into each PCR 
tube. Each 25µl reaction contained: 0.625 units Taq DNA polymerase; 75mM Tris-HCl; 
20mM (NH4)2SO4; 1.5mM MgCl2 and 0.2mM each of dATP, dCTP, dGTP and dTTP.  To this 
was added 1µl of sample DNA.    
All isolates positive for the presence of blaCTX-M genes were then tested to specify the CTX-
M group.  All CTX-M universal positive isolates were tested using primers specific to blaCTX-M 
groups 1 (Carattoli et al., 2005), 2 (Hopkins et al., 2006) and 9 (Batchelor et al., 2005b) 
using the same thermocycler program as used for the blaCTX-M universal PCR.   
All isolates demonstrating ceftazidime resistance on sensitivity testing were tested for the 
presence of blaTEM, blaSHV and blaOXA genes using a multiplex PCR assay (Dallenne et al., 
2010).  Sample DNA (5μl) was added to 4μl 5 x Mastermix (Solis Biodyne) (0.4M Tris-HCl, 
0.1M(NH4)2SO4, 7.5mM MgCl2, 1mM dNTP’s of each)  0.5μl of each primer (10pmol/μl) and 
13μl water.  Reaction mixtures were subjected to an initial denaturation stage of 94oC for 
10 minutes then thirty cycles of 94oC for forty seconds, 60oC for forty seconds and 72oC for 
sixty seconds.  A final elongation step of 72oC for seven minutes was used.   
All isolates demonstrating clavulanic acid potentiated amoxicillin (CAPA) resistance on 
sensitivity testing were tested for the presence of blaCITM using CITM primers (Perez-Perez 
and Hanson, 2002).  A master mix containing 4µl 5 x Mastermix (Solis Biodyne), 0.5µl of 
CITMF and CITMR primers, 15µl water for each sample was made and pipette to each 
reaction tube and 5µl sample DNA added.  Mixtures were then placed in a thermocycler 
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and subjected to: 94oC for 3 minutes; twenty five cycles of 94oC for 30 seconds, 64oC for 30 
seconds and 72oC for 60 seconds.  After this the reaction was held at 72oC for 7 minutes 
and then at 4oC until analysis.   
All isolates identified as producing CTX-M-1 group ESBLs were tested to determine if they 
belonged to serogroup O25 (Clermont et al., 2008), 20μl of each primer (100pmol/μl) was 
added to 1.8ml Reddymix (Abgene) and 24μl of this mixture was added to 1μl sample DNA.  
This reaction mixture was subjected to an initial denaturation step of 94oC for three 
minutes followed by thirty cycles of: 94oC for thirty seconds; 60oC for thirty seconds and 
72oC for sixty seconds.  This was followed by a final elongation step of 72oC for five 
minutes.  
Isolates belonging to serogroup O25 were further tested for markers for sequence type (ST) 
131 (Clermont et al., 2009).  5μl sample DNA was added to 4μl 5x Mastermix (Solis 
Biodyne), 0.5μl each primer and 14μl water.  The reaction mixture was subjected to an 
initial denaturation step of 94oC for four minutes then thirty cycles of 94oC for five seconds 
and 65oC for ten seconds.  This was followed by a final elongation step of 72oC for five 
minutes.   
All isolates demonstrating resistance to nalidixic acid were tested for the presence of qnrA, 
qnrB and qnrS genes using a multiplex PCR assay (Robicsek et al., 2006).  5μl sample DNA 
was combined with 0.5μl each primer, 4μl 5 x mastermix (Solis Biodyne) and 13μl water.  
Reaction mixtures were subjected to 94oC for 3 minutes, then 32 cycles of 94oC for 
45seconds, 53oC for 45 seconds and 72oC for 60 seconds.  A final elongation step of 72oC for 
5 minutes was used.   Table 1 shows all the primers used in this project along with 
annealing temperature and expected amplicon size.   
Sequencing of resistant isolates 
Following successful amplication, products were purified and both forward and reverse 
strands were amplified using a sequencing PCR.  The subsequent products were further 
purified and plates were sent for reading at the Zoology Sequencing Facility, Oxford.  All 
sequencing reactions and clean ups were carried out according to an in-house protocol 
(Appendix I).    Each sequence was examined and primer sequences were removed using 
ChromasPRO v1.7.3 (http://technelysium.com.au), as well as the presence of ambiguous 
background signals.  Samples with poor quality sequence data were excluded from further 
analysis.  Where possible, consensus sequences were derived from both the forward and 
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reverse reads.  BLAST searches were conducted on either consensus or single read 
sequences for each isolate to confirm the blaCTX-M/blaCITM/blaSHV/blaTEM related identity.  All 
sequencing was performed by Chris Ball due to time constraints.  
Table 1: PCR primers used in this project detailing nucleotide sequences, annealing temperatures and expected 
amplicon sizes. 
Target Primer name Sequence (5’-3’) Annealing 
temperature 
Amplicon 
size 
uidA gene (E. coli 
confirmation) 
uidAF 
uidAR 
CCAAAAGCCAGACAGAGT 
GCACAGCACATCAAAGAG 
58oC 623bp 
blaCTX-M universal 
(all CTX-M groups) 
CTXMU1 
CTXMU2 
ATGTGCAGYACCAGTAARGTKATGGC 
TGGGTRAARTARGTSACCAGAAYCAGCGG 
58oC 593bp 
blaCTX-M group 1 CTXMgp1F 
CTXMgp1R 
  CCCATGGTTAAAAAATCACTGC 
  CAGCGCTTTTGCCGTCTAAG 
55oC 876bp 
blaCTX-M group 2 CTXMgp2F 
CTXMgp2R 
  ATGATGACTCAGAGCATTCGC 
  TCAGAAACCGTGGGTTACGAT 
55oC 893bp 
blaCTX-M group 9 CTXMgp9F 
CTXMgp9R 
  ATGGTGACAAAGAGAGTGCAAC 
  TTACAGCCCTTCGGCGATG 
55oC 876bp 
blaTEM, SHV and OXA TSO-TF 
TSO-TR 
TSO-SF 
TSO-SR 
TSO-OF 
TSO-OR 
CATTTCCGTGTCGCCCTTATTC 
CGTTCATCCATAGTTGCCTGAC 
AGCCGCTTGAGCAAATTAAAC 
ATCCCGCAGATAAATCACCAC 
GGCACCAGATTCAACTTTCAAG 
GACCCCAAGTTTCCTGTAAGTG 
 
60oC 
(multiplex) 
800bp 
 
713bp 
 
564bp 
blaCITM CITMF 
CITMR 
  TGGCCAGAACTGACAGGCAAA 
  TTTCTCCTGAACGTGGCTGGC 
64oC 462bp 
qnr qnrAF 
qnrAR 
qnrBF 
qnrBR 
qnrSF 
qnrSR 
  ATTTCTCACGCCAGGATTTG 
  GATCGGCAAAGGTTAGGTCA 
  GATCGTGAAAGCCAGAAAGG 
  ACGATGCCTGGTAGTTGTCC 
  ACGACATTCGTCAACTGCAA 
  TAAATTGGCACCCTGTAGGC 
53oC 
(multiplex) 
520bp 
 
469bp 
 
417bp 
 serogroup O25 rfb.1bis 
rfbO25b.r 
ATACCGACGACGCCGATCTG 
TGCTATTCATTATGCGCAGC 
60oC 300bp 
 O125 ST131 O25pabBspe.F 
rfbO25b.r 
trpA.F 
trpA2.R 
TCCAGCAGGTGCTGGATCGT 
GCGAAATTTTTCGCCGTACTGT 
GCTACGAATCTCTGTTTGCC 
GCAACGCGGCCTGGCGGAAG 
65oC 
(multiplex) 
347bp 
 
427bp 
 
Statistical analysis 
All data were entered into a spreadsheet program (Microsoft Excel 2007, Microsoft 
Corporation) and the dataset was reviewed and checked for coding of all variables.  
Descriptive statistics and 95% confidence intervals for proportions were calculated for 
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prevalence data for each practice and overall.  Resistance to each of the seven 
antimicrobials was considered as a separate outcome. Additionally, the presence in a 
sample of an E. coli with multidrug resistance (to three or more antimicrobial classes) or 
with resistance to third generation cephalosporins were considered.  ESBL and AmpC 
production (both phenotype and  genotype  demonstrated by PCR) were also considered.   
Due to the nature of sampling the data were clustered within veterinary practices and 
within dog so we also estimated the prevalence of antimicrobial-resistant E. coli after 
allowing for the clustering using separate multilevel models with a binomial distribution 
and logit link function. Three-level multilevel models were constructed for each outcome, 
with practice and dog clustering accounted for by incorporation of second- and third-level 
random intercept terms.  Calculations were performed using penalised quasi-likelihood 
estimates (2nd order or 1st order PQL). The true prevalence (PT) was estimated using the 
formula below, by incorporating the constant parameter estimate (β0) derived from the 
random intercept-only three-level models constructed for each of the outcomes 
considered: 
    PT =    e
β0   
       1 + eβo 
95% confidence intervals for all adjusted prevalence estimates were constructed by 
examination of the standard errors of the intercept-only model parameters. Data were 
analysed using the MLwiN statistical software package (MLwiN Version 2.1 Centre for 
Multilevel Modelling, University of Bristol, UK).  
RESULTS 
Samples collected 
A total of 341 faecal samples were collected from 214 animals over a total of 31 sampling 
weeks between 13th May and 21st October 2013 (table 2).  Eight samples were discarded 
from analysis due to being collected from the same animal on the same date.  From these 
333 faecal samples 363 isolates demonstrating resistance to one or more of the 
antimicrobial classes tested were obtained corresponding to 167 (50.1%) faecal samples 
containing E. coli resistant to at least one antimicrobial.   
A total of 257 environmental samples were collected from areas within the five practices 
during the same 31 sampling weeks.  From these samples 86 isolates demonstrating 
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resistance were obtained corresponding to 47 (18.3%) of environmental samples having E. 
coli isolates with antimicrobial resistance. The number and sampling location of 
environmental samples along with the number of faecal samples from each practice are 
shown in table 2.  For some faecal samples (n=13) it was not possible to retrieve clinical 
records so species was not specified.  
 
Table 2: Number of faecal samples obtained from different species and environmental samples from different 
areas from each practice and in total. 
 Faecal samples Environmental samples 
Practice Dogs Cats Unspecified Total Inside 
floors 
Examination 
tables 
Keyboards Outdoors 
walking 
area 
Total 
1 122 14 0 136 28 12 18 7 65 
2 32 0 5 37 30 6 6 6 48 
3 63 10 0 73 24 6 12 6 48 
4 34 0 2 36 24 6 12 6 48 
5 45 0 6 51 30 6 6 6 48 
Total 296 24 13 333 136 36 54 31 257 
 
Resistance phenotypes 
The overall prevalence of faecal and environmental samples with at least one isolate 
resistant to ampicillin, CAPA, chloramphenicol, nalidixic acid, ciprofloxacin, trimethoprim 
and tetracycline is shown in tables 3 and 4 respectively.  The overall prevalence of 
resistance was higher in faecal samples than environmental samples. Resistance to at least 
one antimicrobial was detected in isolates from 167/333 (50.1%) faecal samples and 
47/257 (18.3%) environmental samples.  Overall tetracycline resistance was the least 
common resistance type in faecal samples and chloramphenicol resistance was the least 
common type in environmental samples.  Resistance to ampicillin was the most common 
resistance type in both faecal and environmental samples.   
There was significant variation by practice within results.  This was particularly the case for 
ciprofloxacin resistance with the highest prevalence in faecal samples of 44% in practice 
one compared to 7.8% in practice five.    This level of variation between practice was not 
seen for every resistance phenotype, for example the ampicillin resistance prevalence 
ranged from 38% to 58% between practices, with an overall prevalence when adjusted for 
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clustering, of 45% indicating that levels of certain resistance phenotype are less affected by 
practice.   
Appendix II shows the percentage of samples from each practice (and in total) which 
yielded an isolate demonstrating resistance phenotypes deemed to be clinically important.  
These phenotypes were: CAPA resistance, ciprofloxacin resistance, ESBL-producer 
phenotype, AmpC-producer phenotype, resistance to third generation cephalosporin and 
MDR.  Practice one demonstrated the highest prevalence of CAPA resistance, ciprofloxacin 
resistance and AmpC-producer phenotype in both faecal and environmental samples.  
Practice three demonstrated the highest prevalence of ESBL-producer phenotype and 
MDR.  Practices two and five generally demonstrated low prevalence of resistance.   
Isolates displaying MDR varied with regard to which classes of antimicrobial they were 
resistant to.  Table 5 summarises the different MDR phenotypes, the number of each 
obtained and the proportion of MDR positive samples with isolates of this phenotype for 
both faecal and environmental samples.  In total 18 different MDR phenotypes were 
detected in this study, 17 of these were in faecal samples and 10 in environmental samples 
with substantial overlap between the two.  Many of the different MDR phenotypes 
contained ciprofloxacin and CAPA resistance.  Figure 1 shows MDR types by practice.  
Origin and timing of environmental isolates 
Environmental samples commonly associated with important resistance phenotypes (MDR, 
ESBL-producer and AmpC-producer) were most likely to be isolated from bootsocks from 
either the outside walking areas or internal floors of the ward communal areas.  There was 
variation in the rate of isolation of resistant bacteria between practices and between areas 
within practices.  The frequency of isolation of different resistance phenotypes from 
different areas within each practice is shown in figure 2. 
The isolation of E. coli with important resistance phenotypes varied over the sampling 
period for each practice with different patterns seen in different practices.  Practices two 
and five had relatively low rates of isolation throughout the study, practices three and four 
generally had low rates of isolation with marked increases in one sampling week.  Practice 
one had a consistently moderate level of contamination (appendix III). 
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Table 3: Sample level prevalence of resistance to each antimicrobial, MDR and ESBL and AmpC producer prevalence in faecal samples (n=333) from each practice with 95% confidence 
intervals and adjustment for clustering within practice and animal. TGCR = 3rd generation cephalosporin resistance, Cx = cefotaxime, Cp = cefpodoxime, Cz = ceftazidime.  
 
 
*Estimates from 1
st
 order PQL  # Estimates from intercept-only  multilevel models. 
 
 Practice 1 Practice 2 Practice 3 Practice 4 Practice 5 All practices (N) All Practices All practices 
adjusted for 
clustering# 
Ampicillin resistant 58.1 (49.8-66.4) 37.8(22.2-53.5) 49.3 (37.8-60.8) 41.7 (25.6-57.8) 39.2 (25.8-52.6) 164 49.2 (43.9-54.6) 45.4 (36.6-54.6) 
 
CAPA resistant  42.6 (34.3-51) 24.3 (10.5-38.1) 20.5 (11.3-29.8) 19.4 (6.5-32.4) 15.7 (5.7-25.7) 
 
97 29.1 (24.2-34) 
14.0 (6.7-27.0) 
Chloramphenicol res. 19.9 (13.1-26.6) 24.3 (10.5-38.1) 24.7 (14.8-24.5) 2.8 (0-8.1) 5.9 (0-12.3) 58 17.4 (13.3-21.5) 13.5 (8.7, 20.4) 
Tetracycline res. 12.5 (6.9-18.1) 5.4 (0-12.7) 15.1 (6.9-23.3) 11.1 (0.8-21.4) 19.6 (8.7-30.5) 44 13.2 (9.6-16.9) 12.8 (9.5, 17.0) 
Trimethoprim res. 32.4 (24.5-40.2) 24.3 (10.5-38.1) 30.1 (19.6-40.7) 13.9 (2.6-25.2) 13.7 (4.3-23.2) 87 26.1 (21.4-30.8) 12.7 (6.8, 22.4) 
Nalidixic acid res. 44.1 (35.8-52.5) 10.8 (0.8-20.8) 17.8 (9-26.6) 22.2 (8.6-35.8) 9.8 (1.6-18) 90 27.0 (22.3-31.8) 13.1 (5.5, 28.1) 
Ciprofloxacin res. 44.1 (35.8-52.5) 8.1 (0-16.9) 11.0 (3.8-18.1) 13.9 (2.6-25.2) 7.8 (0.5-15.2) 80 24.0 (19.4-28.6) 9.2(3.2, 23.9) 
MDR 31.6 (23.8-39.4) 24.3 (10.5-38.1) 34.2 (23.4-45.1) 22.2 (8.6-35.8) 9.8 (1.6-18.0) 115 27.0 (22.3-31.8) 13.1 (6.9-23.6) 
TGCR 50.0 (41.6-58.4) 24.3 (10.5-38.1) 41.1 (29.8-52.4) 36.1 (20.4-51.8) 11.8 (2.9-20.6) 126 37.8 (32.6-43) 27.2 (14.9-44.3) 
CxR 39.7 (31.5-47.9) 8.1 (0-16.9) 16.4 (7.9-24.9) 16.7 (8.6-35.8) 2.0 (0-5.8) 76 22.8 (18.3-27.3) 9.9 (3.5-25.4) 
CpR 50.0 (41.6 -58.4) 24.3 (10.5-38.1) 41.1 (29.8-52.4) 36.1 (20.4-51.8) 11.8 (2.9-20.6) 126 37.8 (32.6-43) 27.1 (14.8-44.3) 
CzR 37.5 (29.4-45.6) 13.5 (2.5-24.5) 13.7 (5.8-21.6) 22.2 (8.6-35.8) 3.9 (0-9.2) 76 22.8 (18.3-27.3) 9.9 (3.8-23.4) 
ESBL producer 
phenotype 14.0 (8.1-19.8) 8.1 (0-16.9) 30.1 (19.6-40.7) 25.0 (10.9-39.1) 0.0 
 
53 15.9 (12-19.8) 
 
9.7 (3.4-24.6) 
AmpC producer 
phenotype 33.1 (25.2-41) 0.0 1.4 (0-4) 5.6 (0-13) 2.0 (0-5.8) 
 
49 14.7 (10.9-18.5) 
 
4.3 (1.1-15.6) 
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Table 4: Sample level prevalence of resistance to each antimicrobial class, MDR and ESBL and AmpC producer prevalence in environmental samples (n=257) from each practice with 95% 
confidence intervals.  CxR = cefotaxime resistant, CpR = cefpodoxime resistant, CzR = Ceftazidime resistant, 3GCR = any third gen. cephalosporin resistance. 
 
 Practice 1 Practice 2 Practice 3 Practice 4 Practice 5 All practices (N) Total 
Ampicillin res. 33.8 (22.3-45.3) 6.3 (0-13.1) 25.0 (12.8-37.3) 12.5 (3.1-21.9) 6.3 (0-13.1) 46 17.9 (13.2-22.6) 
CAPA res. 29.2 (18.2-40.3) 6.3 (0-13.1) 8.3 (0.5-16.2) 4.2 (0-9.8) 2.1 (0-6.1) 29 11.3 (7.4-15.2) 
Chloraphenicol res. 6.2 (0.3-12) 0.0 14.6 (4.6-24.6) 4.2 (0-9.8) 0.0 13 5.1 (2.4-7.7) 
Tetracycline res. 6.2 (0.3-12) 6.3 (0-13.1) 6.3 (0-13.1) 4.2 (0-9.8) 4.2 (0-9.8) 14 5.4 (2.7-8.2) 
Trimethoprim res. 12.3 (4.3-20.3) 4.2 (0-9.8) 18.8 (7.7-29.8) 2.1 (0-6.1) 2.1 (0-6.1) 23 8.9 (5.5-12.4) 
Nalidixic acid res. 29.2 (18.2-40.3) 2.1 (0-6.1) 6.3 (0-13.1) 2.1 (0-6.1) 2.1 (0-6.1) 29 11.3 (7.4-15.2) 
Ciprofloxacin res. 29.2 (18.2-40.3) 2.1 (0-6.1) 6.3 (0-13.1) 4.2 (0-9.8) 2.1 (0-6.1) 27 10.5 (6.8-14.3) 
MDR 15.4 (6.6-24.2) 4.2 (0-9.8) 14.6 (4.6-24.6) 4.2 (0-9.8) 4.2 (0-9.8) 23 8.9 (5.5-12.4) 
3GCR 33.8 (22.3-45.3) 2.1 (0-6.1) 22.9 (11-34.8) 8.3 (0.5-16.2) 6.3 (0-13.1) 41 16.0 (11.5-20.4) 
CxR 29.2 (18.2-40.3) 0.0 14.6 (4.6-24.6) 2.1 (0-6.1) 0.0 27 10.5 (6.8-14.3) 
CpR 33.8 (22.3-45.3) 2.1 (0-6.1) 22.9 (11-34.8) 8.3 (0.5-16.2) 6.3 (0-13.1) 41 16.0 (11.5-20.4) 
CzR 26.2 (15.5-36.8) 0.0 12.5 (3.1-21.9) 4.2 (0-9.8) 0.0 25 9.7 (6.1-13.4) 
ESBL-producer 
phenotype 
3.1 (0-7.3) 0.0 16.7 (6.1-27.2) 8.3 (0.5-16.2) 0.0 14 5.4 (2.7-8.2) 
AmpC producer 
phenotype 
16.9 (7.8-26) 0.0 2.1 (0-6.1) 0.0 0.0 12 4.7(2.1-7.2) 
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Table 5: The proportion of different MDR phenotypes in both faecal and environmental samples.  amp = 
ampicillin resistant, aug = CAPA resistant, chl = chloramphenicol resistant, tet = tetracycline resistant, trim = 
trimethoprim resistant, nal = nalidixic acid resistant and cip =ciprofloxacin resistant. 
 
 
 
 
 
 
 
 
 
 
 
 
MDR phenotype Number of 
antimicrobial 
classes 
resistant to 
FAECAL SAMPLES ENVIRONMENTAL SAMPLES 
Number of 
samples 
 % (95% CI) Number of 
samples 
 % (95% CI) 
amp aug chl trim nal cip 4 20 23.3 (14.3-13.2) 2 8.7 (0-20.2) 
amp chl trim 3 13 15.1 (7.5-22.7) 4 17.4 (1.9-32.9) 
amp aug chl tet trim nal cip 5 8 9.3 (3.2-15.4) 4 10.5 (0.8 – 20.3) 
amp aug trim nal cip 3 7 8.1 (2.4-13.9) 3 13 (0-26.8) 
amp aug chl trim 3 6 7.0 (1.6-12.4) 1 4.3 (0-12.7) 
amp tet trim nal cip  4 5 5.8 (0.9-10.8) 2 8.7 (0-20.2) 
amp chl tet trim nal cip 5 5 5.8 (0.9-10.8)   
amp tet nal 3 4 4.7 (0.2-9.1)   
amp aug tet trim nal cip 4 4 4.7 (0.2-9.1) 1 4.3 (0-12.7) 
amp tet trim 3 3 3.5 (0-7.4)   
amp aug tet trim 3 3 3.5 (0-7.4) 2 8.7 (0-20.2) 
amp chl trim nal cip 4 2 2.3 (0-5.5)   
amp trim nal cip  3 1 1.2 (0-3.4)   
amp tet nal cip  3 1 1.2 (0-3.4) 2 8.7 (0-20.2) 
amp chl tet trim nal 5 1 1.2 (0-3.4)   
amp aug chl tet trim 4 1 1.2 (0-3.4)   
amp aug chl nal cip 3 1 1.2 (0-3.4)   
amp chl tet trim 
 
4   2 8.7 (0-20.2) 
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Figure 1: Breakdown of MDR types by practice.  Showing the relative frequency of isolation of each type in each 
practice (practice 1 = dark blue, practice 2 = red, practice 3 = green, practice 4 = purple and practice 5 = light 
blue). 
 
 
 
Figure 2: The percentage of samples from each area (represented by different coloured bars) within each 
practice yielding an isolate positive for MDR, ESBL- or AmpC-producer phenotypes.  The Y axis represents the 
percentage of all samples collected from that area in the whole sampling period that showed the resistance 
phenotype.  The X axis represents the three important resistance types in each practice (one to five). 
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Molecular characterisation of resistance genes  
In total 348/363 faecal sample isolates and 77/86 environmental sample isolates tested 
positive using the uidA PCR test confirming the identity of these isolates.  
Of all isolates (environmental and faecal) 216 were resistant to either cefotaxime or 
ceftazidime.  PCR detected blaCTX-M in 78 (26 environmental isolates and 52 faecal isolates) 
isolates.  Further PCR analysis detected blaCTX-M genes belonging to group one in 32 isolates 
from 22/333 (6.6%) faecal samples and 15 isolates from 12/257 (4.7%) environmental 
samples.   The presence of group one blaCTX-M was detected in isolates from all practices 
except practice five and in environmental samples from practices one, three and four.  
Group nine blaCTX-M production was detected in 5 faecal sample isolates from 3/333 (0.9%) 
samples and 3 environmental isolates from 2/256 (0.8%) environmental samples, all of 
which were from practice one.  No isolates were positive for group two or found to belong 
to O25/ST131.  Of the 78 isolates positive on the universal blaCTX-M PCR the group was not 
identified in 5 isolates.  The inhibitor resistant TEM-158 was detected in one environmental 
sample and in E. coli isolated from ten faecal samples from practice one and was not 
detected in any other practices.  A sample was taken to be a confirmed ESBL producer if it 
either had an ESBL producer phenotype, was positive on the universal blaCTX-M PCR or, in the 
case of TEM and SHV producer types, returned a sequencing result corresponding to an 
ESBL.  The prevalence of confirmed ESBL-producers and AmpC producers (blaCITM positive) 
in faecal and environmental samples is shown in table 6. 
The blaCITM gene was detected in isolates from 81% and 69% of faecal and environmental 
samples which had isolates demonstrating CAPA resistance.  All blaCITM positive isolates 
which returned a result on sequence analysis corresponded to blacmy-2.  There was 
significant masking of ESBL producer phenotype by the production of AmpC with the effect 
being particularly marked in practice one where there was a high level of AmpC-producers.  
Twenty (41%) faecal samples and two (17%) environmental samples with an AmpC 
producer phenotype were also positive for ESBL production.  
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Table 6: Prevalence of confirmed ESBL producer (either phenotype or genotype) and blaCITM positive samples in 
faecal and environmental samples by practice and in total.  For faecal samples overall prevalence with 
adjustment for clustering within animal and practice is also demonstrated. 
 Practice 
1 
Practice 
2 
Practice 
3 
Practice 
4 
Practice 
5 
All 
practic
es (N) 
All 
practice
s (%) 
All 
practices 
adjusted 
for 
clusterin
g (%) 
ESBL-
production  
confirmed* 
(faecal) 
26.5 
(19.1-
33.9) 
8.1 
(0-16.9) 
34.2 
(23.4-
45.1) 
22.2 
(8.6-
35.8) 
2.0 
(0-5.8) 
73 21.9 
(17.5-
26.4) 
14.0 
(5.3,35.0
) 
blaCITM positive 
PCR (faecal) 
38.2 
(30.1-
46.8) 
13.5 
 (2.5-
24.5) 
11.0  
(3.8,18.1) 
13.9 
 
(2.6,25.2) 
3.9  
(0-9.2) 
72 21.6 
(17.2-
26) 
7.7 
(2.5,21.1
) 
ESBL 
production 
confirmed* 
(environmental
) 
13.8  
(5.4-
22.2) 
0.0 16.7 
 (6.1-
27.2) 
10.4 
 (1.8-
19.1) 
0.0 22 8.6 
(5.1-12) 
NA 
blaCITM positive 
PCR 
(environmental
) 
23.1 
(12.8-
33.3) 
2.1 
 (0-6.1) 
4.2 (0-
9.8) 
6.3  
(0-13.1) 
2.1  
(0-6.1) 
22 8.6 
(5.1-12) 
NA 
*Confirmed by PCR, phenotype or sequencing 
 
Not all isolates which were positive on PCR successfully returned sequence analysis results.  
Sequencing results are summarised in table 7.  Group one and nine blaCTX-M were detected 
in isolates from four and one sample respectively by PCR but sequence analysis could not 
confirm the individual gene they carried belonging to these groups.  The remaining isolates 
categorised as ESBL producers were phenotypically ESBL producers but did not amplify 
using PCR.  All TEM-158 and SHV-12 ESBL producers were from the same practice (practice 
one).      
Table 7: Number and percentage of faecal (n = 333) and environmental (n=257) samples with at least one E. coli 
isolate having a resistance gene identified by sequence analysis.  
Gene Faecal samples Environmental samples 
 N % (95% CI) N % (95% CI) 
blaCTX-M-15 20  6 (3.5-8.6) 8 3 (1-5.2) 
blaCTX-M-1 1 0.3 (0-0.9) 1 0.4 (0-1.2) 
blaCTX-M-9 1 0.3 (0-0.9) 0  
blaCTX-M-82 1 0.3 (0-0.9) 0  
blaTEM-158 10 3 (1.2-4.8) 1 0.4 (0-1.2) 
blaSHV-12 0  2 0.8 (0-1.9) 
blaCMY-2 72  22 (17.2-26.0) 22  9 (5.1-12.0) 
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A low prevalence of qnr genes was found with just 3 (1%) faecal samples having at least 
one E. coli isolate which tested positive for the presence of qnr genes on PCR.  Two were 
positive for qnrS and one was positive for qnrB.  Among environmental samples only qnrB 
was detected, in isolates from four (1.5%) samples.  
 
DISCUSSION  
The aim of this study was to determine carriage rates and the level of hospital environment 
contamination with commensal gastro-intestinal bacteria with important antimicrobial 
resistance (AMR) phenotypes and genotypes in small animal referral hospitals.   Overall, in 
isolates from both faecal and environmental samples there were relatively high levels of 
resistance to a number of important antimicrobials including CAPA, fluoroquinolones and 
third generation cephalosporins.  Antimicrobial resistance has important implications for 
veterinary practice from both a clinical and public health perspective.  An initial step 
towards mitigating the problem is first understanding the patterns of prevalence in both 
patients and the practice environment.   
CAPA resistance among samples from all practices was high, 14% overall with some 
variation between practices.  CAPA is an antimicrobial used commonly in companion 
animal practice in the UK (Radford et al., 2011, Mateus et al., 2011) and the frequent 
carriage of resistance is likely to be related to frequent use in veterinary practice and is of 
concern.  In human medicine the incidence of ESBL-producers in hospital has been linked to 
use of CAPA in the community highlighting the importance of interaction between 
community antimicrobial use and the development of AMR in hospitals (Aldeyab et al., 
2012).  Resistance to CAPA has been found in other studies albeit at lower levels: 6.3% in 
hospitalised dogs in Korea (Nam et al., 2010); 3.8% in clinical isolates from pets in Denmark 
(Pedersen et al., 2007); 7% in community dogs in the UK (Wedley et al., 2011) and 8.3% in 
animals about to be hospitalised in the USA (Hamilton et al., 2013).  The high levels in this 
study are likely a reflection of the hospitalised status of animals given that the study of 
dogs in the UK community in a similar geographical area showed a relatively low level of 
CAPA resistance.  CAPA resistance was lower in Korean veterinary hospitals which could 
reflect lower use of CAPA in Korea.  Although there are no published reports of frequency 
of use in Korea in a study of hospitalised dogs in China amoxicillin had only been given to 
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3% of dogs (Lei et al., 2010) which could reflect different prescribing patterns in the region 
compared to the UK.     
The majority of E. coli with CAPA resistance also tested positive for blaAmpC genes making 
this the most likely mechanism responsible.  Previous studies have identified blaAmpC  genes 
at low levels in healthy dogs in the community in the UK (Wedley et al., 2011), Tunisia (Ben 
Sallem et al., 2013), Korea (Tamang et al., 2012), Portugal (Belas, 2014) and Canada 
(Murphy et al., 2009).  They have also been found in clinical E. coli isolates from animals in 
the USA at low levels (Shaheen et al., 2011) and in Holland at high levels (Dierikx et al., 
2012).  Significantly, studies of hospitalised dogs in Korea (So et al., 2012) and Australia 
(Sidjabat et al., 2006) found the prevalence of AmpC-production in E. coli of 23.8% and 
16.5% respectively.  This study concurs with this pattern, with an overall prevalence of 7.7% 
although there was significant variation between practices with practice 1 having a 
significantly higher prevalence.  This suggests that hospitalised animals are more at risk of 
carriage of AmpC-producing E. coli, possibly as a result of infection from the environment 
or other hospitalised animals, increased exposure to antimicrobials or increased levels of 
morbidity among these animals.  The differences between practices suggest that practice 
level factors can have an important influence.  High levels of AmpC have also been found in 
a human healthcare setting where this was putatively linked with a high use of CAPA in the 
same facility (Seiffert et al., 2013a).    
All practices in this study had environmental samples which were positive for E. coli with 
blaAmpC production though again there was significant variation between practices which 
followed a similar pattern to that seen in the faecal samples, suggesting a link between 
commensal faecal and environmental AmpC-producing E. coli.  Colonisation of dogs and 
humans and contamination of the veterinary environment by the same AmpC-producing E. 
coli strains has been reported previously (Sidjabat et al., 2006) and the environmental 
prevalence (4.1%) reported is similar to levels found in most of the practices in this study.  
This study shows that AmpC producing bacteria can contaminate the hospital environment 
and are a potential source of colonisation or infection of patients, though it is likely to be a 
complex picture with exchange between animals and the environment occurring in both 
directions.  ESBL-production in E. coli has been shown to confer better environmental 
survival compared to AmpC production in a human healthcare setting (Starlander et al., 
2014).  The latter is of interest given the high level of AmpC producing E. coli compared to 
45 
 
ESBL producing E. coli in environmental samples from practice one, it is possible this high 
level of AmpC production will reduce over time in the favour of ESBL production.  
The prevalence of resistance to ciprofloxacin was high but variable between practices 
ranging from 8 to 44%.  Recent studies have found ciprofloxacin resistance at 2.2% in dogs 
in the UK community (Wedley et al., 2011), 2.9% in clinical samples from pets in Denmark 
(Pedersen et al., 2007); 1.3% in healthy dogs from the community in Portugal (Costa et al., 
2008), 16.1% in stray dogs in Korea (Nam et al., 2010) and 48.2% in hospitalised dogs and 
cats in China (Lei et al., 2010).  This study demonstrates a substantially higher prevalence of 
ciprofloxacin resistance in hospitalised companion animals compared to those in the UK 
community (Wedley et al., 2011).  Of the 80 faecal samples positive for ciprofloxacin 
resistant E. coli 58 (73%) were MDR, 53 (66%) were AmpC producers and 39 (49%) were 
ESBL producers.  Fluoroquinolones are an important class of antimicrobial for treatment of 
important infections in both human and veterinary medicine and developing resistance to 
these drugs is a serious concern for animal and public health.  The qnr genes were detected 
at low rates among both faecal and environmental samples and are therefore unlikely to be 
a significant contributor to the levels of fluoroquinolone resistance seen in this study.  The 
mechanisms for quinolone resistance in this study were not studied but are most likely to 
be due to chromosomal mutations in the gyrase genes.   
The prevalence of MDR E. coli in faecal samples from this study was 27%, again there was a 
large amount of variation between individual practices.  The similarity of resistance profiles 
between MDR faecal and environmental samples is suggestive of cross contamination 
between animals and their environment.  Particularly of concern is the relatively frequent 
isolation of bacteria with resistance to all seven antimicrobials tested.  Other studies of 
companion animals have found MDR E. coli at rates of: 48% in hospitalised dogs and 32% of 
stray dogs from Korea (Nam et al., 2010); 15% of community based dogs in the UK (Wedley 
et al., 2011) and 9% of animals due to be hospitalised in the USA (Hamilton et al., 2013).  
The level of MDR found by Wedley et al (2011) in community dogs in the UK using similar 
methods is approximately half that found in this study.  Levels of resistance would be 
expected to be higher in a hospitalised setting than a community setting.  It has been 
shown in several studies that MDR organisms are likely to be isolated at a higher rate from 
hospitalised or sick animals compared to non-hospitalised or healthy animals (Nam et al., 
2010, Gibson et al., 2011, Sun et al., 2010) and humans (Cardoso et al., 2012).  It is also 
worth noting that the majority of MDR isolates identified by Wedley et al (2011) were 
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resistant to ampicillin, tetracycline and potentiated sulphonamides, with resistance to 
CAPA occurring infrequently.  MDR isolates in this study frequently included resistance to 
CAPA and fluoroquinolones.   
Resistance to extended spectrum cephaloporins (ESC’s) was detected at high rates in this 
study but were again variable by practice.  Studies of companion animals have found 
resistance to ESC’s at: 60.5% and 30.2% in hospitalised pets treated and not treated with 
antimicrobials respectively in China (Lei et al., 2010); 13% in dogs and cats from the 
community and nursing homes in Switzerland (Gandolfi-Decristophoris et al., 2013) and 
2.4% and 3.9% from stray and hospitalised dogs respectively in Korea (Nam et al., 2010).   
The confirmed prevalence of ESBL-producers in this study was 22%.  ESBL production has 
been detected at prevalences ranging from 54.5% and 24.5% in sick and healthy animals 
respectively in veterinary hospitals in China (Sun et al., 2010) and  33.3% in Korean 
veterinary hospitals (So et al., 2012) to 5% of faecal samples from cats and dogs in shelters 
in Germany (Franiek et al., 2012); 13.2% healthy dogs in Portugal (Belas, 2014) and 16% of 
faecal samples from healthy cats and dogs in Tunisia (Ben Sallem et al., 2013).  ESBL-
producers have also been isolated at lower levels from clinical urinary isolates in the USA 
(Shaheen et al., 2011, O'Keefe et al., 2010) and  Switzerland (Huber et al., 2013).  There is 
clearly variation in ESBL-producer prevalence by location and setting, with hospitalised 
animals being associated with increased isolation rates, though this study demonstrates 
that some hospitals have low levels compared to others and there are likely to be hospital 
level factors which have an important influence.  The prevalence of ESBL production by 
phenotypic findings only led to an underestimation in several practices in this study due to 
masking by AmpC producer phenotypes.  This was particularly the case in the practice 
which had high levels of AmpC production demonstrating the importance of production of 
AmpC not only in the resistance it confers but also in its ability to make the detection of 
ESBL production more difficult.     
The most commonly identified blaESBL in this study was blaCTX-M-15.  While other studies have 
identified blaCTX-M-15 in companion animals at low levels (Dierikx et al., 2012, Huber et al., 
2013, So et al., 2012, Sun et al., 2010) it has been more common for CTX-M-1 production to 
be detected (Costa et al., 2008, Dierikx et al., 2012).  However a recent study in healthy 
dogs found blaCTX-M-15 and blaCTX-M-1 to be the second and third most prevalent types with 
blaCTX-M-32 being the most commonly reported (Belas, 2014).   High levels of blaCTX-M-15 are 
more associated with studies of humans however in Europe blaCTX-M-15 is the second most 
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commonly isolated ESBL gene from companion animals (Ewers et al., 2012), this is not 
surprising given the close contact between humans and companion animals (Westgarth et 
al., 2008) and may reflect transmission into the companion animal population.  It is worth 
remembering that a number of blaESBL positive samples in this study did not return a 
sequencing result and therefore the true prevalence of CTX-M-1 production (and other 
CTX-M type ESBLs) may be higher.     
TEM-158 was the second most prevalent ESBL produced in isolates in this study, it was first 
detected from a faecal sample from an intensive care patient in France and demonstrates 
both ESBL and inhibitor resistant TEM (IRT) characteristics (Robin et al., 2007) and due to 
this is often referred to as a complex mutant TEM (CMT).  Other studies have identified 
TEM-158 production in urinary E. coli isolates in the human community in Morocco 
(Barguigua et al., 2013) and clinical isolates from human patients in Kenya (Kiiru et al., 
2012).  Evolution of TEM-158 has been shown to occur as a result of antimicrobial therapy 
in humans (Jacquier et al., 2013).  Occurrence of this beta lactamase at relatively high levels 
in one hospital is of concern given the resistance it confers and the fact that its inhibitor 
resistant characteristics can make identification difficult.  We are not aware of any other 
studies in companion animals which have identified the presence of blaTEM-158 and as the 
only studies reporting this previously were from humans it may be that inter-species 
transmission has occurred.    
Contamination of the human hospital environment with ESBL-producing 
Enterobacteriaceae originating from patients has been reported, though Klebsiella species 
were reported to be more prolific contaminants compared to E. coli (Guet-Revillet et al., 
2012).  Furthermore in a companion animal veterinary hospital in Canada environmental 
contamination with E. coli  was detected in 92% and CMY-2 producing E. coli in 9% of the 
hospitals sampled (Murphy et al., 2010).  This study concurs with these results and 
confirms that E. coli with important resistance phenotypes are present in the practice 
environment and may act as a source of infection and reservoir of resistance determinants.  
To our knowledge there have been no other reports of E. coli contamination of the 
veterinary hospital environment in the UK.   
For most practices the outside walking area where dogs were taken to urinate and defecate 
(with faeces being picked up and disposed of by practice staff) was most associated with 
isolation of resistant bacteria.  A high level of contamination of this area with E. coli may be 
expected due to a combination of a large number of dogs from different wards mixing on 
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the area and the obvious difficulty with disinfection of the surface.  Practices 1, 2 and 5 all 
had grassy walking areas and practice 4 had a wood chipping surface.  Only practice 3 had a 
concrete surface which would be easily disinfected, and interestingly the isolation rate 
from the outside in this practice was similar to other areas within the practice. Internal 
floors were the area associated with the second highest isolation of important resistance 
phenotypes, tables and keyboards were associated with a low isolation rate in most 
practices which may be due to the ease of disinfection of tables and the lack of direct 
animal contact with keyboards. 
The fact that data were collected in a different six week period for each practice means 
that practice environments cannot be compared temporally, however the changing 
magnitude over time gives a crude picture of the situation in each practice.  It should be 
remembered that practices were not sampled in consecutive six week blocks and the gaps 
between sampling periods varied.  The picture is suggestive of a continually low level of 
contamination in practices two and five, a low level of contamination in practices three and 
four with spikes in the isolation rate suggesting short term contamination of the 
environment and a moderate persistent contamination of the environment in practice one.  
Longer term sampling of the hospital environment may reveal differing patterns. 
The vast majority of isolates were confirmed as E. coli. There was very little change in the 
results for important resistance phenotypes once non E. coli confirmed isolates were 
excluded.  The non E. coli confirmed isolates were included in overall analysis as their 
numbers are small and they may be clinically relevant.    
Due to some practices contributing more samples than others and the repeated sampling 
within dogs, prevalence estimates adjusted for this clustering were calculated.   These 
showed quite different estimates for some outcomes suggesting substantial clustering 
within dogs, as well as practice. 
One problem encountered in this study was the collection of sufficient numbers of samples 
from practices.  Some weeks some practices returned fewer samples than others due to 
low throughput of animals and a lack of hospitalised patients.  In addition faecal samples 
collected were those naturally voided by the animal, due to ethical implications, however 
as many animals (particularly non-ambulatory animals) will not defecate when hospitalised 
over short periods they may be under-represented. Several samples were also lost due to 
inadequate labelling.  Ideally faecal sample collection would be carried out consistently by 
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the same member of staff with a minimal amount of time before processing.  In practice 
this was not possible and there was therefore some variation in time elapsed between 
sample collection and processing which was never more than three days.  Bags were used 
to collect faeces, therefore faecal consistency may have had an impact upon sample 
collection with diarrhoeic dogs underrepresented. We included cats in this study as 
previous estimates of resistance in cats is lacking, however sample numbers were low due 
to lower hospitalisation rates for cats. 
Environmental sample collection was designed to fit around practice routine in order to 
minimise any disruption to practices, in some cases cleaning may have taken place a short 
time before sample collection which would be expected to lower the chances of E. coli 
isolation.  Isolation rate from inhibiton zones was low compared to the isolation rates from 
agar containing cefotaxime/ceftazidime, though this is not directly comparable it 
demonstrates the value of an enrichment step when bacteria are present in low numbers 
in projects like this.       
In summary, this project demonstrates the presence of important AMR phenotypes and 
genes, including the detection of production of the IRT TEM-158 in both commensal and 
environmental E. coli in the practice environment.  Given the demonstration of the 
presence of these phenotypes and genes in pathogenic isolates (Huber et al., 2013, O'Keefe 
et al., 2010, Steen and Webb, 2007, Timofte et al., 2011), there is clearly potential for these  
to limit treatment options for important infections in companion animals.  The close 
contact between pets and their owners (Westgarth et al., 2008) indicates a potential public 
health issue with the zoonotic transmission of resistant organisms, or resistance 
determinants a real concern.  The contamination of the practice environment with these 
bacteria has also been shown in this and other studies, which is of concern as these 
environmental bacteria may act as a source of infection for new animals in the 
environment and a source of resistance genes for exchange with previously susceptible E. 
coli with public health implications for staff and clients in the practice environment.  More 
work is required to look at the transfer of resistant bacteria between companion animals 
and their practice environment and how this contributes to clinical infections with resistant 
organisms and to determine the risk factors associated with both contamination of the 
practice environment and the carriage of resistant commensal E. coli.  
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Chapter 3 
Risk factors for carriage of antimicrobial resistant 
Escherichia Coli in hospitalised companion animals. 
 
INTRODUCTION 
Antimicrobial resistance is an important problem facing human and veterinary medicine.  It 
leads to increased morbidity and mortality among patients by limiting treatment options, 
increased cost and length of treatment and is a potential threat to public health.  
Resistance among E. coli is of particular interest given the ubiquitous nature of these 
bacteria and their potential to act as a reservoir for resistance genes.  Among animals and 
humans E. coli are a common commensal organism in the gastro-intestinal tract (GIT) and 
they are able to readily accept plasmids, thus horizontal gene exchange is common 
meaning that spread of resistance genes can occur rapidly and widely (Hart et al., 2006).  In 
addition to this E. coli can be opportunistic pathogens themselves and have been isolated 
from a variety of infections in companion animals including  urinary tract infections (Huber 
et al., 2013, O'Keefe et al., 2010); wounds (Steen and Webb, 2007) and bile in a case of 
cholangiohepatitis (Timofte et al., 2011).      
 
Beta-lactam antimicrobials are commonly used in UK companion animal practice (Radford 
et al., 2011, Mateus et al., 2011) and resistance to this class of drug is principally conferred 
by production of beta-lactamase enzymes which hydrolyse the beta-lactam ring and confer 
resistance to the penicillins and first generation cephalosporins.  Over the last few decades 
the use of third and fourth generation cephalosporins to treat resistant infections has 
driven the evolution and emergence of extended spectrum beta lactamases (ESBL’s) which 
confer resistance to third and fourth generation cephalosporins.  Resistance to later 
generation cephalosporins can also be conferred by the production of the cephamycinase 
AmpC, which unlike ESBL’s is resistant to beta lactamase inhibitors (Pfeifer et al., 2010).   
 
ESBL-producing bacteria are widely reported in humans in both community and hospital 
acquired infections involving E. coli (Reinert et al., 2007, Pitout and Laupland, 2008) and 
they constitute a major problem in human medicine.  Risk factors for human carriage of 
ESBL-producing bacteria have been identified as: length of hospitalisation; severity of 
illness; urinary catheterisation; length of stay in intensive care unit; mechanical ventilation; 
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multiple co-morbid conditions; non-home residence and previous treatment with 
antibiotics (Pitout and Laupland, 2008, Hayakawa et al., 2013, Jacoby and Munoz-Price, 
2005).  A number of these risk factors are potentially applicable to hospitalised companion 
animals and some have been shown to be risk factors in hospitalised horses (Maddox et al., 
2011). 
 
Multi-drug resistant (MDR), ESBL-producing and AmpC-producing E. coli have been isolated 
from companion animals in the UK (Wedley et al., 2011), Tunisia (Ben Sallem et al., 2013), 
South Korea (Nam et al., 2010), China (Sun et al., 2010), the USA (O'Keefe et al., 2010), 
Switzerland (Huber et al., 2013) and Germany (Franiek et al., 2012).  Thus indicating that 
they are widely found in companion animal populations.  Prior exposure to antimicrobials, 
hospitalisation and lower age have all been implicated as risk factors in the isolation of 
MDR, ESBL-producing and AmpC-producing E. coli from companion animals (Hernandez et 
al., 2014, Sun et al., 2010, Nam et al., 2010, Moreno et al., 2008, Gibson et al., 2011, Belas, 
2014).  However, there have been no detailed studies examining carriage of resistance in 
companion animal referral hospitals in the UK, where improvements in pet care and 
longevity, as well as in the treatment options available, result in an increasing number of 
pets that may be at risk of nosocomial colonisation and infection with these organisms.  
The aim of this study was to determine the risk factors for carriage of important resistance 
phenotypes by faecal commensal E. coli in veterinary referral practices.   
 
MATERIALS AND METHODS 
 
Data and sample collection 
Faecal and environmental samples were collected from five referral practices in Northwest 
England and processed as described previously (chapter 2).  Practices 1 and 4 were referral 
only and 2, 3 and 5 saw first opinion cases in addition to referrals.  In brief all dogs and cats 
hospitalised overnight in the practices were sampled daily from admission until discharge. 
Samples were collected and labelled (with name, ID number, date of collection and where 
the animal was hospitalised at the time of sampling).  Standard bacteriological techniques 
were used to determine resistance to important antimicrobials and ESBL/AmpC production.  
The presence of genes encoding for ESBL or AmpC production was confirmed using PCR and 
sequencing (see methods in chapter two).   
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Data for each animal providing a faecal sample were collected from practices.  Four out of 
five practices elected for data to be collected manually from the practice computer system.  
The author collected all data from these practices.  One practice (practice two) elected to 
provide data themselves using a set group of questions in order to standardise the data 
collected.  Data collected from practices were: species; date of hospitalisation; age; gender 
and neutered status; breed (cats were included with small breed dogs); whether the animal 
had been hospitalised in the last three months, procedures carried out in current hospital 
stay (for example radiography, ultrasound, MRI or CT scan) and antimicrobials used both in 
the three months prior to hospitalisation and whilst being hospitalised up to the date of the 
sample.  Antimicrobial use was assessed as use in the previous 24 hours, 48 hours, 7 days 
and 3 months. Other data considered included the presence of resistance in environmental 
samples taken from the practices at the same time as the animal samples.    Data were 
inputted into a database (Microsoft Excel) along with bacteriology and PCR results for each 
sample.     
 
Statistical methods 
The binary outcomes of interest for each sample were the presence or absence of an E. coli 
isolate with; clavulanic acid potentiated amoxycillin (CAPA) resistance, ciprofloxacin 
resistance, third generation cephalosporin resistance (TGCR), multidrug resistance to 3 or 
more drug classes (MDR), blaAmpC (CITM) detection and blaESBL (CTX-M, TEM or SHV) 
detection.  
 
Due to repeated measures, data were clustered within dogs and therefore factors affecting 
the occurrence of antimicrobial resistant E. coli were examined in multilevel logistic 
regression models. Within animal clustering was accounted for by inclusion of animal as a 
random intercept in all models. Initial univariable screening was performed and all 
variables with p value of <0.25 were considered in a multivariable model.  
 
The correlation of all the exposures was assessed using correlations coefficients and for any 
correlated variables (correlation coefficient >0.8) the one selected to be included in the 
model was the one with the lowest p value.  The days hospitalised and the age of the 
animal were the only continuous variables; the functional form of these variables with 
respect to each outcome was assessed using generalised additive models (GAM). The GAM 
models were fitted using cubic spline smoothers in the S-Plus software package (S-plus 
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2000, Mathsoft Inc). The functional forms of the relationships were then used to inform the 
polynomial fits in the multivariable logistic regression models, which were then tested for 
significance (see figures 1a-f and 2a-f, appendix V). 
 
The final multivariable models for each outcome of interest were constructed using a 
manual backward stepwise procedure where variables with a Wald P-value <0.05 were 
retained in the model.  Confounding was considered if elimination of any one variable 
effected a change of more than 25% in the coefficient of another variable.    First order 
interaction terms were tested for biologically plausible variables remaining in the final 
models. Finally all variables with P<0.25 on univariable analysis and anything considered a 
priori to be of importance, were checked in the final model for significance  
 
Data were analysed using the MLwiN statistical software package (MLwiN Version 2.3 
Centre for Multilevel Modelling, University of Bristol).  Univariable and multivariable 
calculations were performed using penalised quasi-likelihood estimates (2nd order PQL 
except in the case of AmpC outcome where it was necessary to use 1st order).  
 
RESULTS 
Samples  
Of the 333 samples in chapter two 13 were discarded from risk factor analysis due to 
inadequate labelling or data collection.  In total 320 samples from 200 animals remained 
for risk factor analysis.  Cats provided 24 (7.5%) samples and dogs provided 296 (92.5%) 
samples.  Table 1 shows the number and prevalence of resistance for each of the outcomes 
considered. 
 
The average age of animals in the study was 6.1 years ranging from three months to 
eighteen years.  In 111/320 (34.7%) samples the animal providing the sample had been 
hospitalised in the last three months (not including the current period of hospitalisation).  
The average number of days an animal had been hospitalised for when samples were 
collected was 3.5 days, ranging from 0 (collected on day of admittance) to 20 days. Table 2 
shows the numbers of samples in each group for categorical variables and previous 
exposures to different antimicrobials are shown in table 3.    
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Table 1: Number and sample level prevalence (with 95% confidence intervals) from 320 samples from 200 
animals used in analysis. CAPA= clavulanic acid potentiated amoxycillin, MDR = multidrug resistance to three or 
more classes in E. coli.  
Resistance outcomes 
considered 
Numbers of resistant 
samples  (n=320) 
Prevalence Lower and Upper 95% CI 
 
CAPA resistance 95 29.7% 24.7, 34.7 
Ciprofloxacin resistance 79 24.7% 20.0, 29.4 
MDR 86 26.9% 22.0, 31.7 
Resistance to one or more TGC’s 122 38.1% 32.8, 43.4 
ESBL producer* 73 22.8% 18.2, 27.4 
AmpC (CITM confirmed on PCR) 71 22.2% 17.6, 26.7 
* Confirmed by PCR, phenotype or sequencing 
 
 
Table 2: Categorical variables with number and percentage of samples exposed in faecal samples (n=320) 
collected from 200 animals.  Where the variable status could not be accurately determined it was recorded as 
unknown. 
Exposure variable  Number % 
Breed    
Small breed <10kg (including cats) 94 29.4% 
Medium breed dog 10-20kg  113 35.3% 
Large breed dog >20kg 96 30.0% 
Unknown  17 5.3% 
Gender   
Male 113 35.3% 
Male neutered 85 26.6% 
Female 39 12.2% 
Female neutered 80 25.0% 
Case type    
Neurosurgery  56 17.5% 
Orthopaedic  95 30.0% 
Soft tissue surgery 52 16.2% 
Medicine  85 26.6% 
Other (unidentified) 32 10.0% 
X-ray 70 21.9% 
Ultrasound scan 39 12.2% 
MRI or CT scan 78 24.4% 
Environmental MDR E. coli isolated in same week 134 41.9% 
Environmental ESBL-producing E. coli isolated in same week 134 41.9% 
Environmental AmpC-producing E. coli isolated in same week 164 51.3% 
NB some samples had missing data for some variables hence they do not always add to 320 (or 100%)  
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Table 3: Prevalence of exposures to different antimicrobial agents at any point in the three months prior to 
sample collection in faecal samples (n=320) collected from 200 animals.  It should be noted that these have not 
been adjusted for clustering within animal and simply reflect sample level prevalence. 
Antimicrobial Number % (+/- 95% CI) 
Amoxycillin 13 4.1 (1.9-6.2) 
CAPA 120 37.5 (32.2-42.8) 
Cephalexin 27 8.4 (5.4-11.5) 
Cefuroxime 52 16.3 (12.2-20.3) 
Metronidazole 37 11.6 (8.1-15.1) 
Fluoroquinolones 18 5.6 (3.1-8.1) 
Clindamycin 13 4.1 (1.9-6.2) 
Any antimicrobial 185 57.8 (52.4-63.2) 
 
Univariable Analysis  
Univariable analysis showed multiple significant (p<0.05) associations. A summary of these 
is shown in table 4.  Further details are shown in appendix IV tables 1 to 6.  For all 
outcomes increasing number of days hospitalised was significantly associated with 
increasing risk and antimicrobial use was also significant although which antimicrobials 
varied with the outcome considered. The type of case and the practice were was also 
significant as was resistance identified in environmental samples.    
 
The GAM’s (appendix V) showed that the days hospitalised demonstrated a significantly 
non-linear relationship (p >0.05) with many of the resistance outcomes being considered. 
The risk appeared to increase up until approximately 10 days and then there was either no 
further increase or a decrease in risk, however data points after 10 days were sparse.  In 
the final model this variable was explored as linear, as a quadratic polynomial and as a 
piecewise fit allowing risk to increase up to 10 days with no further change in risk after this 
time.  Age had mostly a linear relationship except for CAPA and AmpC resistance and 
quadratic terms were also tested for these outcomes 
 
Significant correlation was found between some variables.  This was primarily between 
variables where the same antimicrobial had been given in different time frames (e.g. 
receiving metronidazole in the last 7 days was strongly correlated with receiving 
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metronidazole in the last 48 hours).  Kennelling area was correlated with species, both of 
which are to be expected.   
 
Table 4: Summary of significant associations with the 6 outcomes (P<0.05) on multilevel univariable analysis of 
320 faecal samples from 200 dogs and cats in 5 referral practices. 
Outcome Significant associations on univariable analysis: 
CAPA Resistance Practice, Hospitalisation length, Environment, Antimicrobial use (various), Case type 
and X-ray 
Ciprofloxacin 
Resistance 
Practice, Hospitalisation length, Environment, Antimicrobial use (various) and Case 
type 
MDR Practice, Hospitalisation length, Environment, Antimicrobial use (various), Breed and 
Case type 
TGCR Practice, Hospitalisation length, Environment, Antimicrobial use (various) and Case 
type 
ESBL producer Practice, Breed, Gender, Antimicrobial use (various) 
AmpC (confirmed 
blaCITM) 
Practice, Hospitalisation length, Environment, Antimicrobial use (various), Case type 
and Xray 
 
Multivariable results 
 
The final multivariable results for each of the six outcomes are shown in tables 5 and 6. 
Practice was a significant risk factor for all outcomes apart from CAPA resistance with 
practice five having generally lower levels of risk compared to other practices.  Practices 
one, two and three were associated with higher risk for third generation cephalosporin and 
ciprofloxacin resistance, with practice 1 and 3 having increased risk of ESBL-producing E. 
coli and practices 1 and 2 with AmpC-producing E. coli.  Case type was significant for some 
resistance outcomes with neurosurgery cases being associated with increased risk for 
CAPA, ciprofloxacin and AmpC resistance outcomes and soft tissue surgery cases associated 
with increased risk for CAPA and ciprofloxacin resistance. Duration of hospitalisation was 
associated with increased risk for some outcomes. The best fit was provided by inclusion as 
a piecewise fit allowing risk to increase up to 10 days.  Breed was also a significant risk 
factor for several outcomes with a consistent pattern of small breeds (which included cats) 
being associated with lower risk than medium and large breeds.  Receiving an X-ray was 
found to be associated with reduced risk of AmpC E. coli isolation and receiving an MRI or 
CT scan was shown to be associated with a higher risk of isolating MDR organisms.  Every 
resistance outcome was positively associated with the use of at least one antimicrobial. 
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Fluoroquinolone use was strongly associated with the outcomes of ciprofloxacin resistance, 
3GCR and ESBL-producing E. coli.  Use of CAPA was associated with CAPA resistance, 3GCR 
and the presence of ESBL and AmpC producers. Cephalexin was associated with CAPA 
resistance and clindamycin with CAPA resistance, 3GCR and AmpC producers.  
Metronidazole exposure in the last 3 months appeared to be associated with MDR E. coli 
faecal isolation. 
 
Isolation of resistant E. coli in the environment in the same week as sampling was assessed 
for association with the outcomes.  There was correlation between environmental MDR E. 
coli and environmental AmpC-producing E. coli (r = 0. 7). In addition practice was correlated 
with both environmental MDR E. coli (r = -0.6) and environmental AmpC-producing E. coli (r 
= -0.695). 
 
With practice ID included in the models only isolation of environmental AmpC-producing E. 
coli was significantly associated with the outcome of CAPA resistance.  Due to the 
correlation between practice and environmental outcomes the effect of removal of 
practice was assessed.  This resulted in environmental AmpC-producing E. coli becoming 
significant for 3GCR (OR=2.4 (1.6-4.9)), ciprofloxacin resistance (OR = 5.2 (2.0-13.1)) and 
AmpC producing E. coli (OR = 7.3 (3.2-16.8)).   
 
In the multivariable models for CAPA, ESBL and 3GCR the variance for the random effect 
was negligible, suggesting these models explained the within dog clustering.  There was 
some remaining clustering of outcomes in animals for ciprofloxacin resistance, MDR and 
AmpC-producing E. coli.  
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Table 5. Results of multivariable multilevel analysis for the outcomes of resistance to CAPA and ciprofloxacin and MDR E. coli in 320 faecal samples from 200 dogs and cats in 5 hospitals in 
North West UK.  
Variable CAPA resistance Ciprofloxacin resistance MDR 
 Odds ratio 95% CI P-value Odds ratio 95% CI  P-value Odds ratio  95% CI  P-value 
Hospital           
1    REF   3.8 1.3-11.2 0.0 
2    0.21 0.05-0.98 0.047 5.0 1.3-18.3 0.02 
3    0.12 0.04-0.3 <0.001 4.5 1.5-13.7 0.009 
4    0.15 0.03-0.7 0.02 2.2 0.5-9.5 0.3 
5    0.07 0.02-0.3 <0.001 REF   
Case Type          
Medicine 1.8 0.7-4.3 0.19 REF      
Neurosurgery 5.5 2.2-13.8 <0.001 7.3 2.3-23.4 0.001    
Soft tissue surgery 3.6 1.4-9.3 0.0078 3.8 1.2-11.8 0.02    
Orthopaedic REF   3.0 0.9-10.4 0.08    
Other (unidentified) 4.6 1.6-12.8 0.004 3.1 0.8 -12.6 0.1    
Number days hospitalised*    1.15  1.02-1.3 0.02    
Breed          
Small REF         
Medium 3.1 1.5-6.7 0.003       
Large 1.7 0.7-3.9 0.25       
Unknown 7.9 2.3 -27.2  0.001       
Environmental sample with AmpC that week 3.7  2.0-6.8 <0.001       
MRI or CT scan       2.2 1.2-4.2 0.01 
Amoxycillin in the last 3 months       6.1 1.7-22.1 0.006 
CAPA in the last 7 days  2.8 1.5-5.2 0.001       
CAPA in the last 3 months      2.1 1.01-4.6 0.05    
Fluoroquinolone in the last 3 months    8.6 2.2-34.1 0.002    
Cephalexin in the last 7 days 3.0  1.0-8.6 0.04       
Clindamycin in the last 3 months 15.8  3.4-72.9 0.001       
Metronidazole in the last 3 months       2.3 1.1-5.2 0.03 
Variance (standard error) 0.0   0.8 (0.6)   0.2 (0.3)  
For antibiotic exposures the reference category is not receiving the antibiotic in the specified time period   
95% CI = 95% confidence intervals; P values are from the Wald chi-squared test 
*Piecewise fit up to 10 days 
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Table 6: Results of multivariable multilevel analysis for the outcomes of resistance to any third generation cephalosporin, ESBL production and AmpC production in faecal E. coli in 320 faecal 
samples from 200 dogs and cats in 5 hospitals in North West UK.  
Variable Any resistance to third generation cephalosporins ESBL producer AmpC producer 
 Odds ratio 95% CI P-value Odds ratio 95% CI P-value Odds ratio 95% CI P-value 
Hospital           
1 10.7 3.4-34.3 <0.001 14.1 1.8-108.2 0.011 27.4 5.2-144.2 <0.001 
2 5.4 1.3-21.4 0.02 4.1 0.4-42.3 0.24 13.6 1.9-95.7 0.009 
3 7.7 2.3-25.9 0.001 24.4 3.1-192.5 0.002 2.8 0.4-18.6 0.27 
4 3.5 0.9-13.3 0.07 8.3 0.95-71.9 0.06 4.4 0.6-35.0 0.16 
5 REF   REF   REF   
Case Type          
Medicine       REF   
Neurosurgery       3.9 1.2-12.3 0.020 
Soft tissue surgery       2.1 0.6-6.9 0.23 
Orthopaedic       3.2 0.9-10.3 0.06 
       8.1 2.4-27.6 0.001 
Number days hospitalised* 1.1 1.02-1.23 0.02    1.2 1.1-1.4 0.003 
Breed          
Small REF   REF      
Medium 2.2 1.1-4.5 0.03 2.8 1.2-6.2 0.01    
Large 2.9 1.4-6.0 0.006 3.4 1.4-8.0 0.005    
Other (unidentified) 3.2 1.0-10.4 0.05 5.6 1.5-20.5 0.009    
Xray        0.2 0.07-0.60 0.004 
CAPA in the last 7 days  2.5 1.3-4.8 0.004 2.0 1.1-3.8 0.03 2.7 1.1-6.3 0.03 
CAPA in the last 3 months            
Fluoroquinolone in the last 24 hours    9.4 2.0-45.2 0.005    
Fluoroquinolone in the last 7 days 5 1.2-21.2 0.03       
Clindamycin in the last 3 months 9.7 2.3-41.8 0.002    8.4 1.5-46.8 0.01 
Variance (standard error) 0.0 0.0 0.7(0.5) 
For antibiotic exposures the reference category is not receiving the antibiotic in the specified time period   
95% CI = 95% confidence intervals; P values are from the Wald chi-squared test 
*Piecewise fit up to 10 days
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DISCUSSION 
This study is one of the first to investigate risk factors for carriage of antimicrobial 
resistance in companion hospital referral hospitals in the UK.  Risk factors identified for the 
different resistance outcomes were similar in many cases. This is not unexpected as some 
resistance outcomes are very similar to one another, for example any bacteria producing 
an AmpC or ESBL is expected to be resistant to third generation cephalosporins.  In addition 
resistance genes maybe co-located on the same plasmids leading to correlation of 
outcomes.  
More than half of samples in this study were from animals which had been exposed to 
antimicrobials in the previous three months. High levels of exposure to antimicrobials are 
expected in a population of animals from a referral hospital as a number of cases will have 
a history of illness which has resulted in prior use of antimicrobials, as well as the use of 
antimicrobials once hospitalised.  This represents exposure of the animal concerned up to 
the day before sampling only and is not representative of all the antimicrobial exposures 
the animal may have subsequently received.  It is also possible that some exposure to 
antimicrobials in the prior three months may have not been recorded as in some cases the 
referral history was incomplete; it is therefore possible that the exposure prior to 
hospitalisation has been underestimated.  It should also be remembered that the 
prevalence figures are sample level rather than animal level and animals hospitalised for 
longer (and therefore contributing more samples) may be more likely to be exposed to 
antimicrobials.  However this clustering was accounted for in the multilevel modelling used 
to determine risk factors.     
The most common antimicrobial exposure was CAPA, followed by cephalosporins and 
metronidazole.  This is in agreement with other studies of antimicrobial use in veterinary 
practice (Mateus et al., 2011, Radford et al., 2011). Our study combined with these studies 
show there is a high exposure of companion animals to CAPA in UK veterinary practice, 
however the use of important antimicrobials such as fluoroquinolones and third/fourth 
generation cephalosporins was low in this study.  The use of metronidazole was 
significantly associated with MDR in E. coli which is an interesting association given that 
metronidazole is not expected to have in vivo activity against E. coli and is therefore 
unlikely to exert a direct selection pressure.  However this has been reported in 
hospitalised animals previously.  In a case control study in an Australian veterinary hospital 
treatment with metronidazole was found to be a significant risk factor, increasing the odds 
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for MDR E. coli isolation by a factor of ten (Gibson et al., 2011). In this study we found a 
lower level of risk, however the same association in two studies of different design is 
suggestive that metronidazole is a true risk factor for MDR E. coli isolation.  It may be that 
metronidazole is indirectly favouring the proliferation of E. coli generally in the gut by 
removing part of the resident microflora, which is metronidazole-sensitive and allowing E. 
coli to take its place.  If MDR E. coli were already present this could result in an increase in 
numbers and an increased likelihood of detection.  This could have a significant impact as  
metronidazole is generally viewed as a ‘safe’ antimicrobial to use with low levels of 
resistance found in obligate anaerobes from samples from dogs (Lawhon et al., 2013).  It 
may be that this needs to be revised due to its indirect effects on populations of E. coli 
(including resistant) in the gut.  Further work is required to determine the effect of 
different agents on the change of quantity of resistance in susceptible populations of E. 
coli.  
Similarly to metronidazole the use of clindamycin would not be expected to exert a direct 
selection pressure on E. coli.  High levels of clindamycin resistance have been found in 
other bacteria in dog faeces (Cinquepalmi et al., 2013) suggesting that the use of 
clindamycin may have an effect on the faecal microflora sufficient to drive the generation 
of resistance.  It may be that there are indirect effects on E. coli which favour the 
dissemination of resistance.  It is worth noting that estimates for the effect of clindamycin 
had wide confidence intervals, probably as a result of relatively infrequent exposure to this 
antimicrobial. 
Use of fluoroquinolones was associated with several resistance outcomes.  It is not 
unexpected that exposure to a fluoroquinolone would be associated with ciprofloxacin 
resistance as it provides a direct selection pressure.  However use was also associated with 
general TGCR and ESBL-producer isolation.  High levels of fluoroquinolone resistance have 
been found among ESBL-producing bacteria in humans (Balkhed et al., 2013) and use of 
fluoroquinolones has been identified as a risk factor for ESBL isolation (Soraas et al., 2013, 
Kaya et al., 2013).  In a case control study of animals those exposed to enrofloxacin were 
more likely to have ESBL-producers isolated (Moreno et al., 2008).  This link between 
fluoroquinolone and ESBL-producer isolation is likely to be due to co-location of blaESBL and 
fluoroquinolone resistance genes on the same plasmids (Hawkey and Jones, 2009). Such 
plasmids would be expected to confer advantageous resistance to bacteria in a clinical 
environment.   
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Compared to other antimicrobials, both in first opinion practice (Mateus et al., 2011, 
Radford et al., 2011) and in this study, fluoroquinolones are used relatively infrequently 
though the results from this study suggest that they can exert a potent selection pressure.  
The fact that their use is not just associated with fluoroquinolone resistance but also 3GCR 
is of great concern as these two classes of antimicrobial are important in human medicine 
(WHO, 2011).  The selection for co-resistance to different antimicrobial classes has 
important implications, resistance to antimicrobials does not necessarily require the direct 
exposure to those particular antimicrobials.  This is demonstrated by the high level of 3GCR 
seen in this study whilst no exposure to these was recorded in animals providing samples, 
although exposure to first and second generation cephalosporins was recorded.  The 
results of this study highlight the particular need for cautious and judicious use of 
fluoroquinolones in both first opinion and referral veterinary practice.   
Use of cephalexin was associated with CAPA resistance and is not unexpected given that 
they are both beta-lactam antimicrobials; it may be that cephalexin use drives the selection 
of resistance mechanisms like AmpC production which would confer resistance to CAPA 
though no significant association was detected in this study.  More interesting is the fact 
that cephalosporin use was not associated with 3GCR or ESBL production.  The majority of 
cephalosporin use in this study was cefuroxime which was always given intravenously 
perioperatively, either before or during general anaesthesia prior to surgery, rather than a 
longer course of medication, which might be expected to exert different selection 
pressures for resistance.  It may also be that not enough animals were exposed to 
cephalosporins in this study making the power to detect associations low.    The use of 
cephalosporins has been associated with: fluoroquinolone resistance in humans (Batard et 
al., 2013); ESBL-producing bacteria in pigs (Agerso and Aarestrup, 2013) and MDR E. coli 
from hospitalised dogs (Gibson et al., 2011).  None of these were found in this study 
although it is likely that use of any cephalosporin will create, or add to, an overall selection 
pressure for mechanisms conferring resistance to third generation cephalosporins.   
CAPA use was associated with every resistance outcome except MDR.  Association with 
CAPA resistance and AmpC production is expected as CAPA use would exert a direct 
selection pressure for these resistances.  Driving the generation of AmpC mediated 
resistance would also have implications for 3GCR.  Use of CAPA has been shown to be 
associated with an increase in levels of ciprofloxacin resistance in human hospitals and was 
implicated as a significant driver in levels of ciprofloxacin resistance overall (Cuevas et al., 
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2011).   Given that exposure of animals to CAPA is frequent in both this study and first 
opinion practice (Mateus et al., 2011, Radford et al., 2011) the wide range of resistance 
associated with its use is of great concern.  More than any other antimicrobial CAPA has 
the potential to generate resistance simply due to its widespread use in practice. 
Practice remained a significant risk factor in this study after allowing for other variables, 
with a reasonably consistent pattern. Practice one was associated with higher levels of risk 
for third generation cephalosporin resistance (3GCR), AmpC production and ciprofloxacin 
resistance whilst practice three was associated with higher risk for ESBL production and 
MDR E. coli.  Practice five was associated with low risk for all outcomes where practice was 
a significant risk factor.  This is broadly in agreement with the prevalence of the respective 
resistance outcomes detailed in chapter two.  This suggests some other unmeasured 
variable(s) at the practice level are important.  It was impossible to account for all the 
differences between practices within our model, for example practice size and either 
number of animals hospitalised or staff numbers could have an effect. Case numbers were 
not available for all practices and using staffing levels was not considered accurate due to 
practices having different levels of part time staff and variable numbers of students.  Case 
load could also be an influence with some practices receiving predominantly routine 
orthopaedic cases, some seeing first opinion as well as referral cases and some seeing a 
wide range of tertiary referrals.  In human medicine gram negative isolates from ICU 
departments within hospitals in Europe and the USA have been shown to have lower 
antimicrobial susceptibilities compared to other areas in the same hospitals (Sader et al., 
2014), it may be that the differences seen between departments within hospitals are due 
to similar factors to those differences seen between different hospitals in this study.  ICU 
departments are likely to see the most critically ill patients with multiple co-morbid 
conditions.  Human spinal cord injury patients have been shown to be at higher risk of 
isolation of resistant bacteria in a hospitalised setting as opposed to the community (Yoon 
et al., 2014) which may reflect similar factors influencing practice level risk seen in this 
study.   
Hospitalisation was a significant risk factor for the presence of ciprofloxacin resistance, 
3GCR and AmpC-production, and of borderline significance (P=0.05) for ESBL production, 
with odds of resistance increasing between 1.1 and 1.2 per additional day hospitalised.  
Thus the risk of ciprofloxacin resistance, TGCR and AmpC production at day 10 of 
hospitalisation is 4.0, 2.6 and 6.2 respectively compared to the day of admission.  Increased 
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duration of stay in hospital has been associated with increased risk of isolation of ESBL-
producers in humans (Tham et al., 2013, Ko et al., 2013).  Studies of MDR E. coli in 
hospitalised horses have shown an increased burden of MDR organisms over time 
hospitalised (Williams et al., 2013, Maddox et al., 2011).  In companion animals 
hospitalisation for more than six days has been implicated as a risk factor for the isolation 
of MDR organisms in a case-control study in an Australian veterinary hospital (Gibson et al., 
2011).  Studies of hospitalised companion animals tend to show higher prevalence of 
antimicrobial resistance compared to community studies in similar areas (Nam et al., 2010, 
So et al., 2012, Sun et al., 2010), suggesting that there are factors involved in 
hospitalisation which increase risk of AMR acquisition.  The acquisition of a nosocomial 
MDR E. coli urinary infection has been demonstrated in a cat (Hernandez et al., 2014) which 
demonstrates the consequences of increased risk of acquisition of AMR bacteria in 
hospitalised patients. This increase in risk of hospitalisation could reflect increased 
likelihood and duration of exposure to antimicrobials, although individual exposure was 
included we were unable to estimate total antimicrobial usage in the hospital at the time 
and this may also represent a source of exposure to the hospitalised animal.  Increased 
duration of hospitalisation also represents increased duration of exposure to an 
environment contaminated with resistant bacteria, and of exposure to other patients 
which may be carriers of resistant bacteria. Furthermore it may also reflect more 
debilitated patients which are likely to hospitalised for longer periods.  In reality it is likely 
to be a combination of multiple factors however if the duration of hospitalisation can be 
minimised, without compromising patient welfare, then this could have an  impact on the 
rates of carriage of some antimicrobial resistance.  
Environmental AmpC-producing bacteria detection in the same week as sample collection 
was associated with an increase in risk for CAPA resistance in faecal E. coli, after removing 
practice from the final models with the same observation for ciprofloxacin and AmpC 
producer outcomes.  AmpC-producing E. coli have been isolated from the environment in 
an Australian veterinary hospital (Sidjabat et al., 2006).  Initial contamination of the 
practice environment is likely to be of animal (or human) origin, however it is likely that 
exchange can occur in both directions and the fact that AmpC-producers in the 
environment appear to be associated with resistance outcomes in animals hospitalised in 
the environment in this study is suggestive that this is the case.   
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Where breed was significant it was generally consistent with small breeds being associated 
with low risk and medium and large breeds being associated with higher risk.  It may be 
that this is a reflection of different case types being more common in different breeds and 
the inclusion of a different species (cats) in the small breed group compared to the other 
groups may be skewing these results, although the number of cats in the study was low.  It 
was not possible to specify the breed more precisely than small, medium or large and we 
did not have data on what the dogs were fed, or their home environment, therefore we are 
unable to speculate whether larger breeds have different resistance levels due to these 
factors. 
The case type was a significant risk factor for some resistance outcomes in this study with 
neurosurgery cases generally being associated with a high level of risk compared to 
orthopaedic and medical cases.  The high risk for neurosurgery cases could be a reflection 
of the often high functional dependence of these cases.  Studies in humans have shown 
that a high degree of functional dependence is a risk factor for the isolation of important 
resistance phenotypes in E. coli (Nicolas-Chanoine et al., 2012, Hayakawa et al., 2013).  
Placement of a urinary catheter is a common part of treatment of neurosurgery cases 
where the bladder is affected, this has frequently been identified as a risk factor in human 
studies (Hayakawa et al., 2013, Pitout and Laupland, 2008) and is likely to contribute to the 
overall increased risk among these patients.  It would be interesting to determine the 
proportion of these patients which get urinary tract infections, and the proportion of those 
with resistant E. coli as this might give a better understanding of the degree of effect that 
urinary catheterisation has on these patients. Neurosurgery often has long duration of 
surgery and they may receive more preoperative antibiotics, or different regimes.  
Although we included previous antimicrobials there may be some subtleties of 
antimicrobial administration that were not captured in this study.   Further longitudinal 
studies would be useful in this subset of patients. Soft tissue surgery cases were at 
increased risk for some resistance outcomes compared to medical and orthopaedic cases.  
In humans spending time in the surgical department of a hospital was shown to be a risk 
factor (Tham et al., 2013).  It may be that the higher risk of soft tissue and neurosurgery 
cases represents sub-populations of animals with greater morbidity, greater likelihood to 
stay in higher risk environments, longer anaesthetics and other unidentified factors 
compared to orthopaedic and medical cases.  Certainly among orthopaedic cases it would 
be expected that there would be a low level of exposure to antimicrobials and a higher 
proportion would be expected to be routine cases with low functional dependency 
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compared to neurosurgical cases.  Medical cases in this study included a varied caseload 
including gastroenterology and cardiology patients and within this there is a great deal of 
variation. The identification of cases which may be at increased risk of acquiring E. coli with 
important AMR types is useful to guide infection control measures, allowing for specific 
high level infection control procedures to be put in place with these animals which might 
not be feasible to apply to the whole population of hospitalised animals.   
Receiving an MRI or CT scan was associated with an increased risk of isolation of MDR E. 
coli.  It is unlikely that the act of such a scan is likely to increase risk inherently, however in 
all practices the policy for MRI or CT scanning was to maintain animals under general 
anaesthetic for the duration of the scan, it is possible this may be associated with more of a 
risk.  It also may reflect the type of case which is likely to receive an MRI or CT scan 
although case type was assessed in the model.  Interestingly radiography was associated 
with a lower risk of AmpC-producer isolation.  Again there is no obvious biological 
explanation for a direct influence of this and it may reflect an unidentified confounding 
factor.   
This study has demonstrated the association of several different risk factors with important 
resistance outcomes in E. coli.  The principle among these is exposure to various 
antimicrobials, which has been reported previously in companion animals.  It is worth 
noting that several associations were found in this project which suggests co-selection for 
resistance to different antimicrobial classes can occur with antimicrobial use in companion 
animal practice.  This implies that reduction of resistance to a certain antimicrobial may not 
be achieved by simply reducing the use of that antimicrobial and a more wide ranging 
approach to antimicrobial stewardship is necessary.  Hospitalisation and case type were 
also significantly associated with some outcomes, with implications for infection control. If 
hospitalisation times can be minimised and high risk cases identified and specific infection 
control measures implemented then the incidence of important AMR among E. coli in 
companion animals may be reduced.   
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Chapter 4 
Concluding discussion 
Antimicrobial resistance has become an issue of major importance globally in both human 
and veterinary medicine. Multidrug-resistant (MDR) bacterial infections are becoming more 
common in veterinary hospitals and the incidence of these infections is expected to 
increase. This along with the emergence of specific resistance mechanisms, such as ESBL or 
AmpC production (Donati et al., 2014, Belas, 2014), in companion animals make this a 
major concern for animal welfare as there are limited therapeutic options to manage such 
infections and an increased risk of treatment failure. In addition companion animals may 
play an important role as a reservoir of resistant bacteria or resistance genes due to their 
frequent exposure to antimicrobials and their close contact with human beings  
 
The overall aim of this project was to further our understanding of the epidemiology  and 
microbiology of antimicrobial resistant E. coli in hospitalised companion animals, 
concentrating particularly on several important antimicrobial resistant (AMR) phenotypes 
and genotypes, such as multidrug resistance, third generation cephalosporin resistance 
(including resistance via ESBL or AmpC production), fluoroquinolone resistance and 
resistance to the most commonly used antimicrobial in veterinary practice, clavulanic acid 
potentiated amoxicillin (CAPA). Specific objectives included determining the prevalence 
and risk factor for carriage of resistance and determining the frequency of environmental 
contamination with resistant E coli. Finally, further characterisation of genes associated 
with resistance was performed to allow comparisons between hopsitals and with other 
published work in animals and humans.  
 
These objectives were met by conducting longitudinal studies in five referral hospital 
practices in the North West UK with repeated sampling of hospitalised animals and the 
hospital environment, resulting in a total of 333 faecal samples and 257 environmental 
samples.  
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Overall resistance in E. coli to one or more of the antimicrobial classes was high (50.1%) in 
faecal samples, however perhaps of more concern is the high levels, in some cases, of 
resistance to critically important antimicrobials.    
 
Resistance to CAPA was a significant finding throughout this project with a high prevalence 
of resistance found.  CAPA was the most common antimicrobial to which animals providing 
samples were exposed, this is in agreement with other studies in the UK (Mateus et al., 
2011, Radford et al., 2011).  It is likely that this high level of exposure is a significant driver 
of the high levels of resistance seen.  Most isolates demonstrating resistance to CAPA were 
also identified as producers of AmpC directly implicating the production of AmpC with high 
levels of clinically relevant AMR in UK veterinary practice.  Previous exposure to CAPA was 
associated with every resistance outcome except MDR, in some cases this can be attributed 
to a direct selection pressure exerted by the antimicrobial (CAPA resistance, AmpC 
production) while in other cases (ciprofloxacin) it is likely to be due to co-carriage of 
different resistance genes on the same plasmid.  This is of great concern as the impact of 
this is likely to be high given both the widespread use of this antimicrobial in UK companion 
animal practice and therefore the large numbers of animals exposed to it and the 
significant resistance outcomes that appear to be associated with its use.  This study 
indicates that use of CAPA is likely to be a significant contributor to the burden of AMR in 
animals in UK referral hospitals and likely more widely.  Neurological and soft tissue surgery 
cases were more likely to have CAPA resistant isolates, this may reflect a high degree of 
functional dependence, intra-operative use of antimicrobials or other factors.  Further work 
is required to identify levels of similar resistance in pathogenic isolates in these animals (for 
example uropathogenic bacteria) as opposed to the commensal organisms in this study. 
Urinary catheterisation has been identified as a significant risk factor in humans (Pitout and 
Laupland, 2008, Hayakawa et al., 2013) and this may go some way to explaining the 
particularly high levels seen in neurosurgery cases.   
High levels of AmpC production were identified in this study among faecal E. coli, but there 
was large between practice variation.  In addition there was clustering of outcomes within 
animals, with some animals providing 2 and 3 samples all positive for AmpC-producing E. 
coli.  Once within animal and within practice clustering was taken into account the 
prevalence of AmpC producing E. coli was lower, with wider confidence intervals, 
demonstrating the need to take this into account when analysing results from similar 
projects, particularly when disparate numbers of samples are collected from different 
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practices, which is often inevitable as some hospitals are larger and busier than others. 
Ideally to get a good estimate of the prevalence of AmpC production among E. coli in UK 
referral practices samples would be collected from a wider range of practices to maximise 
the applicability of results to practices as a whole.  This was not logistically possible in this 
project however analytical methods have accounted for the issue of clustering.  The 
prevalence of AmpC production in this project was 4.3% (CI 1.1, 15.6) which still indicates a 
significant overall contribution to resistance, with potentially more of a contribution to 
resistance in some practices.  It would be of great interest to study the dynamics of AmpC 
levels in practice one over time.  It is possible that these high levels do not reflect the usual 
situation. This project was only carried out over six weeks spaced out over a few months, 
constant monitoring over a longer period may provide a more accurate picture.  It has been 
shown that in environmental E. coli isolates from human hospitals AmpC production is 
reduced in favour of ESBL production over time (Starlander et al., 2014),  it would be 
interesting to discover if this is similar in veterinary practice.  Multivariable analysis did not 
account for the differences seen in AmpC levels between practices and further 
identification of the practice level factors would be very helpful both for addressing the 
problem in this practice specifically and mitigation of risk more generally.   
Levels of resistance to ciprofloxacin were high in this study, again there was significant 
practice variation with practice remaining a significant risk factor in final multivariable 
models.  In comparison to levels in the UK community (Wedley et al., 2011) levels in this 
study were high, which may be expected when comparing a population of hospitalised 
animals to community animals as disease and hospitalisation are significant risk factors for 
carriage of resistance (Nicolas-Chanoine et al., 2012, Hayakawa et al., 2013, Gibson et al., 
2011).  However once adjusted for clustering the levels of resistance found in this study are 
significantly lower than those found in a similar study of hospitalised animals carried out in 
China indicating that levels of resistance are likely to have significant variation by 
geographic location, this is similar to the situation described in humans (Thomson, 1999).  
Ciprofloxacin resistance frequently coexisted with MDR and AmpC production and just 
under half of ciprofloxacin resistant samples also produced ESBLs.  This is probably a 
reflection of co-selection for multiple resistances.  Ciprofloxacin resistance was also more 
likely to be found alongside resistance to other, unrelated antimicrobials, which is of great 
concern as it is an indicator for general fluoroquinolone resistance.  Fluoroquinolone 
resistance alone presents a challenge to treatment in both humans and animals, co-
resistance to other important antimicrobial classes will only reduce treatment options.  The 
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mechanism for ciprofloxacin resistance was not identified in this study with qnr genes 
being found at low levels, it may be of interest for further studies to identify the primary 
mechanisms involved.      
Case types were identified as a significant risk factor with a similar pattern, again the exact 
reason for this is unclear and further study is indicated for this.  Duration of hospitalisation 
was a significant risk factor with risk increasing over the time spent in hospital.  This could 
reflect a longer time spent in a contaminated environment, increased contact with other 
animals or could reflect animals with more severe illnesses with higher functional 
dependence/multiple conditions, or more likely a combination of these factors.  
Antimicrobial use was a significant risk factor for ciprofloxacin resistance with 
fluoroquinolone use being associated with an eight-fold increase in risk.  This is 
understandable from a biological point of view as exposure to a fluoroquinolone will exert 
a direct selection pressure for ciprofloxacin resistance, though the degree of increase in risk 
is high and indicates the use of fluoroquinolones in practice is strongly associated with 
resistance development.  It is also worth noting that it was use of a fluoroquinolone in the 
three months prior to the date of sample collection which was the most significant 
fluoroquinolone exposure; this time period included the use in first opinion practice in 
many cases (as opposed to use within referral hospitals).  Further study to look at the 
changes in resistance over time after antimicrobial exposure is indicated.   
It is worth emphasising the difference between animals included in this study and both the 
general small animal population and those attending first opinion practice.  The vast 
majority of animals in this study were cases referred to specialist referral centres (though a 
very small number were first opinion cases seen at these centres), these animals are more 
likely to have had recent treatment, possibly including hospitalisation prior to referral.  As a 
population they may have had greater exposure to antimicrobials for longer periods, be 
hospitalised for longer periods and in some cases be more debilitated than a population of 
animals in a first opinion setting.  Due to these factors it is possible that the results in this 
study are not directly applicable to first opinion practice, hospitalisation is likely to occur 
less frequently in a first opinion setting however the use of antimicrobials is frequent in 
first opinion practice (Radford et al., 2011, Mateus et al., 2011) and indeed the total 
number of animals exposed to antimicrobials in first opinion practice is likely to greatly 
exceed that in a referral setting purely due to the number of animals involved.  The levels 
of exposure to different antimicrobials in this project were broadly similar to those in the 
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two studies of antimicrobial use in first opinion practices mentioned previously, this 
suggests resistance patterns seen in first opinion practice may not be very different to 
those seen in this project due to similar antimicrobial exposures.   Therefore it is likely that 
while there are differences in the study population in this study to that in a study of first 
opinion animals it is likely that this study has at least a fair degree of relevance to first 
opinion practice as well as referral practice.      
 Fluoroquinolones are an essential antimicrobial class in human medicine and are useful in 
veterinary medicine.  Animals were relatively infrequently exposed to a fluoroquinolone in 
this study which concurs with other studies (Mateus et al., 2011, Radford et al., 2011), 
however it was still an important risk factor not just for ciprofloxacin resistance but also for 
resistance to other important antimicrobials. There is an urgent need for effective 
stewardship of these antimicrobials in practice.  
The prevalence of ESBL producing E. coli was lower in this study compared to other studies 
of hospitalised animals in China (Sun et al., 2010) and Korea (So et al., 2012) and higher 
than comparable studies of community animals.  There was significant masking of ESBL-
producer phenotype due to AmpC production in this study.  This demonstrates the 
limitations of using phenotypic methods alone for the detection of ESBL-producers, 
particularly where high levels of AmpC production are suspected, molecular methods are 
essential for confirmation.  The most frequently detected type of ESBL in this study was 
CTX-M which is a common finding in both human and animal studies.  The most common 
ESBL found was CTX-M-15 which is commonly found in human studies but is also commonly 
reported in studies of animals in Europe (Ewers et al., 2012). Importantly this may reflect 
human to animal transmission of ESBL-producers and it is logical to assume that 
transmission can occur in both directions, suggesting a possible public health risk for AMR 
in companion animals.  Linking AMR in humans and animals means that effective control of 
the problem in either is likely to require effective control in the other, highlighting the need 
for a ‘One Health’ approach to this important issue.  The finding of TEM-158 in this project 
is important, it was the second most frequently identified ESBL in this project and it is 
worth noting that all TEM-158 positive samples were from the same practice. Further study 
would be useful to determine what factors may be responsible for this, including examining 
the referring population of animals in the community.  It may simply be due to chance, 
however this hospital also had the highest levels of ciprofloxacin resistance and AmpC 
producing E. coli.  Further study of hospitals with higher levels of resistance, particularly 
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looking at initial antimicrobial burdens and how they change over time is indicated.  There 
are no other studies reporting blaTEM-158 in companion animals but it has been reported 
occasionally in humans (Kiiru et al., 2012, Jacquier et al., 2013, Robin et al., 2007).  TEM-
158 is a complex mutant TEM (CMT) with inhibitor resistant properties and is of concern as 
the resistance to inhibitors means that there is both a wider spectrum of resistance to 
common antimicrobial treatments and the potential for masking of ESBL presence.  
Molecular methods including sequencing are required to distinguish TEM-158 production 
from that of AmpC and other ESBL variants. 
Fluoroquinolone and CAPA use were associated with increased risk of isolation of ESBL-
producing E. coli from faeces.  A fluoroquinolone would not be expected to directly select 
for ESBL production and it is likely this is due to co-selection for multiple resistance genes 
located on the same plasmid which is well described (Hawkey and Jones, 2009).  Further 
analysis looking at plasmids to identify both the plasmid types and the resistance genes 
located on them would be interesting and it would be expected from these results that 
multiple resistance genes conferring resistance to a range of important antimicrobials 
would be identified.   
3GCR was detected at relatively high rates in this study, which is a significant concern given 
the importance of these antimicrobials in human medicine.  It is particularly interesting to 
note that the prevalence of 3GCR was higher in this study than that of CAPA resistance, 
given the much higher levels of exposure of animals to CAPA than 3GC’s, it would be 
expected that a more potent selection pressure would exist for CAPA resistance.  In this 
project no exposure to third or fourth generation cephalosporins was recorded however 
there was significant exposure to first and second generation cephalosporins, it may be 
that these are exerting a selection pressure for general cephalosporin resistance.  Other 
significant contributors could be the use of fluoroquinolones and CAPA which are 
significant risk factors for mechanisms which would confer resistance to 3GC’s.  This is 
important as it demonstrates the potential for resistance to develop to a specific 
antimicrobial even when an animal has not been directly exposed to that antimicrobial.   
There were many different MDR profiles identified in this study, as MDR is simply an 
umbrella term for many different resistance combinations.  The clinical relevance generally 
depends on which classes of antimicrobial there is resistance to.  A large number of the 
MDR isolates in this study featured resistance to CAPA and ciprofloxacin which is of 
concern as treatment options for these samples are likely to be limited.  This probably 
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reflects the fact that the samples in this project came from a population of hospitalised 
animals in a referral environment.  By their nature referral cases are likely to be non-
routine and may have had previous hospitalisation and been exposured to antimicrobials.  
Comparison of MDR profiles from this project to a similar project (Wedley et al., 2011) 
looking at community based animals in northwest England show a stark difference in the 
MDR profiles in the community.  This is expected however further study between more 
directly comparable animals is indicated: for example dogs in the same household where 
one is hospitalised and the other not.  MDR samples with resistance to all classes of 
antimicrobial were found at a reasonably high frequency in this project.  In some cases 
certain MDR profiles were prevalent in single practices compared to others, suggesting that 
these may be acquired within the hospital rather than the community, though we cannot 
rule out a geographical or case type based influence.  It is interesting that the only 
antimicrobial exposures associated with increased risk of MDR were metronidazole and 
amoxicillin, this may simply reflect a lack of power in this project as antimicrobial exposure 
is a key risk factor for AMR and it would be expected that exposure to many antimicrobials 
would favour MDR development.  However many antimicrobial exposures were significant 
in univariable analysis but were not significant in our final model.  Further study directly 
comparing animals in the community, first opinion practice and referral practice is 
indicated, it would be hoped that this could provide information on the differences 
between MDR profiles in these populations, and some idea of the drivers of these 
differences, which could go some way to informing measures to mitigate the impact of 
MDR infections.   
All types of AMR examined in this study were found in both faecal and environmental 
samples.  Indeed patterns across practices were similar between the two sample types 
which is suggestive of transfer in one or both directions between the two.  Invariably the 
prevalence was lower in environmental samples compared to faecal samples, perhaps 
reflecting lower survivability of these bacteria in the environment, perhaps due to hygiene 
measures or environmental conditions.  Useful future studies could look directly at the 
transfer of resistant bacteria between animals, their hospital environment and humans to 
try to identify transmission dynamics.  This could greatly inform infection control measures.  
Only one MDR phenotype was found in environmental samples which was not found in 
faecal samples, the source for this contamination is likely to be either human or animal,  
faecal sample coverage of hospitalised animals was not 100%, if complete coverage had 
been achieved then it is possible this MDR phenotype would have been identified.  Results 
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of genotype analysis were similar to that in faecal samples with CTX-M-15 the most 
common ESBL and TEM-158 also found in the environment of practice one.  It is interesting 
to note that SHV-12 was only found in the environment, this probably reflects incomplete 
coverage of faecal sample collections. 
The origin of the environmental sample seemed to have an influence, resistance 
consistently seemed more likely from outside walking areas.  This may reflect mixing of 
patients in this area, increased likelihood of defaecation, reduced disinfection or some 
unidentified factor.  This is useful information for infection control measures as changes 
such as use of artificial surfaces which are easier to disinfect, or reduced mixing of animals 
from different wards, may have a beneficial effect.  Study of the exact dynamics of bacteria 
populations in animals and their environment is indicated. 
Although the different timescales are not directly comparable between practices (samples 
collected on different dates with different intervals between collection periods), it is 
interesting that the pattern of contamination levels appeared to vary between practices.  
One practice seemed to have a consistently moderate level of contamination and two 
practices a consistently low level of contamination while the two remaining practices 
generally had low levels of contamination but had transient periods of high contamination.  
This difference in patterns suggests different dynamics due to practice level factors, further 
study to confirm this and identify reasons is indicated.  There were several limitations 
encountered for environmental sampling in this study, it was not possible to time sample 
collection around cleaning as timing was often variable due to workload and it was not 
possible for this to be fitted around sampling.  Environmental disinfection is likely to have a 
significant effect of bacterial isolation rates from environmental samples.  Also sampling 
timing was made as regular as possible but there was some variation between practices 
and even for the same practices between different sampling blocks, it is possible this has 
introduced some bias to the results.   
Probably the main limitations of this project are the number of samples collected and the 
restriction to five hospitals in northwest England.  As a result of this some results are 
imprecise with wide confidence intervals both for prevalence and risk factor analysis.  
Future similar projects should consider the difficulty of faecal sample collection as it is likely 
to be done by members of practice staff who have multiple other duties. Sample collection 
was greatly enhanced by collection from multiple practices at the same time and improving 
communication.  As far as breed was concerned cats were included in the small breed 
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category.  This may be a limitation for this study as cats have a very different lifestyle to 
dogs and indeed a small breed dog is likely to be much more similar to a large breed dog in 
terms of lifestyle, illnesses for which veterinary treatment might be required and the type 
of treatment (including different antimicrobial agents) which may be given.  This are all 
potentially relevant factors which may influence outcomes in this study, in future studies it 
would be better to include cats in their own breed category.  It is worth re-iterating the fact 
that cats contributed only a very small proportion of the samples in this project and for this 
reason any effect is likely to be small.    
In conclusion this study has identified that companion animals are carriers of antimicrobial 
resistant bacteria, in some cases at high levels.  The level of carriage appears to be 
associated with hospitalisation, reason for hospitalisation and antimicrobial use among 
other factors.  This information will help inform measures to tackle what is probably the 
most important issue facing medicine and veterinary medicine in the future. Further 
studies are needed to determine the effect that antimicrobial stewardship or specific 
infection control measures have on the rates of carriage of resistance and hence infection 
in these populations. 
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Appendix I – In house sequencing protocol 
CONTENTS 
 
PCR – reactions        p3 
 
PCR product clean-up (PEG precipitation)     p5 
 
Sequencing reactions        p6 
 
Sequencing reaction clean-up (ethanol precipitation)    p7 
 
Reactions in tubes (repeats)       p7 
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PCR - reactions 
 
Reagents/Equipment required -  
    PCR reagents (dNTPs [10mM], 10x buffer, MgCl2  
    [25mM], Taq DNA polymerase [5Uµl
-1
], primers  
    [10µM], molecular grade H2O) 
    96-well non-skirted microtitre plates (AbGene) 
    Adhesive PCR film (AbGene) 
DNA extracts 
    Thermal cycler 
    Centrifuge with microtitre plate rotor 
    Plate vortexer 
 
1. In Excel create a spreadsheet to indicate which DNA isolate will be in each well of the half-
microtitre plate.  This sheet will act as a sample tracking sheet throughout the MLST 
process.  Remember to include a negative control.  2. 
2. Mix PCR reagents together (Master mix) in the following quantities; 
 
1x Master Mix  52x Master Mix (for 1 full 
plate) 
 
Sigma molecular grade H2O     37.25l   1936l 
10x buffer          5.0l   260l 
MgCl2 (25mM)   3.0µl   156µl 
dNTPs (20mM stock)        0.5l   26l 
Forward primer (10M stock)    1.0l   52l 
Reverse primer (10M stock)     1.0l   52l 
Taq polymerase (5 units/l)   0.25l   13l  
 
 
3. Aliquot 48 l master mix per microtitre well and tap plate gently to ensure liquid is in the bottom of 
the well.  Pipette 2 l DNA onto the side of each well as per plate layout created in Excel. 
 
4. Gently tap plate to move DNA to well bottom and carefully seal the plate.  Vortex and spin plate 
briefly at 500 rpm. 
 
5. Place plate in thermal cycler and load program. 
 
6. Once PCR is finished, mix 5 l of each sample (or a selection of samples) with 1 l 6x loading 
buffer and load into wells of a 2% agarose gel containing  ethidium bromide 0.5 g / ml.  
Electrophorese at about 120 V for 20 min and visualise DNA on a U.V. transilluminator. 
 
The method can be halted here indefinitely, with products being stored at 4°C for up to 2 weeks, 
or at -20°C for indefinite storage. 
 
 
 
 
PCR product clean-up (PEG precipitation) 
 
1. Aliquot 60 l 20% (w/v) PEG8000, 2.5M NaCl per well, using a multichannel pipette, seal 
wells with adhesive film, vortex and briefly spin the plate at 500 rcf to ensure mix is at the 
bottom of the wells.  Incubate the plates for either 15 min at 37 C, 30 min at 20 C or 
overnight at 4 C. (Longer incubations do not have a detrimental effect on the clean up 
procedure). 
 
2. Spin at 2750 rcf at 4 C for 60 min. 
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3. To remove PEG, place folded blue tissue into the bottom of the centrifuge plate holders and 
gently invert the plate onto blue tissue.  Spin at 500 rpm for  60 sec. 
 
4. Wash pellet twice with 150 l 70% ice-cold ethanol.  i.e. add 150 l per well and spin at 
2750 rcf for 10 min.  Remove ethanol by inversion of plate onto blue tissues, and then spin 
inverted plate on folded clean blue at 500 rpm for 60 sec.  Repeat. 
 
5. Air dry plate on bench for 10 min. 
 
6. Re-suspend pellet in STERILE water.  Re-suspension volume is dependent on intensity of 
PCR product observed following PCR e.g. Barely visible products are re-suspended in 5 l 
with more intense products re-suspended in volumes up to 50 l.  Volumes for each locus 
batch are determined with reference to intensity of product band on gel image.  Seal lid 
carefully, vortex and spin briefly. 
 
7. Resuspended products can be stored long-term at -20°C, or short-term at 4°C. 
Sequencing reactions 
 
1. Create a spreadsheet in Excel to indicate which isolate/primers will be in which wells, such 
that the PCR product from well A1 will be in A1 and A2, the forward primer will be A1 and 
the reverse in A2.  PCR product from A2 in A3 and A4 etc, according to the sequence plate 
pipetting guide sheet in Appendix VII.   
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 
806.a
spA1 
806.a
spA2 
869.a
spA1 
869.a
spA2 
1030.a
spA1 
1030.a
spA2 
1200.a
spA1 
1200.a
spA2 
1267.a
spA1 
1267.a
spA2 
1431.a
spA1 
1431.a
spA2 
B 
808.a
spA1 
808.a
spA2 
875.a
spA1 
875.a
spA2 
1062.a
spA1 
1062.a
spA2 
1202.a
spA1 
1202.a
spA2 
1280.a
spA1 
1280.a
spA2 
1434.a
spA1 
1434.a
spA2 
C 
809.a
spA1 
809.a
spA2 
882.a
spA1 
882.a
spA2 
1075.a
spA1 
1075.a
spA2 
1209.a
spA1 
1209.a
spA2 
1291.a
spA1 
1291.a
spA2 
1491.a
spA1 
1491.a
spA2 
D 
815.a
spA1 
815.a
spA2 
892.a
spA1 
892.a
spA2 
1079.a
spA1 
1079.a
spA2 
1210.a
spA1 
1210.a
spA2 
1293.a
spA1 
1293.a
spA2 
1495.a
spA1 
1495.a
spA2 
E 
818.a
spA1 
818.a
spA2 
912.a
spA1 
912.a
spA2 
1094.a
spA1 
1094.a
spA2 
1212.a
spA1 
1212.a
spA2 
1310.a
spA1 
1310.a
spA2 
1506.a
spA1 
1506.a
spA2 
F 
825.a
spA1 
825.a
spA2 
920.a
spA1 
920.a
spA2 
1190.a
spA1 
1190.a
spA2 
1218.a
spA1 
1218.a
spA2 
1417.a
spA1 
1417.a
spA2 
1540.a
spA1 
1540.a
spA2 
G 
834.a
spA1 
834.a
spA2 
923.a
spA1 
923.a
spA2 
1192.a
spA1 
1192.a
spA2 
1219.a
spA1 
1219.a
spA2 
1418.a
spA1 
1418.a
spA2 
1558.a
spA1 
1558.a
spA2 
H 
850.a
spA1 
850.a
spA2 
935.a
spA1 
935.a
spA2 
1196.a
spA1 
1196.a
spA2 
1221.a
spA1 
1221.a
spA2 
1423.a
spA1 
1423.a
spA1 blank blank 
 
 
2. Make up master mix in required volume.  Make two batches of 50 aliquots per sequencing 
plate : 
1x Master Mix     50x 
Master Mix 
  
Molecular grade H2O    2.38 l   
 119   l 
5x buffer           1.87 l   
 93.5 l 
Big Dye     0.25 l      12.5 l 
Primer (forward OR reverse) [0.67µM] 4 µl   
 200 µl 
 
N.B. Sequencing primers are at 0.67µM i.e. 1:15 dilution of PCR primer 
concentration (see Appendix I).  Sequencing primers are not necessarily the same as the PCR 
primers. 
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3. Add 8.5l of master mix containing forward primer to wells of columns  1,3,5,7,9 and 11; 
8.5l of master mix containing reverse primer to wells of columns  2,4,6,8,10 and 12 
 
4. Pipette 1.5 l of the first PCR product onto the side of wells A1 and A2.  Repeat for 
remainder of wells as per plate layout.  Spin briefly to move DNA template to bottom of 
wells. 
 
5. Place plate in thermal cycler and load program with the following conditions; 
     
96 C for 10 sec      
50 C for 5 sec      
             60 C for 2 min      
4 C forever. 
7. Do not stop at this point.  Proceed immediately to precipitation unless sequencing reaction 
runs overnight. 
 
Sequencing reaction clean-up (ethanol precipitation) 
 
   
a. Per plate mix 7000 l 100% ethanol and 280 l 3M sodium acetate and aliquot 52 
l per well.   
 
b. Replace adhesive film, vortex and briefly spin (500 rpm).  Incubate at room temp 
for 45 min and spin at 2750 rcf (4 C) for 1 h.   
 
c. Remove adhesive film and gently invert plate onto absorbent tissue.  Spin inverted 
plate on fresh tissue (500 rpm) for < 1min.   
 
d. Wash pellet once by addition of 150 l ice-cold 70% ethanol per well, cover plate 
with film and spin at 2750 rcf for 10 min.    
 
e. Remove adhesive film, invert plate onto absorbent tissue and give a final short 
inverted spin at 500 rpm.    
 
f. Air dry at room temp for 10 minutes. Recover plate with adhesive film and store at 
–20 C prior to sending away. 
 
 
Reactions in tubes (repeats) 
 
PCR 
 
1. To carry out MLST PCR in tubes use a 0.2 ml thin-walled tube and use the same reaction mixture, 
quantity and thermal cycler conditions as for a 96-well plate.   
 
2. Run 5 l out on a gel.   
 
3. To PEG precipitate; add 50 l water to each tube and transfer total volume to a 1.5 ml tube. Then 
add 60 l PEG / NaCl, vortex, incubate as for plates and spin at 13000g for 30 min. 
 
4. Pipette off PEG and wash once with 500 l 70% ethanol (13000g 10 min).  Air dry and resuspend 
as per usual. 
 
 
SEQUENCING 
 
1. Use 0.2 ml tubes and set up sequencing reactions as per 96 well plate. 
 
X 30 
93 
 
2. Add 10 l water per tube and transfer reactions to1.5 ml tubes.  Add 52 l ethanol/Na acetate, 
incubate as per plates and spin 13000g for 30 min. 
 
3.  Wash once with 70% ethanol as above. 
Stock primers are kept at 100 M (100 pmol/l) and diluted 1:10 for use in PCR and further diluted 
1:15 for use in sequencing reactions (0.67 M). 
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Appendix II: Figures showing AMR phenotype prevalence in 
environmental and faecal samples collected from practices 
 
 
 
Figure 1: The prevalence of each important AMR type found in faecal samples from each practice and in total 
  
 
Figure 2: The prevalence of each important AMR type found in faecal samples from each practice and in total 
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Appendix III: Origin and timing of environmental samples  
 
 
Figure 1: The proportion of potential ESBL, AmpC and MDR samples which were positive from each practice in 
each sampling week (X axis) giving a crude indication of the overall resistance burden in the environment in 
each week of sampling for each practice (practices are represented by different coloured lines) and changes in 
this burden between sampling weeks.  For example: if all samples collected from a practice in a week were 
positive for ESBL production, AmpC production and MDR then the proportion (Y axis) would be one, if all 
samples were positive for one of the three outcomes only (but no others) the proportion would be 0.33.  It is 
important to note that the gaps between sample weeks 2 and 3 and 4 and 5 are variable, there is no gap 
between weeks 1 and 2, 3 and 4 and 5 and 6.  
 
 
 
 
 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
P
ro
p
o
rt
io
n
 o
f 
e
n
vi
ro
n
m
e
n
ta
l s
am
p
le
s 
co
lle
ct
e
d
 s
h
o
w
in
g 
M
D
R
, E
SB
L 
an
d
 
A
m
p
C
 p
h
e
n
o
ty
p
e
s 
Week of sampling for each practice 
1
2
3
4
5
96 
 
Appendix IV: Univariable analysis results 
Table 1 Results of univariable  multilevel analysis for the outcome of MDR in 320 faecal samples from 200 dogs and cats in 5 
hospitals in North West UK.  
variable  B SD z ratio odds 
ratio 
lower95odds
r 
upper95oddsrati
o 
P 
value 
Practice (Compared to 1)        0.068 
 2 -0.022 0.50500
0 
-
0.0430 
0.98 0.36 2.64 0.966 
 3 0.182 0.3780 0.4810 1.20 0.57 2.52 0.630 
 4 -1.076 0.6290 -1.710 0.34 0.10 1.17 0.087 
 5 -1.297 0.5940 -2.182 0.27 0.09 0.88 0.029 
Days hospitalised  0.054 0.038 1.427 1.055 0.98 1.137 0.154 
Days hospitalised10  0.094 0.046 2.016 1.098 1.003 1.203 0.044 
Environment contaminated with 
MDR 
 0.31 0.299 1.036 1.363 0.758 2.449 0.300 
Environment contaminated with 
ESBL 
 0.134 0.304 0.442 1.144 0.63 2.075 0.659 
Environment contaminated with 
AmpC 
 0.032 0.307 0.105 1.033 0.566 1.885 0.916 
Age  -0.033 0.037 -0.903 0.967 0.9 1.04 0.366 
Breed (compared to small breed)        0.110 
 Medium 0.953 0.409 2.331 2.593 1.164 5.777 0.020 
 Large 0.831 0.424 1.958 2.295 0.999 5.273 0.050 
 Unidentifie
d 
0.927 0.697 1.331 2.527 0.645 9.898 0.183 
Gender (compared to mn)        0.115 
 m 0.584 0.382 1.53 1.794 0.849 3.792 0.126 
 f -0.342 0.567 -0.603 0.71 0.234 2.159 0.547 
 fn -0.215 0.436 -0.492 0.807 0.343 1.898 0.623 
Previous hospitalisation  -0.12 0.32 -0.375 0.887 0.473 1.661 0.708 
Case type (compared to neuro)        0.050 
 Ortho -0.747 0.436 -1.713 0.474 0.201 1.114 0.087 
 STS 0.024 0.462 0.052 1.024 0.414 2.535 0.958 
 Medical -1.11 0.459 -2.416 0.33 0.134 0.811 0.016 
 Unidentifie
d 
-0.131 0.543 -0.241 0.877 0.303 2.54 0.809 
Xray performed  -0.186 0.361 -0.516 0.83 0.409 1.684 0.606 
Ultrasound performed  -0.391 0.489 -0.801 0.676 0.26 1.762 0.423 
MRI or CT performed  0.587 0.332 1.77 1.798 0.939 3.444 0.077 
Any antimicrobial given in the last 3 months 0.427 0.302 1.411 1.532 0.847 2.772 0.158 
Cefuroxime given in the last 3m  0.034 0.408 0.084 1.035 0.465 2.302 0.933 
Amoxycillin given in the last 3m  1.457 0.694 2.099 4.293 1.101 16.741 0.036 
CAPA given in the last 3m  0.186 0.306 0.608 1.204 0.661 2.194 0.543 
Metronidazole given in the last 3m  0.902 0.422 2.138 2.465 1.078 5.638 0.033 
Fluoroquinolone given in the last 3m  0.255 0.636 0.401 1.29 0.371 4.489 0.688 
Cephalexin given in the last 3m  0.412 0.496 0.832 1.511 0.572 3.992 0.405 
Clindamycin given in the last 3m  x x x x x x x 
Cefuroxime given in the last 24h  -1.222 1.224 -0.999 0.295 0.027 3.244 0.318 
Cefuroxime given in the last 48h  -0.659 0.733 -0.9 0.517 0.123 2.174 0.368 
Cefuroxime given in the last 7d  -0.573 0.549 -1.043 0.564 0.192 1.655 0.297 
CAPA given in the last 24h  0.227 0.363 0.624 1.254 0.615 2.557 0.533 
CAPA given in the last 48h  0.144 0.357 0.402 1.154 0.573 2.325 0.688 
CAPA given in the last 7d  0.214 0.333 0.641 1.238 0.644 2.379 0.521 
Metronidazole given in the last 24h  0.23 0.573 0.402 1.259 0.41 3.872 0.688 
Metronidazole given in the last 48h  0.23 0.573 0.402 1.259 0.41 3.872 0.688 
Metronidazole given in the last 7d  0.163 0.532 0.307 1.178 0.415 3.339 0.759 
Fluoroquinolone given in the last 24h  -0.272 0.925 -0.294 0.762 0.124 4.673 0.769 
Fluoroquinolone given in the last 48h  0.241 0.789 0.305 1.272 0.271 5.978 0.760 
Fluoroquinolone given in the last 7d  -0.234 0.773 -0.303 0.791 0.174 3.597 0.762 
Cephalexin given in the last 24h  -0.322 0.759 -0.424 0.725 0.164 3.21 0.672 
Cephalexin given in the last 48h  0.012 0.69 0.017 1.012 0.262 3.91 0.987 
Cephalexin given in the last 7d  0.69 0.58 1.19 1.994 0.64 6.213 0.234 
Any antimicrobial given in the last 
24h 
 0.023 0.314 0.073 1.023 0.553 1.893 0.941 
Any antimicrobial given in the last 
48h 
 0.117 0.304 0.385 1.124 0.619 2.04 0.701 
Any antimicrobial given in the last 7d  0.248 0.297 0.833 1.281 0.715 2.295 0.405 
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Table 2 Results of univariable  multilevel analysis for the outcome of CITM in 320 faecal samples from 200 dogs and cats in 
5 hospitals in North West UK.  
variable  B SD z ratio odds 
ratio 
lower95odds
r 
upper95oddsrati
o 
P 
value 
Practice (Compared to 1) Overall       0.003 
 2 -1.207 0.518 -2.33 0.299 0.108 0.825 0.020 
 3 -1.615 0.414 -3.9 0.199 0.088 0.448 0.000 
 4 -1.535 0.561 -2.738 0.215 0.072 0.646 0.006 
 5 -2.588 0.743 -3.482 0.075 0.017 0.323 0.000 
Days hospitalised  0.156 0.037 4.216 1.169 1.087 1.257 0.000 
Days hospitalised10  0.215 0.044 4.843 1.240 1.137 1.353 0.000 
Environment contaminated with 
MDR 
 2.029 0.35 5.797 7.606 3.831 15.105 0.000 
Environment contaminated with 
ESBL 
        
Environment contaminated with 
AmpC 
 2.317 0.418 5.549 10.15
0 
4.477 23.012 0.000 
Age  0.027 0.032 0.844 1.027 0.965 1.094 0.407 
Breed (compared to small breed) Overall       0.006 
 medium 0.493 0.342 1.440 1.637 0.837 3.202 0.150 
 large  -0.176 0.388 -0.453 0.839 0.392 1.796 0.651 
 unidentified 1.628 0.555 2.935 5.096 1.717 15.119 0.003 
Gender (compared to mn) Overall       0.047 
 m -0.168 0.331 -0.506 0.846 0.442 1.619 0.613 
 f -0.077 0.444 -0.174 0.926 0.388 2.210 0.862 
 fn -1.206 0.447 -2.696 0.300 0.125 0.719 0.007 
Previous hospitalisation  0.498 0.277 1.801 1.646 0.957 2.831 0.072 
Case type (compared to ortho)        0.000 
 Neurosurger
y 
1.562 0.443 3.530 4.770 2.003 11.356 0.000 
 STS 1.445 0.455 3.178 4.244 1.740 10.349 0.001 
 Medical 0.305 0.464 0.657 1.357 0.546 3.371 0.511 
 Unspecified 1.644 0.502 3.274 5.178 1.935 13.859 0.001 
Xray performed  -1.135 0.426 -2.664 0.321 0.139 0.741 0.008 
Ultrasound performed  -0.115 0.422 -0.272 0.891 0.390 2.039 0.785 
MRI or CT performed  0.359 0.303 1.185 1.431 0.791 2.590 0.236 
Any antimicrobial given in the last 3 months 0.87 0.297 2.933 2.387 1.335 4.269 0.003 
Cefuroxime given in the last 3m  0.872 0.327 2.670 2.392 1.261 4.536 0.008 
Amoxycillin given in the last 3m  1.488 0.574 2.594 4.430 1.439 13.638 0.009 
CAPA given in the last 3m  0.629 0.272 2.309 1.876 1.100 3.199 0.021 
Metronidazole given in the last 
3m 
 0.6 0.38 1.578 1.822 0.865 3.840 0.115 
Fluoroquinolone given in the last 
3m 
 1.11 0.495 2.243 3.035 1.150 8.006 0.025 
Cephalexin given in the last 3m  0.002 0.484 0.005 1.002 0.388 2.587 0.996 
Clindamycin given in the last 3m  1.835 0.593 3.096 6.266 1.961 20.024 0.002 
Cefuroxime given in the last 24h  x x x x x x x 
Cefuroxime given in the last 48h  -0.443 0.645 -0.688 0.642 0.181 2.271 0.492 
Cefuroxime given in the last 7d  -0.515 0.506 -1.018 0.598 0.222 1.610 0.309 
CAPA given in the last 24h  0.647 0.319 2.028 1.909 1.022 3.566 0.043 
CAPA given in the last 48h  0.603 0.312 1.933 1.827 0.992 3.366 0.053 
CAPA given in the last 7d  0.914 0.286 3.192 2.493 1.423 4.370 0.001 
Metronidazole given in the last 
24h 
 0.919 0.478 1.924 2.508 0.983 6.398 0.054 
Metronidazole given in the last 
48h 
 0.919 0.478 1.924 2.508 0.983 6.398 0.054 
Metronidazole given in the last 7d  0.749 0.44 1.700 2.114 0.892 5.011 0.089 
Fluoroquinolone given in the last 
24h 
 1.308 0.647 2.019 3.697 1.039 13.151 0.043 
Fluoroquinolone given in the last 
48h 
 1.505 0.621 2.422 4.505 1.333 15.225 0.015 
Fluoroquinolone given in the last 
7d 
 1.479 0.536 2.758 4.390 1.534 12.563 0.006 
Cephalexin given in the last 24h  -0.047 0.666 -0.070 0.955 0.259 3.519 0.944 
Cephalexin given in the last 48h  -0.138 0.66 -0.209 0.871 0.239 3.177 0.835 
Cephalexin given in the last 7d  -0.071 0.58 -0.123 0.931 0.299 2.900 0.902 
Any antimicrobial given in the last 
24h 
 0.57 0.282 2.024 1.769 1.018 3.073 0.043 
Any antimicrobial given in the last 
48h 
 0.682 0.276 2.470 1.978 1.151 3.399 0.014 
Any antimicrobial given in the last 
7d 
 0.934 0.275 3.402 2.545 1.486 4.359 0.001 
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Table 3 Results of univariable  multilevel analysis for the outcome of ciprofloxacin resistant in 320 faecal samples from 200 
dogs and cats in 5 hospitals in North West UK.  
variable  beta se z-ratio odds 
ratio 
CI95low CI95hi p-value 
Practice (Compared to 1) Overall       0.000 
 2 -2.073 0.647 -3.205 0.126 0.035 0.447 0.001 
 3 -1.861 0.417 -4.462 0.156 0.069 0.352 0.000 
 4 -1.775 0.564 -3.150 0.169 0.056 0.511 0.002 
 5 -2.078 0.554 -3.748 0.125 0.042 0.371 0.000 
Days hospitalised  0.154 0.037 4.21 1.167 1.086 1.253 0.000 
Days hospitalised10  0.209 0.044 4.755 1.233 1.131 1.344 0.000 
Environment contaminated with MDR  1.491 0.315 4.736 4.442 2.396 8.234 0.000 
Environment contaminated with ESBL         
Environment contaminated with AmpC  1.513 0.303 4.994 4.541 2.507 8.225 0.000 
Age  -0.025 0.033 -0.771 0.975 0.914 1.04 0.441 
Breed (compared to small breed) Overall       0.350 
 medium 0.469 0.336 1.395 1.599 0.827 3.092 0.163 
 large 0.078 0.363 0.215 1.081 0.531 2.202 0.830 
 unidentified 0.73 0.586 1.247 2.076 0.658 6.546 0.213 
Gender (compared to mn) Overall       0.255 
 m 0.037 0.327 0.114 1.038 0.546 1.972 0.909 
 f -0.612 0.496 -1.232 0.542 0.205 1.435 0.218 
 fn -0.536 0.382 -1.403 0.585 0.277 1.237 0.161 
Previous hospitalisation  0.283 0.276 1.027 1.328 0.773 2.28 0.304 
Case type (compared to ortho) Overall       0.000 
  1.619 0.41 3.949 5.05 2.261 11.282 0.000 
  1.303 0.425 3.069 3.682 1.602 8.462 0.002 
  0.346 0.415 0.833 1.413 0.626 3.19 0.405 
  0.377 0.549 0.686 1.458 0.497 4.28 0.493 
Xray performed  -0.239 0.333 -0.718 0.788 0.41 1.512 0.473 
Ultrasound performed  0.167 0.399 0.419 1.182 0.541 2.583 0.675 
MRI or CT performed  0.636 0.298 2.135 1.888 1.054 3.385 0.033 
Any antimicrobial given in the last 3 months 1.148 0.3 3.83 3.153 1.752 5.675 0.000 
Cefuroxime given in the last 3m  0.766 0.328 2.333 2.15 1.13 4.091 0.020 
Amoxycillin given in the last 3m  1.64 0.599 2.74 5.156 1.595 16.664 0.006 
CAPA given in the last 3m  0.933 0.272 3.435 2.542 1.493 4.329 0.001 
Metronidazole given in the last 3m  1.088 0.369 2.951 2.967 1.441 6.111 0.003 
Fluoroquinolone given in the last 3m  1.926 0.527 3.653 6.859 2.441 19.274 0.000 
Cephalexin given in the last 3m  -0.728 0.577 -1.261 0.483 0.156 1.497 0.207 
Clindamycin given in the last 3m  0.704 0.601 1.171 2.022 0.622 6.572 0.242 
Cefuroxime given in the last 24h  x x x x x x x 
Cefuroxime given in the last 48h  -0.613 0.661 -0.928 0.541 0.148 1.979 0.354 
Cefuroxime given in the last 7d  -0.686 0.517 -1.327 0.504 0.183 1.387 0.184 
CAPA given in the last 24h  0.659 0.318 2.07 1.932 1.036 3.604 0.038 
CAPA given in the last 48h  0.604 0.311 1.94 1.829 0.994 3.365 0.052 
CAPA given in the last 7d  1.002 0.285 3.521 2.723 1.559 4.756 0.000 
Metronidazole given in the last 24h  0.969 0.483 2.007 2.636 1.023 6.791 0.045 
Metronidazole given in the last 48h  0.969 0.483 2.007 2.636 1.023 6.791 0.045 
Metronidazole given in the last 7d  0.937 0.438 2.141 2.553 1.083 6.021 0.032 
Fluoroquinolone given in the last 24h  2.568 0.808 3.179 13.041 2.677 63.524 0.001 
Fluoroquinolone given in the last 48h  2.698 0.794 3.396 14.847 3.129 70.451 0.001 
Fluoroquinolone given in the last 7d  2.238 0.606 3.692 9.374 2.857 30.758 0.000 
Cephalexin given in the last 24h  -1.493 1.057 -1.412 0.225 0.028 1.785 0.158 
Cephalexin given in the last 48h  -1.572 1.054 -1.491 0.208 0.026 1.64 0.136 
Cephalexin given in the last 7d  -1.874 1.061 -1.766 0.154 0.019 1.228 0.077 
Any antimicrobial given in the last 24h  0.576 0.279 2.065 1.779 1.03 3.073 0.039 
Any antimicrobial given in the last 48h  0.576 0.279 2.065 1.779 1.03 3.073 0.039 
Any antimicrobial given in the last 7d  0.836 0.267 3.128 2.307 1.366 3.895 0.002 
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Table 4 Results of univariable  multilevel analysis for the outcome of CAPA resistance in 320 faecal samples from 200 dogs 
and cats in 5 hospitals in North West UK.  
variable  beta se z-ratio odds 
ratio 
CI95lo
w 
CI95hi p-value 
Practice (Compared to 1) Overall       0.001 
 2 -0.695 0.448 -1.552 0.499 0.207 1.201 0.121 
 3 -1.043 0.345 -3.025 0.352 0.179 0.693 0.002 
 4 -1.263 0.493 -2.561 0.283 0.108 0.743 0.010 
 5 -1.381 0.455 -3.034 0.251 0.103 0.613 0.002 
Days hospitalised  0.117 0.035 3.369 1.124 1.05 1.203 0.001 
Days hospitalised10  0.034 0.011 3.183 1.035 1.013 1.056 0.001 
Environment contaminated with MDR  1.382 0.282 4.904 3.981 2.292 6.916 0.000 
Environment contaminated with ESBL  1.584 0.3 5.281 4.876 2.708 8.78 0.000 
Environment contaminated with AmpC         
Age  0.035 0.03 1.149 1.035 0.976 1.098 0.251 
Breed (compared to small breed) Overall       0.008 
 medium 0.725 0.325 2.227 2.064 1.091 3.905 0.026 
 large 0.179 0.352 0.509 1.196 0.6 2.383 0.611 
 unidentified 1.633 0.568 2.877 5.119 1.683 15.568 0.004 
Gender (compared to mn) Overall       0.060 
 m -0.208 0.315 -0.661 0.812 0.438 1.505 0.509 
 f -0.399 0.439 -0.908 0.671 0.284 1.587 0.364 
 fn -1.005 0.381 -2.638 0.366 0.174 0.772 0.008 
Previous hospitalisation  0.234 0.263 0.891 1.264 0.755 2.116 0.373 
Case type (compared to ortho) Overall       0.000 
 Neurosurger
y 
1.628 0.42 3.874 5.095 2.235 11.614 0.000 
 STS 1.675 0.429 3.905 5.337 2.303 12.369 0.000 
 Medical 0.637 0.41 1.552 1.891 0.846 4.226 0.121 
 unidentified 1.615 0.483 3.341 5.03 1.95 12.976 0.001 
Xray performed  -1.005 0.363 -2.771 0.366 0.18 0.745 0.006 
Ultrasound performed  -0.122 0.398 -0.307 0.885 0.406 1.929 0.759 
MRI or CT performed  0.511 0.287 1.783 1.667 0.951 2.924 0.075 
Any antimicrobial given in the last 3 months 0.892 0.269 3.318 2.44 1.441 4.131 0.001 
Cefuroxime given in the last 3m  0.543 0.323 1.679 1.721 0.913 3.244 0.093 
Amoxycillin given in the last 3m  1.056 0.587 1.798 2.876 0.909 9.094 0.072 
CAPA given in the last 3m  0.514 0.256 2.006 1.672 1.012 2.762 0.045 
Metronidazole given in the last 3m  0.774 0.367 2.11 2.168 1.056 4.447 0.035 
Fluoroquinolone given in the last 3m  0.878 0.505 1.739 2.405 0.895 6.468 0.082 
Cephalexin given in the last 3m  0.675 0.42 1.605 1.964 0.861 4.477 0.108 
Clindamycin given in the last 3m  2.186 0.69 3.17 8.901 2.304 34.386 0.002 
Cefuroxime given in the last 24h  x x x x x x x 
Cefuroxime given in the last 48h  -0.535 0.599 -0.893 0.586 0.181 1.895 0.372 
Cefuroxime given in the last 7d  -0.514 0.457 -1.125 0.598 0.244 1.465 0.261 
CAPA given in the last 24h  0.504 0.309 1.631 1.655 0.903 3.033 0.103 
CAPA given in the last 48h  0.436 0.302 1.443 1.546 0.856 2.792 0.149 
CAPA given in the last 7d  0.75 0.274 2.737 2.118 1.237 3.625 0.006 
Metronidazole given in the last 24h  0.479 0.488 0.981 1.614 0.62 4.201 0.326 
Metronidazole given in the last 48h  0.479 0.488 0.981 1.614 0.62 4.201 0.326 
Metronidazole given in the last 7d  0.269 0.451 0.597 1.309 0.541 3.171 0.551 
Fluoroquinolone given in the last 24h  0.845 0.666 1.27 2.329 0.632 8.583 0.204 
Fluoroquinolone given in the last 48h  1.032 0.635 1.625 2.807 0.808 9.749 0.104 
Fluoroquinolone given in the last 7d  1.003 0.55 1.824 2.725 0.928 8.005 0.068 
Cephalexin given in the last 24h  0.304 0.588 0.517 1.355 0.428 4.286 0.605 
Cephalexin given in the last 48h  0.496 0.558 0.889 1.642 0.55 4.905 0.374 
Cephalexin given in the last 7d  0.802 0.492 1.63 2.231 0.85 5.853 0.103 
Any antimicrobial given in the last 24h  0.334 0.269 1.244 1.397 0.825 2.365 0.213 
Any antimicrobial given in the last 48h  0.439 0.261 1.68 1.551 0.929 2.587 0.093 
Any antimicrobial given in the last 7d  0.656 0.253 2.592 1.927 1.173 3.163 0.010 
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Table 5 Results of univariable  multilevel analysis for the outcome of cephalosporin resistance in 320 faecal samples from 
200 dogs and cats in 5 hospitals in North West UK.  
variable  beta se z-ratio odds 
ratio 
CI95lo
w 
CI95hi p-value 
         
Practice (Compared to 1) Overall       0.000 
 2 -0.951 0.436 -2.183 0.386 0.165 0.907 0.029 
 3 -0.356 0.297 -1.201 0.7 0.391 1.252 0.230 
 4 -0.741 0.409 -1.814 0.477 0.214 1.062 0.070 
 5 -2.323 0.554 -4.193 0.098 0.033 0.29 0.000 
Days hospitalised  0.107 0.034 3.158 1.113 1.041 1.189 0.002 
Days hospitalised10  0.14 0.04 3.514 1.15 1.064 1.244 0.000 
Environment contaminated with MDR  1.065 0.248 4.293 2.9 1.784 4.715 0.000 
Environment contaminated with ESBL  1.171 0.255 4.587 3.224 1.955 5.316 0.000 
Environment contaminated with AmpC         
Age  0.001 0.028 0.031 1.001 0.947 1.058 0.975 
Breed (compared to small breed) Overall       0.030 
 medium 0.607 0.305 1.99 1.835 1.009 3.338 0.047 
 large 0.519 0.317 1.638 1.681 0.903 3.127 0.101 
 unidentified 1.544 0.569 2.714 4.682 1.535 14.277 0.007 
Gender (compared to mn) Overall       0.170 
 m 0.254 0.303 0.838 1.289 0.712 2.333 0.402 
 f -0.019 0.413 -0.046 0.981 0.437 2.204 0.963 
 fn -0.465 0.343 -1.355 0.628 0.32 1.231 0.175 
Previous hospitalisation  0.115 0.249 0.463 1.122 0.689 1.827 0.644 
Case type (compared to ortho) Overall       0.005 
 Neurosurger
y 
0.872 0.375 2.325 2.392 1.147 4.99 0.020 
 STS 1.246 0.385 3.237 3.477 1.635 7.393 0.001 
 Medical 0.323 0.346 0.933 1.381 0.701 2.722 0.351 
 Unidentified 1.114 0.443 2.515 3.045 1.278 7.254 0.012 
Xray performed  -0.465 0.298 -1.558 0.628 0.35 1.127 0.119 
Ultrasound performed  0.222 0.36 0.615 1.248 0.616 2.528 0.538 
MRI or CT performed  0.34 0.275 1.238 1.406 0.82 2.41 0.216 
Any antimicrobial given in the last 3 months 0.856 0.249 3.443 2.354 1.446 3.833 0.001 
Cefuroxime given in the last 3m  0.461 0.313 1.47 1.585 0.858 2.93 0.142 
Amoxycillin given in the last 3m  1.338 0.625 2.142 3.811 1.12 12.968 0.032 
CAPA given in the last 3m  0.743 0.245 3.036 2.102 1.301 3.396 0.002 
Metronidazole given in the last 3m  0.721 0.363 1.985 2.056 1.009 4.189 0.047 
Fluoroquinolone given in the last 3m  1.515 0.552 2.744 4.551 1.542 13.433 0.006 
Cephalexin given in the last 3m  0.592 0.414 1.428 1.807 0.802 4.07 0.153 
Clindamycin given in the last 3m  1.809 0.692 2.613 6.105 1.572 23.713 0.009 
Cefuroxime given in the last 24h  -1.749 1.071 -1.633 0.174 0.021 1.42 0.102 
Cefuroxime given in the last 48h  -0.331 0.524 -0.632 0.718 0.257 2.005 0.527 
Cefuroxime given in the last 7d  -0.404 0.409 -0.987 0.668 0.299 1.489 0.323 
CAPA given in the last 24h  0.797 0.299 2.67 2.219 1.236 3.984 0.008 
CAPA given in the last 48h  0.679 0.289 2.347 1.972 1.118 3.476 0.019 
CAPA given in the last 7d  0.957 0.267 3.587 2.603 1.543 4.391 0.000 
Metronidazole given in the last 24h  0.737 0.478 1.542 2.09 0.819 5.336 0.123 
Metronidazole given in the last 48h  0.737 0.478 1.542 2.09 0.819 5.336 0.123 
Metronidazole given in the last 7d  0.61 0.431 1.417 1.841 0.791 4.283 0.156 
Fluoroquinolone given in the last 24h  2.747 1.068 2.573 15.601 1.924 126.507 0.010 
Fluoroquinolone given in the last 48h  2.85 1.055 2.702 17.286 2.187 136.61 0.007 
Fluoroquinolone given in the last 7d  1.948 0.668 2.918 7.016 1.895 25.968 0.004 
Cephalexin given in the last 24h  -0.109 0.585 -0.187 0.896 0.285 2.822 0.852 
Cephalexin given in the last 48h  0.081 0.555 0.147 1.085 0.366 3.219 0.883 
Cephalexin given in the last 7d  0.389 0.488 0.796 1.475 0.566 3.84 0.426 
Any antimicrobial given in the last 24h  0.606 0.255 2.376 1.833 1.112 3.022 0.017 
Any antimicrobial given in the last 48h  0.638 0.248 2.569 1.893 1.163 3.081 0.010 
Any antimicrobial given in the last 7d  0.767 0.241 3.186 2.153 1.343 3.45 0.001 
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Table 6 Results of univariable  multilevel analysis for the outcome of ESBL- producer in 320 faecal samples from 200 dogs 
and cats in 5 hospitals in North West UK.  
variable  beta se z-ratio odds 
ratio 
CI95lo
w 
CI95hi p-value 
         
Practice (Compared to 1) Overall       0.030 
 2 -1.247 0.637 -1.958 0.287 0.082 1.001 0.050 
 3 0.369 0.314 1.176 1.447 0.782 2.677 0.240 
 4 -0.157 0.449 -0.35 0.855 0.355 2.059 0.726 
 5 -2.762 1.023 -2.701 0.063 0.009 0.469 0.007 
Days hospitalised  0.088 0.034 2.59 1.092 1.022 1.167 0.010 
Days hospitalised10  0.116 0.042 2.746 1.123 1.034 1.22 0.006 
Environment contaminated with MDR  0.408 0.276 1.479 1.504 0.876 2.584 0.139 
Environment contaminated with ESBL  0.478 0.276 1.735 1.613 0.94 2.768 0.083 
Environment contaminated with AmpC  0.496 0.28 1.768 1.642 0.948 2.845 0.077 
Age  -0.009 0.033 -0.262 0.991 0.929 1.058 0.793 
Breed (compared to small breed) Overall       0.048 
 medium 0.903 0.381 2.372 2.467 1.17 5.201 0.018 
 large 0.886 0.392 2.261 2.425 1.125 5.224 0.024 
 unidentified 1.336 0.6 2.226 3.803 1.173 12.332 0.026 
Gender (compared to mn) Overall       0.630 
 m -0.007 0.336 -0.02 0.993 0.514 1.92 0.984 
 f -0.248 0.474 -0.523 0.78 0.308 1.976 0.601 
 fn -0.437 0.39 -1.121 0.646 0.3 1.388 0.263 
Previous hospitalisation  0.507 0.273 1.858 1.66 0.973 2.832 0.063 
Case type (compared to ortho) Overall       0.195 
 Neurosurger
y 
-0.101 0.394 -0.256 0.904 0.418 1.956 0.798 
 STS 0.405 0.429 0.945 1.5 0.647 3.477 0.345 
 Medical -0.627 0.432 -1.45 0.534 0.229 1.247 0.147 
 Unidentified -0.174 0.529 -0.33 0.84 0.298 2.367 0.742 
Xray performed  0.113 0.324 0.35 1.12 0.594 2.114 0.726 
Ultrasound performed  -0.146 0.431 -0.34 0.864 0.372 2.008 0.734 
MRI or CT performed  0.474 0.295 1.604 1.606 0.9 2.864 0.109 
Any antimicrobial given in the last 3 months 0.596 0.287 2.077 1.815 1.034 3.185 0.038 
Cefuroxime given in the last 3m  0.39 0.348 1.122 1.478 0.747 2.923 0.262 
Amoxycillin given in the last 3m  0.432 0.639 0.677 1.541 0.441 5.388 0.499 
CAPA given in the last 3m  0.573 0.275 2.082 1.773 1.034 3.042 0.037 
Metronidazole given in the last 3m  0.092 0.42 0.22 1.097 0.482 2.497 0.826 
Fluoroquinolone given in the last 3m  1.761 0.527 3.344 5.818 2.073 16.333 0.001 
Cephalexin given in the last 3m  0.179 0.471 0.381 1.197 0.476 3.011 0.703 
Clindamycin given in the last 3m  0.792 0.596 1.328 2.208 0.686 7.106 0.184 
Cefuroxime given in the last 24h  -1.009 1.085 -0.93 0.364 0.043 3.058 0.352 
Cefuroxime given in the last 48h  0.218 0.549 0.397 1.243 0.424 3.644 0.692 
Cefuroxime given in the last 7d  0.098 0.439 0.223 1.103 0.466 2.61 0.823 
CAPA given in the last 24h  0.28 0.334 0.839 1.323 0.688 2.544 0.402 
CAPA given in the last 48h  0.249 0.326 0.765 1.283 0.677 2.43 0.444 
CAPA given in the last 7d  0.784 0.289 2.712 2.19 1.243 3.859 0.007 
Metronidazole given in the last 24h  -0.168 0.587 -0.287 0.845 0.268 2.67 0.774 
Metronidazole given in the last 48h  -0.168 0.587 -0.287 0.845 0.268 2.67 0.774 
Metronidazole given in the last 7d  -0.171 0.53 -0.323 0.843 0.299 2.38 0.747 
Fluoroquinolone given in the last 24h  2.335 0.733 3.185 10.326 2.455 43.434 0.001 
Fluoroquinolone given in the last 48h  2.022 0.666 3.036 7.556 2.048 27.881 0.002 
Fluoroquinolone given in the last 7d  1.606 0.566 2.838 4.983 1.644 15.107 0.005 
Cephalexin given in the last 24h  -0.602 0.792 -0.76 0.548 0.116 2.588 0.448 
Cephalexin given in the last 48h  -0.693 0.79 -0.877 0.5 0.106 2.352 0.380 
Cephalexin given in the last 7d  -0.112 0.594 -0.189 0.894 0.279 2.864 0.850 
Any antimicrobial given in the last 24h  0.192 0.291 0.661 1.212 0.685 2.143 0.509 
Any antimicrobial given in the last 48h  0.24 0.283 0.849 1.272 0.73 2.215 0.396 
Any antimicrobial given in the last 7d  0.651 0.274 2.373 1.917 1.12 3.281 0.018 
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Appendix V: GAM plots 
Fig. 1a to 1e. Graphs representing the functional forms of the continuous variable days hospitalised modelled in 
a generalised additive model (where the continuous fixed effects are fitted using smoothers) to determine the 
shape of the relationship between the predictor variable and the outcome (log odds of different resistance 
outcomes). The plots show the fitted curves with 95% confidence intervals (dashed lines). The rug plots along 
the x-axis represent the number of data points. The P-value is a chi-square test for non-linearity. 
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Fig 1d. ESBL Phenotypic resistance 
 
 
Fig 1e. AmpC (by PCR) 
 
 
Fig 1f. CAPA Resistance 
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Fig. 2a to 2f . Graphs representing the functional forms of the continuous variable age modelled in a generalised 
additive model (where the continuous fixed effects are fitted using smoothers) to determine the shape of the 
relationship between the predictor variable and the outcome (log odds of different resistance outcomes). The 
plots show the fitted curves with 95% confidence intervals (dashed lines). The rug plots along the x-axis 
represent the number of data points. The P-value is a chi-square test for non-linearity. 
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Fig 2d. ESBL Phenotypic resistance 
 
 
Fig 2e. AmpC (by PCR) 
 
 
Fig 2f. CAPA Resistance 
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Appendix VI – Sampling guidelines for practices 
Sampling Plan – preliminary information for practices 
Thank-you for your assistance in taking samples for this study, your help is very much appreciated.   Our study 
aims to help understand the factors affecting the prevalence of some antibiotic resistant bacteria in referral 
hospitals in the North-West.  By participating you are helping increase our understanding of the development 
and spread of antibiotic resistance within veterinary practice.  We will also be taking some samples from your 
hospital, which will be used to give your practice some information about the potential for colonisation with 
antibiotic resistant bacteria.  However, your practice will not be identified in any subsequent publications.    
We aim to keep sampling as simple as possible and minimise the amount of time it takes.  Please let us know if 
you have any problems as we want to make this as easy as possible for you.  
We plan to carry out sampling over several periods, which we will arrange with your practice. Our sampling plan 
is: 
 On sampling days we would like you to collect a faecal sample from ALL cats and dogs that have 
passed faeces (where the owners have consented) while hospitalised in your practice (for more than 
24 hours)  and place it in the bags provided.  Please use a different bag for each sample using the 
labels provided to identify the individual animal (by name and case number) and the date it was 
collected.     
 
 Please only collect one sample per day from each animal that passes faeces.   
 
 We appreciate many animals will only be staying for a short period and thus may only provide one 
sample but collection of daily samples from animals hospitalised over longer periods is also required.  
 
 Please store samples in a fridge or cool box which can be provided 
 
 During each sampling period we will visit your hospital twice/three times weekly to both collect the 
faecal samples and take the environmental samples. 
Once again thank-you for participating, your assistance is very much appreciated and without it this study 
would not be possible.  Please contact us if there are any problems 
Ian Tuerena MRCVS  (Ian.Tuerena@liv.ac.uk)  
Dr Gina Pinchbeck MRCVS (ginap@liv.ac.uk)  
Dr Tim Nuttall MRCVS (timn@liv.ac.uk)  
Other contact details: 
Mobile: 07872315340 (weekdays 9-5) 
Address:  The University of Liverpool School of Veterinary Science, Leahurst Campus , Chester High Rd, Neston, 
CH64 7TE 
Independent Complaints Procedure 
If you have any concerns about the study or its conduct that we cannot satisfactorily resolve or you feel that 
you cannot ask us, you can use the university complaints procedure. Complaints should be addressed to the 
Research Governance Officer in Research and Business Services (RBS) – email: ethics@liv.ac.uk; tel.: 0151 794 
8727. The information on this sheet will enable them to identify the study and the investigators. 
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Appendix VII – Combined information and consent form for owners 
 
Detection of antibiotic resistant bacteria in animal faecal samples:  Participant  Information Sheet and 
informed consent form 
 
Please read the following information carefully. You may also request a copy for yourself. 
 
Dear dog or cat owner, 
 
Your veterinary surgeon has kindly agreed to help The University of Liverpool Veterinary School with a new 
study looking at antibiotic resistant bacteria. As part of this study, you and your animal(s) are invited to take 
part. We would be very grateful if you would allow us to take some samples from your dog or cat whilst it is in 
hospital, and allow us to record some data on your animal and its treatment.  
 
Please read the following information carefully and please ask if you would like more information or if there is 
anything you do not understand. Your vet may be able to answer some questions; otherwise my contact details 
are at the end of this letter. We would like to emphasise that you do not have to accept this invitation and you 
should only agree to take part if you want to. If you decide not to participate this will not affect the care and  
treatment of your animal 
 
Why are we getting these samples? 
All animals carry bugs (such as bacteria) in their guts (and other places too). Most of them cause no problem, 
but some cause infections that need treatment with antibiotics. Bacteria that are not killed by antibiotics 
(antibiotic resistant bacteria) are now becoming more of a concern in animal and human medicine, especially in 
hospitals. We are trying to see how much antibiotic resistance there is in the normal bacteria that animals 
carry. This will give us a greater understanding of how antibiotic resistance occurs in hospitals and hopefully can 
lead to the development of new ways to combat the problem. This is especially important for our animals, as 
increasing antibiotic resistance could result in real problems treating infections in the future. 
 
What samples are we collecting? 
For this study we are interested in obtaining samples of the poo (faecal samples) that your cat or dog does 
whilst in hospital.  
 
What does this involve? 
A faecal sample (poo sample) will be collected from your cat or dogs kennel (if available), or picked up off the 
ground when your dog is taken outside, and collected or posted back to us at the University of Liverpool. If your 
animal is hospitalised for several days we may collect more than one sample. We would also like obtain data on 
your dog or cat from the records your veterinary surgeon holds, such as the reason for hospitalisation and what 
treatment your animal has had. Your dog or cat will not be affected by the collection of their faeces in any way. 
 
Further information 
Samples and the information obtained may be retained for up to seven years and possibly used in future 
projects. All data will be kept strictly confidential and will be stored in a secured database accessible only by 
people working on the project. If you decide you want to withdraw from the study you may do so without 
explanation, and any information you have given can be destroyed. 
 
Results from the study will be printed in veterinary journals and the non-veterinary animal press, but no-one 
will be identifiable from any published work. 
 
Is there an independent complaints procedure? 
Yes - if you have any concerns about the study, its conduct or the investigators that we cannot satisfactorily 
resolve or you feel that you cannot ask us, you can use the university complaints procedure. Complaints should 
be addressed to the Research Governance Officer in Research and Business Services (RBS) – email: 
ethics@liv.ac.uk; tel.: 0151 794 8727. The information on this sheet will enable them to identify the study and 
the investigators.  
The Research Governance Officer will document the complaint and refer it to the Chair of the relevant sub-
committee or departmental committee within two working days. The Chair is responsible for investigating the 
complaint and for responding to you within two weeks.  
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What next? 
If you are happy to allow your dog or cat to become involved, then please read and sign the consent form, and 
the vet can start getting the samples. Please note that due to the large number of samples involved in this 
project we will not be able to give you back any individual results from your animal. 
 
Many thanks, 
 
Dr Gina Pinchbeck MRCVS 
 
 
Consent form: “Detection of antibiotic resistant bacteria in hospitalised animal faecal 
samples.” 
 
Researchers: Gina Pinchbeck/Ian Tuerena/Tim Nuttall/Nicola Williams 
Ple
ase initial box 
 
 
 
 
If you agree with the above-stated conditions please sign below:- 
 
 
          
Participant Name                                                 Date                   Signature 
 
 
 
                 
       Name of Person taking consent                         Date                  Signature 
 
 
 
        
       Researcher                                                         Date                   Signature 
 
      
The contact details of lead Researcher (Principal Investigator) are: [Contact: Gina Pinchbeck, 
Leahurst campus, University of Liverpool, Neston, Wirral, CH64 7TE, telephone: 0151 794 6195, 
email: ginap@liverpool.ac.uk]. If there are any problems, please let us know and we will try to help.  
       
 
 
1. I confirm that I have read and have understood the information sheet for the above 
study. I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily.   
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my rights being affected. If I do not 
participate this will not affect the care and treatment of my animal. 
 
 
3. I understand that, under the Data Protection Act,  I can at any time ask for access 
to the information I provide and I can also request the destruction of that 
information if I wish. 
 
4. I allow participation of my animal in the above study.    
 
 
